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ABSTRACT
The work described in this thesis is concerned with the relation¬
ship between prostaglandin I2 and the renin-angiotensin system.
In a conscious dog model, intravenous infusion of PGI2 lowered
systemic blood pressure but had very little effect on renal haemodynamics
or renin release. It was postulated that in the dog, PGI2 was not a
potent renal vasodilator or renin-secretagogue.
Urinary 6-keto-PGFia, the stable hydrolysis product of PGI2 , was
quantified by gas chromatography-mass spectrometry. Using this method
a linear relationship was demonstrated between circulating PGI2 and
urinary 6-keto-PGFia and a maximum rate of entry of PGI2 into the cir¬
culation was estimated.
Following blockade of the renin-angiotensin system with the angio¬
tensin I converting enzyme inhibitor captopril, systemic blood pressure
fell and renal plasma flow and sodium excretion increased in both sodium
replete and sodium deplete conscious dogs. These results emphasized
the importance of the renin-angiotensin system in the control of systemic
and renal haemodynamics under both sodium depleted and normal con¬
ditions. Urinary 6-keto-PGFjct levels increased following captopril
administration and showed a close correlation with the increase in renal
plasma flow. It was suggested that PGI2 may be involved in the renal
vasodilator response to captopril but PGI2 was not thought to_ participate
in the vasodepressor, natriuretic or renin secretory actions of captopril.
Inhibition of angiotensin II formation by captopril had little effect
on the hypotensive, renal vasodilator or renin secretory action of PGI2
in either sodium replete or sodium deplete conscious dogs.
iv.
It was concluded that PGI2 is not an important factor in the control
of renin release in the conscious dog and that in comparison to angio¬
tensin II, PGI2 plays a very minor role in the control of systemic blood
pressure and renal function.
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The prostaglandins are a family of cyclopentane fatty acids. They
have been found to occur naturally in almost every animal species and
in every cell or tissue studied. Many naturally occurring prostaglandins
and chemically synthesised analogues possess high biological potency
and show a great diversity of pharmacological effects (for review, see
Horton, 1979).
Prostaglandins are biosynthesised from the polyunsaturated fatty
acids cis-8,11,14-eicosatrienoic (dihomo-y-linolenic acid), cis-5,8,11,14-
eicosatetraenoic acid (arachidonic acid) and cis-5,8,11,14,17-eicosapenta-
enoic acid which give rise to the mono-, bis- and trienoic prostaglandins
respectively. Arachidonic acid is the most common fatty acid precursor
of prostaglandins and is incorporated as a structural component of
phospholipids into cell membranes and other sub-cellular structures of
all tissues of the body. Arachidonic acid is released from cell membranes
by the action of phospholipases, which can be activated by changes in
the chemical environment. Once released from the membrane phospho¬
lipids, arachidonic acid is metabolised by two types of enzyme. One
type of enzyme is a series of lipoxygenases which peroxidise arachidonic
acid to form unstable hydroperoxides. These hydroperoxides break
down to form the stable hydroxyacids or are further transformed into
other products, e.g. leukotrienes. The other enzyme is a cyclo-oxygenase
which oxidises arachidonic acid to form the unstable endoperoxides PGG2
and PGH2. These endoperoxides break down enzymatically or non-
enzymatically to the stable substances PGA2, PGB2, PGC2, PGD2, PGE2
and PGF2a as well as 12L-hydroxy-5,8,10-heptadecatrienoic acid (HHT)








and PGB compounds have not been elucidated but they are easily formed
chemically from PGE compounds by action of base or acid. The prosta¬
glandin endoperoxides are also enzymatically transformed into two other
unstable products, thromboxane A2 (TxA2) and prostacyclin (PGI2)
(Figure 1.1). Unlike PGE2, PGD2 and PGF2a, these products cannot
result from chemical breakdown. TxA2 (t£ = 32 sec at 37°C) is the
intermediate in the formation of the stable TxB2 and is a potent aggregator
of blood platelets. PGI2, an unstable enol-ether (t i = 2-3 min at 37°C)
is the intermediate in the formation of the stable 6-keto-PGFia which
is in equilibrium with its lactol form (Figure 1.2). PGI2 is the main
metabolite of arachidonic acid in vascular tissue and is a potent inhibitor
of platelet aggregation (for review see Moncada and Vane, 1978).
The prostaglandin content of most tissues and body fluids is in
the range 10-10to 10~8 gram per gram of tissue, although the capacity
to synthesise and release prostaglandins far exceeds the basal levels
detected (for review see Cuthbert, 1973). It can be concluded that
prostaglandins are not stored and release can be equated with de novo
biosynthesis. The release of essential fatty acids from the stores bound
in phospholipids is probably the rate-limiting step in prostaglandin bio¬
synthesis .
Prostaglandin biosynthesis can be inhibited by steroidal anti¬
inflammatory drugs, e.g. dexamethasone . These steroids
inhibit the action of the phospholipase and prevent the release of
arachidonic acid. Prostaglandin synthesis can also be inhibited by non¬
steroidal anti-inflammatory drugs, e.g. indomethacin and aspirin. These
drugs inhibit the action of the cyclo-oxygenase enzyme and therefore
prevent the conversion of arachidonic acid into its prostaglandin








(6-keto-PGFia. lactol form) (6-keto-PCF ia keto form)
FIGURE 1.2: Transformation of endoperoxides into PGI2 and
6-keto-PGFxa.
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1.2 Renal Prostaglandin Production
In 1965, Lee et al. demonstrated the existence of several vaso¬
depressor acidic lipids in extracts of rabbit renal medulla (Lee, Covino
and Takman). These acidic lipids were later characterised as PGE2,
PGF2^ and PGA2 (Lee, Growshaw, Takman, Attrep and Gougoutas,
1967; Daniels, Hinman, Leach and Muirhead, 1967). The biosynthesis
of PGE2 and PGF2<* by renal medulla microsomes has been confirmed
by many studies but enzymatic biosynthesis of PGA2 could not be demon¬
strated in rabbit kidney microsomes (Blackwell, Flower and Vane, 1975)
and GC-MS analysis did not detect PGA2 in either the medulla or cortex
of rabbit kidney (Larsson and Anggard, 1976). Since PGE2 dehydrates
rapidly to PGA2, it is probable that the previously identified PGA2 was
formed artifactually from PGE2 during the isolation procedure. PGD2
has been detected following incubation of rabbit kidney microsomes with
arachidonic acid (Blackwell et al., 1975) .
Although it was originally thought that the renal cortex was unable
to synthesise prostaglandins (Crowshaw and Szlyk, 1970), it was later
demonstrated that rabbit cortical microsomes had a small capacity to
synthesise PGE2 (Anggard, Bohman, Griffin, Larrson and Maunsbach,
1972). Further dissection of the kidney revealed that prostaglandin
synthesising capacity increased from the cortex towards the inner medulla
(Larsson and Anggard, 1973). Within the medulla, histochemical and
immunochemical localisation of prostaglandin synthetase demonstrated
highest enzyme activity to be localised in the collecting tubules with
less activity in the medullary interstitial cells (Janszenand Nugter.eu ,
1971; Smith and Wilkin, 1977).
6.
Zenser et al. identified 6-keto-PGFiCx , reflecting PGI2, in homo-
genates of rat renal cortex following incubation with PGH2 but only
negligible traces were found in the medulla (Zenser, Herman, Gorman
and Davis, 1977). Rabbit cortical microsomes, incubated with either
PGH2 or arachidonic acid were found to synthesise PGI2 whilst the medul¬
lary microsomes synthesised almost exclusively PGE2 (Whorton, Smigel,
Oates and Frolich, 1978). These studies led to attempts to compartment¬
alise renal prostaglandins into a PGI2-vascular component and a PGE2-
tubular component. However, subsequent experimental evidence has
not supported this theory. In rabbits the medulla has a greater capacity
to synthesise a PGI2-like substance than does the cortex (Silberbauer
and Sinzinger, 1978). With a GC-MS technique, Oliw et at. found high
levels of 6-keto-PGFxa accumulated in cortex, medulla and papillae of
post mortem rabbit kidney. Although the papillae 6-keto-PGFia level
was highest, the cortex contained five times more 6-keto-PGFxa than
it did PGE2 and PGF2a (Oliw, Lunden, Sjoquist and Anggard, 1979).
Homogenates of isolated rabbit collecting tubule cells produced predom¬
inantly 6-keto-PGFxa unless incubated with arachidonic acid when PGE2
was the major prostaglandin formed (Grenier and Smith, 1978). Contrary
to thi^ cultured rabbit collecting tubule cells synthesised predominantly
PGE2 irrespective of incubating conditions (Grenier, Rollins & Smith,
1981; Schlondorff, Zanger, Satriano, Folkert and Eveloff, 1982). Sun
et al. demonstrated that 6-keto-PGFxa could only be detected when rabbit
cortical and medullary microsomes were prepared under an atmosphere
of argon to prevent inactivation of the PGI2 synthetase by organic
peroxides (Sun, Taylor, McGuire and Wong, 1981). Under these conditions,
the medullary microsomes produced more PGI2 than the cortical microsomes.
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Within the cortex, immunohistochemical localisation of the prosta¬
glandin synthetase has revealed the highest enzyme activity to be in
theendothelial cells of the arteries and arterioles with lesser activity
in the epithelial cells of the collecting tubules (Smith and Bell, 1978).
The prostaglandin synthetase activity of the cortical collecting tubules
was found to be less than in the medullary collecting tubules. Terragno
et al. demonstrated that the arteries and arterioles isolated from pig
kidney cortex by microdissection had a high capacity for PGI2 biosynthesis
(Terragno, McGiff and Terragno, 1978). Cultured rat glomerular epithel¬
ial and mesangial cells produce primarily PGE2 (Petrulis, Aikawa and
Dunn, 1981; Scharschmidt and Dunn, 1983). Incubation of these cells
with arachidonic acid preferentially stimulates PGE2 synthesis. Some
investigators using post mortem rat isolated glomeruli have found PGE2
to be the major prostaglandin produced ( Sraer, Sraer, Chansel, Rusio-
Marie, Kouznetzora and Ardoullou, 1979; Sraer, Siess, Moulonquet-
Doleris, Oudinet, Dray and Ardoullou, 1982) whilst others found PGI2
and PGF2a to be the principal prostaglandins synthesised (Schlondorff,
Roczniak, Satriano and Folkert, 1980; Kreisberg, 1982). Although
TxA2 was thought to be, produced in the kidney only in conditions
of renal damage (Morrison, Nishikawa and Needleman, 1977), several
studies have identified TxB2 in glomerular homogenates (Hassid et a I. ,
1979; Sraer et al., 1982; Petrulis et al., 1981).
There have been few studies on renal prostaglandin production in
the dog or human. Satoh and Satoh demonstrated that dog cortical and
medullary microsomes synthesised predominantly PGI2 but that the addition
of glutathione to the incubation increased PGE2 production at the expense
of PGI2 (Satoh and Satoh, 1980). A recent study investigating prosta¬
glandin production by dog renal artery, vein, cortex and outer and inner
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medulla demonstrated that in all zones, PGI2 production was higher
than that of PGE2 or PGF2 a. The vessels synthesised almost exclusively
PGI2 but the inner medulla had the highest capacity to synthesise PGI2
(Okahara, Imanishifc Yamamoto, 1983). Human cortical and medullary
microsomes incubated with arachidonic acid were found to synthesise
PGI2 and PGF2awith very little PGE2. The medulla showed a greater
synthetic capacity than the cortex (Hassid and Dunn, 1980).
The literature has demonstrated qualitative and quantitative in¬
consistencies in prostaglandin production by different regions of the
kidney and by different animal species. These inconsistencies most
probably arise from differences in the in vitro experimental conditions.
It seems likely that medulla and cortex contain isomerases for the produc¬
tion of PGE2 and PGI2. These two enzymes, however, have wide dif¬
ferences in substrate affinity and cofactor requirements. Therefore,
any difference in substrate concentration, incubation time, or the
presence of cofactors used in each study may lead to differences in
prostaglandin product distribution. Furthermore, if the cyclooxygenase
in an enriched tissue such as the kidney medulla, is allowed to operate
at optimal conditions, the endoperoxide generated may be more than
its isomerases can consume. The excess will randomly decompose to
PGE2, PGF2 a and PGD2. This may explain why in several studies the
production of PGE2 and PGF2a was apparently much higher than that
of PGI2. It is possible that in vivo, the endoperoxide metabolising enzymes
are coupled with specific cyclo-oxygenases for efficient and rapid conver¬
sion of released arachidonic acid to specific products.
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1.3 Metabolism and Urinary Excretion of Prostaglandin
PGE2 and PGF2ct have a half-life of less than 30 seconds in the
bloodstream due to their rapid degradation by the enzymes 15-hydroxy-
prostaglandindehydrogenase and prostaglandin 13a reductase. Oxidation
of the 15-OH group to the corresponding 15-keto group by 15-hydroxy
dehydrogenase is the first step in prostaglandin degradation and, in
general, the 15-keto metabolites have only io th the biological activity
of the parent prostaglandin (Pike, Kupiecki and Weeks, 1967). Highest
15-hydroxyprostaglandin dehydrogenase activity has been demonstrated
to be in the lung, renal cortex and spleen (Anggard, Larsson and
Samuellsson, 1971; Larsson and Anggard, 1973) and more than 90% of
intravenously infused PGE2 or PGF2a is removed in one circulation through
the lungs (Ferreira and Vane, 1967). Highest prostaglandin 13a reductase
activity is found in the adipose tissue, spleen, renal cortex and liver
(Anggard et a!., 1971). In man, the main PGE2 and PGF2a metabolites
in the blood are 15-keto-13,14-dihydro-PGE2 and 15-keto-13,14-dihydro-
PGF2a (Hamberg and Samuellsson, 1971; Granstrom, 1972). Further
steps in the metabolic pathway proceed at a comparatively slower rate.
The 15-keto-13,14-dihydro metabolites are transformed by a series of
6 -oxidation and w-oxidation reactions into a number of more polar
derivatives which are excreted in the urine and faeces. The g-oxidation
processes occur in the liver (Hamberg, 1968). kidney and lung (Nakano
and Morsy, 1971). PGE and PGF metabolites, differing in the degrees
of g-oxidation and oj-oxidation have been identified in the urine, and
in man, the major urinary metabolites of PGE2 and PGF2a are 7a-hydroxy-
5,11-diketo-tetranor-prostane-l, 16-dioic acid and 5a, 7a ,dihydroxy-ll-
keto-tetranor-prostane-1,16-dioic acid, respectively (Hamberg and
Samuelsson, 1971; Granstrom and Samuelsson, 1971).
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PGE2 and PGF2a can also be interconverted enzymatically within
the kidney. A 9-keto-reductase has been isolated in rabbit renal cortex
which reduces PGE2 to PGF2a (Stone and Hart, 1975). The activity
of this enzyme is thought to be positively correlated to sodium intake
(Weber, Larsson and Scherer, 1977). A 9-hydroxy prostaglandin
dehydrogenase has also been isolated from mammalian renal cortex (Pace-
Asciak, 1975; Moore and Hoult, 1978). This enzyme oxidises 15-keto-
13,14-dihydroPGF2a to 15-keto-13,14-dihydroPGE2 in most species but
has only been shown to oxidise PGF2 a directly to PGE2 in rabbit kidney
(Hoult and Moore, 1977). The physiological significance of these inter-
conversions between PGE2 and PGF2ct remains unclear.
The high capacity of the lung and kidney to metabolise prosta¬
glandins leaves little opportunity for PGE2 or PGF2a in the circulation
to enter'the urine in an unmetabolised form. Intact PGE2 and PGF2a in
the urine has been demonstrated to be of renal origin (Frolich, Wilson,
Sweetman, Smigel, Nies, Carr, Watson and Oates, 1975) and measurement
of urinary PGE2 and PGF2a levels taken to reflect solely renal synthesis
of the prostaglandins. Infusion of large quantities of PGE2 or PGF2a
into the renal artery results in the appearance of these prostaglandins
in the urine. They enter the urine primarily by secretion via the organic
acid pathway in the proximal tubule and also by filtration at the glomerulus
(Rennick, 1977; Rosenblatt, Patak and Lifschitz, 1978). However,
substantial amounts of the prostaglandins infused into the kidney are
metabolised prior to excretion presumably due to ready access to cortical
structures through the glomerular and peritubular capillaries. Using
a stop-flow technique, Williams et at. demonstrated that endogenous
PGE2 and PGF2a enters the nephron distal to the proximal tubule and
suggests that the loop of Henle is the major site of entry of PGE2 and
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PGF2ct into the urine (Williams, Frolich, Nies and Oates, 1977). It
seems likely, therefore, that PGE2 and PGF2a synthesised in the renal
medulla enter the nephron at the loop of Henle and are excreted in the
urine unmetabolised. PGE2 and PGF2ct reaching the kidney via the renal
artery are mostly metabolised in the renal cortex. However, they may
enter the urinary space by filtration at the glomerulus and secretion
in the proximal tubule.
PGI2 is a good in vitro substrate for 15-hydroxyprostaglandin-
dehydrogenase (McGuire and Sun, 1978). However, in vivo, 35-65%
of an infusion of PGI2 escapes inactivation in one complete circulation
(Dusting, Moncada and Vane, 1978). Infusion of PGI2 through the liver
or hindlimb results in partial inactivation similar to that demonstrated
with PGE2. However, infusion of PGI2 through the lung does not result
in inactivation. It has therefore been proposed that PGI2 is a poor
substrate for the lung uptake mechanism. It was originally thought that
6-keto-PGFict, the stable hydrolysis product of PGI2, was not a substrate
for 15-hydroxyprostaglandindehydrogenase (McGuire and Sun, 1978).
However, the presence of monoketo and diketo metabolites in rat urine
following both PGI2 and 6-keto-PGFia infusion, suggests that although
6-keto-PGF]a is a poor substrate, it does undergo ISstehydrogenation
(Sun and Taylor, 1978; Sun, Taylor, Sutter and Weeks, 1979).
PGI2 is metabolised by the blood vessels (Wong, Sun and McGiff,
1978), kidney (Wong, McGiff, Cagen, Malik and Sun, 1979) and liver
(Wong, Malik, Desiderius, McGiff and Sun, 1980). The blood vessels
are very rich in 15-hydroxyprostaglandindehydrogenase and the main
metabolic product of PGI2 is 6,15-diketo-PGFia. In the kidney, there
are two metabolic pathways; (1) PGI2 is hydrolysed to 6-keto-PGFia
which is then g-oxidised to 2,3-dinor-6-keto-PGFia and (2) PGI2 and/or
12.
FIGURE 1.3: Main urinary metabolites of PGI2.
1. 6-keto-PGFxa.
2. 2,3-dinor-6-keto-PGF;ia.







6-keto-PGFia are metabolised by 15-hydroxyprostaglandindehydro-
genase and prostaglandin 13A reductase to 6,15-diketo-13,14-dihydro-
PGFict which is then g-oxidised to 2,3-dinor-6,15-diketo-13,14-dihydro-
PGFia. In the liver, there is very little 15-hydroxyprostaglandindehydro-
genase and metabolism takes place primarily by g oxidation and oj hydroxy-
lation and oxidation. A 9-hydroxy prostaglandin dehydrogenase has
been isolated in rabbit liver and human platelets which converts PGI2
and/or 6-keto-PGFxa to 6-keto-PGEx (Wong, Lee, Reiss and McGiff,
1980; Grans and Wong, 1981). This enzyme is not the same one that
converts PGF2a to PGE2 in the rabbit renal cortex. 6-keto-PGEi has
similar biological activity to PGI2 (Quilley, Wong and McGiff, 1979).
Urinary metabolic profiles of PGI2 have been determined in the
rat (Sun and Taylor, 1978), monkey (Sun and Taylor, 1981), and in
man (Rosenkranz, Fischer, Weimer and Frolich, 1980). Up to twelve
different metabolites of PGI2 have been identified in the urine and
although the same metabolites have been identified in all three species
the relative proportions of the different metabolites varies. The main
urinary metabolites of PGI2 are shown in Figure 1.3. In the rat, the
primary metabolic pathway appeared to be via|grdehydrogenation followed
by substantial g and w oxidation and the main urinary metabolite was
2,3,19,20-tetranor-6,15-diketo-13,14-dihydro- 18-carboxyl-PGFxa • No
unchanged 6-keto-PGFxa was detected but 2,3-dinor-6-keto-PGFxa and
2 , 3-dinor-19-hydroxy-6-keto-PGFxa also represented major urinary
metabolites indicating that some PGI2 was hydrolysed to 6-keto-PGFiCi
without prior 15-hydrogenation. In the monkey and in man ,ISdehydrogena-
tion appears to play only a small role in the metabolism of PGI2 , the
major metabolic pathway being hydrolysis to 6-keto-PGFx<x followed by
g -oxidation and 19 or 20 hydroxylation and oxidation to the dicarboxylic
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acid. In the monkey, unchanged 6-keto-PGFxa represents the main
urinary metabolite of PGI2 whilst in the human, 2,S-dinor-6-keto-PGFxa
and 2,3-dinor-6,15-diketo-13,14-dihydro-20-carboxyl-PGFxa are the
main metabolites of PGI2 in the urine.
Circulating 6-keto-PGF1a can be excreted unchanged into the urine
(Sun et at., 197 9;Rosenkranz et.al.l980a) and appears to be freely filtered
at the glomerulus (Rosenkranz, Kitajima and Frolich, 1981a). Pretreat-
ment with probenecid has no effect on the urinary excretion of 6-keto-
PGFxct suggesting that, unlike PGE2 and PGF2a, it is not secreted into
the tubule via an organic acid pathway (Rosenkranz et a I. , 1981). How¬
ever, no studies on other tubular secretory pathways have been
performed and it is possible that in addition to glomerular filtration
6-keto-PGFxa enters the urine at a site distal to the proximal tubule.
1.4 Prostaglandins and Renal Function
Infusion of PGEi and PGE2 into the renal artery of anaesthetised
dogs results in dose-dependent increases in renal blood flow, sodium
excretion, urine volume and free water clearance. There is no change
in glomerular filtration rate and variable change in potassium excretion
(Vander, 1968; Stranhoy, Ott, Schneider, Willis, Beck, Davis and
Knox, 1974). PGD2 also increases renal blood flow when infused into
the renal artery of anaesthetised dogs but has no consistent natriuretic
or diuretic action (Fresinger , 1977; Bolger, Eisner, Shea,
Ramwell and Slotkoff, 1977). In contrast, intrarenal infusion of PGF2a
has no consistent effect on renal blood flow or sodium and water excretion
(Gross and Bartter, 1973). Infusion of arachidonic acid into the renal
artery results in a detectable increase in prostaglandin levels in renal
venous blood and increases renal blood flow, sodium excretion and urine
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volume (Tannenbaum, Splawinski, Oates and Nies, 1975). Similar changes
in renal function can be obtained following infusion of the prostaglandin
endoperoxides PGH2 and PGG2 into the renal artery (Oliver, Sciacca
and Cannon, 1979). Arachidonic acid and prostaglandin endoperoxides
are, however, much less potent than exogenous PGE2 in increasing renal
blood flow. The reasons for these differences are most likely related
to differences in access to sites of action. PGE2 infused into the renal
artery has direct access to the pre- and postglomerular resistance vessels
and peritubular capillaries of all nephrons. However, PGE2 is synthesised
from arachidonic acid primarily in the renal medulla and is therefore
only likely to affect the vessels of the juxtamedullary nephrons.
A reduction in p-aminohippurate extraction during intrarenal
»
PGE2 infusion suggested a redistribution of intrarenal . blood flow (Vander,
1968; Gross and Bartter, 1973) and radioactive microsphere techniques
have demonstrated that intrarenal infusion of PGE2 or arachidonic acid
causes a redistribution of blood flow towards the juxtamedullary cortex
(Chang, Splawinski, Oates and Nies, 1975; Larsson and Anggard, 1974).
Whilst such changes in renal haemodynamics could result in increased
sodium excretion, there is evidence to suggest that PGE2 may exert
a direct action on the renal tubule to inhibit sodium reabsorption.
Infusion of low concentrations of PGE2 which do not increase renal plasma
flow, still induce a natriuresis (Vander, 1968). Using in vivo micro-
puncture techniques, PGE2 was demonstrated to have no effect on sodium
transport in the rat proximal tubule or loop of Henle but to decrease
fractional sodium reabsorption along the distal nephron (Fulgraff and
Meiforth, 1971). Using in vitro microperfusion techniques, PGE2 was
found to inhibit sodium transport in medullary and cortical collecting
tubules of both normal and DOCA-salt loaded rabbits (Stokes and Kokko,
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1977; lino and Imai, 1978). PGE2 was also found to inhibit chloride
transport in the medullary thick ascending limb of Henle" but not in the
cortical thick ascending limb (Stokes, 1979). Contrary to this, Fine
and Trizna were unable to demonstrate any effect of PGE2 on rabbit
isolated medullary collecting tubules or medullary thick ascending limbs
of Henle (Fine and Trizna, 1977). Part of the discrepancy between
these studies may be due to differences in experimental techniques and/
or due to the heterogenecity of nephron segments. The question as
to whether PGE2 has a direct effect on the renal tubule to inhibit sodium
reabsorption, remains unresolved.
The diuresis during intrarenal.^ PGE2 infusion is associated with
an increase in free water clearance and decrease in fractional water
reabsorption (Gross and Bartter, 1973; Tannenbaum ef al., 1975).
This may be related to changes in medullary blood flow resulting in
decreased proximal sodium reabsorption, increased delivery of sodium
to the distal tubule and increased sodium reabsorption in the distal tubule
with increased free water clearance. Alternatively, water excretion
may be increased by direct antagonism of vasopressin-mediated water
transport. Vasopressin increases water permeability by increasing cyclic
AMP formation and accumulation within the epithelial cell. PGEX has
been shown to inhibit the water permeability response to vasopressin
but not to exogenous cyclic AMP in isolated rabbit collecting ducts
(Grantham and Orioff, 1968). PGEi also reduces the accumulation of
cyclic AMP in renal medulla slices exposed to vasopressin (Beck, Kaneto,
Zeor, Field and Davis, 1971). Studies demonstrating that inhibition
of prostaglandin synthesis with indomethacin enhanced the water per¬
meability and medullary cAMP response to low concentrations of vaso¬
pressin (Anderson, Berl, McDonald andSchrier, 1975; Lum, Aisenbrey,
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Dunn, Berl, Schrier and McDonald, 1977) together with the demonstra¬
tion that PGE2 was the major prostaglandin synthesised by the renal
medulla (Larrson and Anggard, 1973) suggested that PGE2 may be
important in antagonising the actions of vasopressin. However, PGE2
failed to inhibit an increase in cAMP in a rat medullary collecting tubule
cell preparation incubated with vasopressin (Jackson, Edwards and
Dousa, 1980). This lack of effect of PGE2 may have been due to a
biphasic action of PGE2 on adenyl cyclase since it has been demonstrated
that low concentrations of PGE2 inhibit while high stimulate adenyl cyclase
activity (Kather and Simon, 1979). However, PGE2, over a range of
concentrations, stimulated basal water permeability in isolated rat
papillary collecting ducts (Ray and Morgan, 1981). The ability of PGE2
to stimulate water permeability was much less than that of vasopressin
and their effects were found not -to be additive. It was therefore
postulated that PGE2 may act as a competitive partial agonist for vaso¬
pressin with weaker intrinsic effect. The evidence towards an action
of PGE2 to antagonise the effects of vasopressin remains unconvincing.
Infusion of PGI2 into the renal artery of anaesthetised dogs results
in an increase in total renal blood flow and a redistribution of blood
flow away from the outer cortex to the juxtamedullary area. There
is no change in glomerular filtration rate, therefore filtration fraction
decreases. Intrarenal infusion of PGI, also increases sodium and potas¬
sium excretion but, unlike PGE2, has no effect on free water clearance
(Bolger, Eisner, Ramwell and Slotkoff, 1978; Gerber, Nies, Friesinger,
Gerkens, Branch and Oates, 1978b; Hill and Moncada, 1979). Although
Bolger et al. found PGI, and PGE2 to be equipotent in causing renal
vasodilatation, a comparison of the dose-response relationships of PGI2
and PGE2 infused into the renal artery of salt-loaded and salt-depleted
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anaesthetised dogs revealed that PGE2 was up to three times more potent
than PGI2 in increasing renal blood flow (Jones, Watson and Ungar,
1981). PGE2 was also more potent than PGI2 in increasing urine flow,
sodium and potassium excretion and free water clearance. It is interest¬
ing to note that arachidonic acid infused into the renal artery is also
less potent than PGE2 in causing vasodilatation and natriuresis
(Tannenbaum ef al., 1975). It may be that although PGE2 is the more
active prostaglandin, arachidonic acid in the kidney is converted prefer¬
entially to PGI2.
There is some evidence to suggest that the natriuresis caused by
intrarenal PGI2 infusion is due to a direct effect of PGI2 on the nephron.
An increase in solute delivery to the distal tubule and a decrease in
distal tubular sodium reabsorption has been demonstrated during intra-
renal PGI2 infusion in anaesthetised dogs (Gullner, Nicolaou and Bartter,
1980). However, these changes in sodium reabsorption may also be
the consequence of alterations in renal haemodynamics during the PGI2
infusion. An in vitro study demonstrated that PGI2 could decrease
sodium reabsorption in isolated rabbit cortical collecting ducts (lino
and Brenner, 1981). It seems likely, however, that the natriuresis
is due, at least in part, to the increase in total renal blood flow and
redistribution of intrarenal blood flow observed during PGI2 infusion.
Since, unlike PGE2 , PGI2 did not increase free water clearance, it is
unlikely that PGI2 antagonises the actions of vasopressin on the collect¬
ing duct.
A change in the loop of Henle flow rate of a single nephron induces
an inverse change in glomerular filtration rate, a phenomenon generally
referred to as tubuloglomerular feedback. This feedback response is
blunted during inhibition of prostaglandin synthesis by indomethacin
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(Schnermann, Schubert, Hermle, Herbst, Stowe, Yarimizu and Weber,
1979). Both PGI2 and PGE2 are capable of reversing the inhibition of
the feedback response (Schnermann and Weber, 1982) but since PGI2
is ten times more potent in its effect and is the major arachidonate
metabolite in the cortex, it may be the main prostaglandin involved in
the tubuloglomerular feedback mechanism. Other investigators, infusing
PGI2 without prior indomethacin failed to demonstrate an effect on tubulo¬
glomerular feedback and at high concentrations of PGI2, an attenuation
of the feedback response was demonstrated (Boberg, Hahne and Persson,
1981). However, this attenuation was associated with a fall in systemic
blood pressure and was thought to be a consequence of a PGI2-induced
change in vascular tone rather than a specific influence on the feedback
pathway.
6-keto-PGFid, the stable hydrolysis product of PGI2, has no effect
on renal blood flow (Hill and Moncada, 1979). However, the stable PGI2
metabolite, 6-keto-PGEx, has been found to be equipotent with PGI2
in increasing renal blood flow when infused into the renal artery of
anaesthetised rats and dogs (Quilley et al. , 1979; Jackson, Herzer,
Zimmerman, Branch, Oates and Gerkens, 1981). This has led to the
proposal that 6-keto-PGE-| may be responsible for some of the biological
actions of infused PGI2. However, an intravenous infusion of PGI2
into human subjects which caused systemic haemodynamic changes, did
not alter plasma levels of 6-keto-PGEi (Jackson, Goodman, Fitzgerald,
Oates and Branch, 1981). It is therefore unlikely that 6-keto-PGE i is
responsible for the renal'vasodilatation observed during PGI2 infusion.
Renal prostaglandin synthesis increases during conditions such
as renal ischaemia (McGiff, Crowshaw, Terragno, Lonigro, Strand,
Williamson, Lee and Ng , 1970) and repeated renal nerve stimulation
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(Dunham and Zimmerman, 1970) and in response to vasoactive peptides
such as bradykinin (McGiff, Terragno, Malik, Lonigro, 1973) and
angiotensin II (McGiff, Crowshaw, Terragno and Lonigro, 1970a). Under
these conditions, prostaglandins are thought to help maintain renal blood
flow. Evidence for a role of basal prostaglandin production in the control
of renal haemodynamics and electrolyte excretion under normal conditions
is conflicting.
Inhibition of prostaglandin synthesis by indomethacin or meclofen-
amate in the anaesthetised lapQrotamised dog results in a reduction
in renal blood flow (Lonigro, Itskovitz, Crowshaw and McGiff, 1973).
However, in the conscious dog at rest, indomethacin or meclofenamate
administration has no effect on renal blood flow (Terragno, Terragno
and McGiff, 1977; Zimmerman, 1978). When the renin-angiotensin system
is stimulated by sodium depletion, inhibition of prostaglandin synthesis
by indomethacin or meclofenamate in the conscious dog results in a reduc¬
tion in renal blood flow (Blasingham, Shade, Share and Nasjletti, 1980;
De Forrest, Davis, Freeman, Seymour, Rave, Williams and Davis, 1980).
This suggests that prostaglandins only contribute to the control of renal
blood flow during activation of the renin-angiotensin system. Investiga¬
tions into the effect of prostaglandin synthesis inhibition on sodium
excretion have produced similarly conflicting results. Administration
of indomethacin or meclofenamate to conscious sodium replete dogs has
been reported to increase, decrease or have no effect on sodium excretion
(Kirschenbaum and Stein, 1976; Fejes-Toth, Mahyar and Walker, 1977;
Zambraski and Dunn, 1979). The effect of prostaglandin synthesis
inhibition on sodium excretion is not altered by sodium status since
sodium excretion was unchanged following indomethacin or meclofenamate
administration in both sodium replete and deplete conscious dogs
(Blasingham et at. , 1980a; De Forrest et at. , 1980).
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It would seem, therefore, that although exogenous infusion of
prostaglandins, namely PGE2 and PGI2, significantly influences renal
blood flow and sodium excretion, the physiological importance of the
endogenous production of these prostaglandins remains unclear.
1.5 Prostaglandins and the Renin-Angiotensin System
7. 5. 7 Prostaglandins and renin release
The demonstration by Strong et al. that the renin and prosta¬
glandin content were elevated in the ischaemic half of a kidney from
a woman with renovascular hypertension suggested that prostaglandins
may participate in the control of renin release (Strong, Boucher,
Nowaczynski and Genest, 1966). Although Vander failed to demonstrate
any effect of an intrarenal infusion of PGEi or PGE2 on plasma renin
activity in the anaesthetised dog (Vander, 1968), Werning et at. using
a similar preparation observed an increase in plasma renin activity
following infusion of PGEi into the renal artery (Werning, Vetter,
Weidmann, Schweikert, Stiel and Siegenthager, 1971). Infusion of
arachidonic acid into the renal artery or the lower aorta of the anaes¬
thetised rabbit, rat or dog results in an increase in plasma renin activity
which can be prevented by prior administration of indomethacin (Larsson,
Weber and Anggard, 1974; Weber, Holzgreve, Stephan and Herbst,
1975; Bolger, Eisner, Ramwell and Slotkoff, 1976). Several studies
have demonstrated that PGE2 infused into the renal artery of anaesthet¬
ised dogs results in an increase in plasma renin activity (Yun, Kelly,
Bartter and Smith Jr., 1977; Osborn, Noordeiner, Hook and Bailie,
1978).. Bolger et al. demonstrated that PGD2 was equipotent with PGE2
in increasing plasma renin activity when infused intrarenally in the
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anaesthetised dog (Bolger et al., 1977). Gerber et al. failed to observe
any effect of PGD2 on plasma renin activity but showed that PGI2 infused
into the renal artery of anaesthetised dogs was twice as active as PGE2
in increasing renin release (Gerber, Branch, Nies, Gerkens, Shand,
Hollifieldand Oates, 1978a). The action of intrarenal and intravenous
infusion of PGI2 to increase plasma renin activity has been confirmed
in both animals and man (Jones et a/., 1981; Patrono, Pugliese,
Ciabattoni, Maseri, Chierchia, Peskar, Cinotti, Simonetti and Pierucci,
1982). A role for prostaglandins in the control of renin release has
also been implied from studies demonstrating that indomethacin administra¬
tion decreases basal plasma renin activity in man (Rumpf, Frenzel, Lowitz
and Scheler, 1975; Frolich, Hollifield, Dormais, Frolich, Seyberth,
Michelakis and Oates, 1976), conscious rabbits (Romero, Dunlop and
Strong, 1976), rats (Suzuki, Franco-Saenz, Tan and Mulrow, 1981&)
and in anaesthetised dogs (Seymour and Zehr, 1979). However, no
effect of indomethacin could be demonstrated in conscious dogs
(Blasingham et al •, 1980b).
Since infusion of arachidonic acid or prostaglandins into the renal
artery also results in changes in renal haemodynamics and electrolyte
excretion, isolated renal preparations have been used to study the direct
effect of prostaglandins on renin release. Incubation of low concentra¬
tions of PGE2 with a rabbit cortical cell preparation resulted in an in¬
crease in renin release although higher concentrations of PGE2 had no
effect. Incubation with PGF2a resulted in an inhibition of renin release
(Dew and Michelakis, 1974). Similarly, PGF2a caused a dose-dependant
inhibition of renin release when incubated with rabbit renal cortical
slices (Weber, Larsson, Anggard, Hamberg, Corey, Nicolaou and
Samuelsson, 1976). PGE2 failed to have any effect on renin release
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in this preparation although incubation of the cortical slices with either
arachidonic acid or the endoperoxide PGG2 resulted in an increase in
renin release. Whorton et al. also failed to demonstrate any effect on
renin release during incubation of rabbit renal cortical slices with PGE2
but showed that incubation with PGI2 resulted in a large increase in
renin release (Whorton, Misono, Hollifield, Frolich, Inaganii and Oates,
1977). Later studies, however, demonstrated PGE2 to be equipotent
with PGI2 in increasing renin release in rabbit and rat renal cortical
slices and PGF2cc and PGD2 to be inactive or weak agonists at high con¬
centrations (Whorton, Lazar, Smigel and Oates, 1981; Suzuki et al.,
1981b). 6-keto-PGFia has no effect on renin release either in vitro
(Whorton et al. , 1977) or in vivo (Jackson et al., 1980) but the enzym-
atically produced PGI2 metabolite, 6-keto-PGEi has been demonstrated
to be more potent than PGI2 in increasing renin release when infused
into the renal artery of anaesthetised dogs (Jackson et al., 1980),
incubated with rabbit renal cortical slices (McGiff, Spokas and Wong,
1982) or infused into the isolated rat or rabbit kidney (Schwertschlag,
Stahl and Hackenthal, 1982). The degree to which PGI2 is metabolised
to 6-keto-PGEi in the kidney in vivo is not known and therefore the
physiological significance of the renin secretory activity of 6-keto-PGEi
remains undefined. Since PGI2 is the predominant prostaglandin
synthesised in the renal cortex and has been shown to consistently
increase renin release in both in vivo and in vitro preparations, it seems
probable that it is this arachidonate metabolite which is most closely
involved in the control of renin release.
Results from the isolated renal tissue studies demonstrated that
prostaglandins could increase renin release by a direct effect on the
juxtaglomerular cells. Other studies were undertaken to determine which
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of the known intrinsic mechanisms of renin release were mediated by
prostaglandins.
There are essentially three intrinsic mechanisms for renin release
from the mammalian kidney (for review see Davis and Freeman, 1976).
The renal vascular baroreceptor located in the afferent arteriole senses
changes in either renal perfusion pressure or vascular wall tension to
alter renin release such that a decrease in perfusion pressure increases
renin release. The macula densa, located at the distal end of the cortical
thick ascending limb of the loop of Henle' modulates renin release in
response to alterations in the distal delivery of sodium chloride. There
was originally controversy as to whether renin release was directly or
inversely related to sodium transport at the macula densa. It is now
accepted that a decrease in the distal tubular delivery of sodium chloride
results in renin release, whereas an increase in distal tubular delivery
of sodium chloride results in an inhibition of renin release. The afferent
and efferent arterioles and the juxtaglomerular cells of the kidney are
innervated by sympathetic fibres. The sympathetic nervous system
participates in the release of renin such that stimulation of renal sym¬
pathetic nerves results in an increase in renin release. Renal nerve
activity is controlled by several neural arc reflexes and accelerated
renal sympathetic nerve activity has been implicated as a cause for the
increased renin release that accompanies upright posture, exercise and
psychosocial stimuli. The increase in renin release following renal
sympathetic nerve stimulation is thought to be due primarily to the action
of noradrenaline on 3-adrenergic receptors. The role of a-adrenergic
receptors in the control of renin release in response to renal sympathetic
nerve stimulation is controversial. Some studies have demonstrated
an increase in renin release in response to a-adrenergic activation
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(Hong, 1980) and an inhibition by phentolamine of the increase in plasma
renin activity after renal nerve stimulation (Cootes, Johns, MacLeod
and Singer, 1972). Other investigators have failed to observe any effect
of a-adrenergic receptor antagonists on the sympathetically mediated
increase in renin release (Ganong, 1973) and in vitro studies have sug¬
gested that renal a-adrenergic stimulation may inhibit renin release
(Vandongen and Peart, 1974).
Data et aI. used an anaesthetised dog model to demonstrate a role
for prostaglandins in the renal baroreceptor control of renin release
(Data, Gerber, Crump, Frolich, Hollifield and Nies, 1978). In this
model the renal baroreceptor is isolated from the macula densa and
sympathetic rftechanisms of renin release. Ligation of the ureter and
occlusion of the renal artery of one kidney for two hours, two days
before the study renders that kidney non-filtering, the contralateral
kidney being excised on the day of the study. In the non-filtering
kidney, the macula densa is not functional due to the cessation of tubular
fluid flow. The effects of the sympathetic system and circulating
catecholamines on renin release were abolished by renal denervation
and a continuous infusion of propranolol. Under these conditions, the
increase in plasma renin activity following a decrease in renal perfusion
pressure due to supra-renal aortic constriction was completely inhibited
by indomethacin. This suggested that prostaglandin synthesis was
necessary for the increase in renin release following stimulation of the
renal baroreceptor. These results were confirmed by Berl et al. who
also demonstrated that prostaglandin synthesis inhibition prevented
an increase in plasma renin activity following supra-renal aortic constric¬
tion (Berl, Henrich, Erickson and Schrier, 1979). These studies indicate
that prostaglandins are involved in the baroreceptor mechanism of renin
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release, but they give no indication as to which prostaglandins are
important. In an anaesthetised uninephrectomised dog model, in which
the remaining kidney was denervated and non-filtering, infusion of
PGI2, PGE2 or 13,14-dihydro-PGE2 into the renal artery resulted in
an increase in renal blood flow and plasma renin activity (Gerber, Keller
and Nies, 1979). PGI2 was more potent than PGE2 although the PGE2
metabolite, 13,14-dihydro-PGE2 was found to be most potent in increas¬
ing plasma renin activity. An intrarenal infusion of papaverine resulted
in a similar increase in renal blood flow but had no effect on plasma
renin activity indicating that prostaglandins were having an effect on
renin release which was independent of their renal vasodilator activity.
It would seem, however, that prostaglandins are only important in the
renal baroreceptor mechanism of renin release when the drop in renal
perfusion pressure is within the renal autoregulatory range. Blackshear
et al. demonstrated that whilst indomethacin prevented an increase in
renin release in response to a decrease in perfusion pressure which
was within the autoregulatory range, if perfusion pressure was lowered
such that it was accompanied by a decrease in renal blood flow, indo¬
methacin failed to prevent an increase in renin release (Blackshear,
Spielman, Knox and Romero, 1979). Thus whilst prostaglandins may
be necessary for increased renin release upon stimulation of the renal
baroreceptor by a moderate reduction in renal perfusion pressure, when
perfusion pressure is lowered below the autoregulatory range, the renal
baroreceptor and/or some secondary mechanism is capable of stimulating
renin release independent from prostaglandin synthesis. This prosta-
glandin-independent mechanism of renin release in response to a large
drop in perfusion pressure may explain why other investigators have
failed to observe any effect of indomethacin on the increased plasma renin
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activity following a 50% reduction in renal perfusion pressure in un-
inephrectomised renal d enervated anaesthetised dogs (Seymour and
Zehr, 1979).
Dietary sodium deprivation is associated with a decrease in early
distal tubular sodium delivery which results in a macula densa mediated
increase in renin release. Initial studies investigating the role of prosta¬
glandins in the macula densa mechanism of renin release failed to demon-
state any effect of indomethacin on the increase in plasma renin activity
in response to sodium deprivation in either humans or conscious dogs
(Norbiato, Bevilacqua, Raggi, Micossi, Moroui and Fasoli, 1978; Opgenorth,
Wappel and Zehr, 1980). However, it was later demonstrated that if
3-adrenergic activity was blocked with propranolol, indomethacin administra¬
tion resulted in a decrease in plasma renin activity in both sodium depleted
humans and conscious dogs (Frolich, Hollifield, Michelakis, Vesper,
Wilson, Shand, Seyberth, Frolich and Oates, 1979; De Forrest et al.,
1980). This suggested that in addition to the macula densa mechanism
of renin release, which may be mediated by prostaglandins, sympathetic
nerve activity also contributed to the increased renin release during
sodium deprivation by a mechanism independent of prostaglandin synthesis.
In an anaesthetised, uninephrectomised dog model, in which the remaining
kidney was denervated and infused with propranolol and the renal baro-
receptor was inactivated by an infusion of papaverine, a supra-renal
aortic constriction which reduced renal perfusion pressure by 50% resulted
in a 90% reduction in urinary sodium excretion and an increase in plasma
renin activity (Gerber, Nies and Olsen, 1981). Indomethacin or meclo-
fenamate administration had no effect on the reduced sodium excretion
in response to aortic constriction but prevented the associated increase
in plasma renin activity. This would suggest that the macula densa
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mechanism of renin release is mediated by prostaglandins. It should
be noted, however, that this conclusion is dependent upon the assump¬
tion that the renal baroreceptor was inactivated. In the conscious rat,
prior indomethacin administration partially inhibited an increase in plasma
renin activity when the animals were subjected to dietary sodium depriva¬
tion (Suzuki et al. , 1981b). In a study using a micropuncture technique
in anaesthetised rats, dietary sodium deprivation produced a decrease
in early distal tubular delivery of sodium and an increase in plasma
renin activity (Francisco, Osborne and Di Bona, 1982). This response
occurred in a denervated kidney, when mean arterial pressure was con¬
stant within the renal autoregulatory range, renal blood flow was stable
and renal perfusion pressure was not changing. This indicates that
the increase in plasma renin activity was due to stimulation of the macula
densa. Under the same conditions, indomethacin administration had no
effect on the early distal tubular sodium delivery but inhibited the in¬
crease in plasma renin activity suggesting that prostaglandins were
involved in mediating the increase in renin release following stimulation
of the macula densa.
Intravenous infusion of isoprenaline into uninephrectomised renally
denervated anaesthetised dogs results in an increase in plasma renin
activity presumably as a consequence of direct stimulation of g receptors
in the juxtaglomerular cells. Prior administration of indomethacin was
found to have no effect on the increase in plasma renin activity in res¬
ponse to isoprenaline infusion suggesting that g -adrenergic stimulation
of renin release is not mediated by prostaglandins (Berl et al., 1979;
Seymour and Zehr, 1979). In a superfused preparation of isolated rat
glomeruli, isoprenaline increased the amount of renin released into the
effluent without having any effect on the quantity of PGE2 released
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(Beierwaltes, Schryver, Olson and Romero, 1980). Prior inhibition
of prostaglandin synthesis with mecJofenamate had no effect on the
ability of isoprenaline to increase renin release. Isoprenaline also in¬
creased renin release in the isolated perfused rabbit kidney (Vandogen,
Tunney, Mahoney and Barden, 1981). In this preparation, the quantity
of 6-keto-PGFxa released by the kidney was not altered by isoprenaline
and indomethacin had no effect on the renin response to isoprenaline.
The results of these studies suggest that neither PGE2 nor PGI2 are
involved in mediating the increase in renin release following g-adrenergic
receptor stimulation with isoprenaline. Contrary to this, however,
Campbell et at. demonstrated that in conscious rats, indomethacin could
inhibit the increase in plasma renin activity due to reflex activation of the
sympathetic system by hydrallazine, g-adrenergic receptor stimulation by
isoprenaline and stimulation of a site distal to the g-adrenergic receptor
by dibutyryl cyclic AMP (Campbell, Graham and Jackson, 1979). These
results were supported by a similar study in conscious rats which demon¬
strated a partial inhibition of the renin response to isoprenaline by indo¬
methacin (Suzuki et a!., 198lb)and indicated a participation of prosta¬
glandins in the release of renin following sympathetic stimulation. Kopp
et at. showed that during low level renal nerve stimulation in the anaes¬
thetised dog there was very little change in renal haemodynamics and the
increase in plasma renin activity was mediated by gx-adrenergic receptors.
During high level renal nerve stimulation, the increase in plasma renin
activity was partly mediated by gx-adrenergic receptors but was also second¬
ary to the cradrenergic receptor mediated renal vasoconstriction (Kopp,
Aurell, Nilson and Ablad, 1980). Indomethacin had no effect on the increase
in plasma renin activity during low level renal nerve stimulation but
partially inhibited the increase in plasma renin activity during high level
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renal nerve stimulation (Kopp, Aurell, Sj'olander and Ablad, 1981).
The a-adrenergic antagonist, phenoxybenzamine had no additional effect
to the indomethacin in preventing the increase in plasma renin activity.
However, administration of the gx -adrenergic receptor antagonist
metoprolol in addition to the indomethacin resulted in the renin response
to high level renal nerve stimulation being abolished. These results
implied that the gx-adrenergic receptor component of renin release follow¬
ing renal nerve stimulation did not require prostaglandin synthesis whilst
the a-adrenergic receptor component, probably secondary to haemo-
dynamic changes, was dependent upon prostaglandins to mediate renin
release. Intrarenal infusion of the a-adrenergic receptor agonist,
phenylephrine into anaesthetised dogs in which the g-adrenergic recep¬
tors were blocked with sotalol, resulted in a decrease in renal blood
flow and sodium excretion and an increase in plasma renin activity (Olsen,
Nies and Gerber, 1981). Indomethacin prevented the increase in plasma
renin activity during phenylephrine infusion but had no effect on the
decreased blood flow or sodium excretion. In this model, phenylephrine
infusion had no effect on plasma renin activity if the kidney was rendered
non-filtering, therefore it would seem that the phenylephrine-induced
increase in renin release was secondary to stimulation of the macula
densa which required prostaglandins to mediate the increase in renin
release. Seymour et at. failed to observe an a-adrenergic receptor com¬
ponent in renin release during noradrenaline infusion in conscious dogs
and rats and demonstrated that a-adrenergic receptor block with phentol-
amine potentiated the renin response to noradrenaline, suggesting that
a -adrenergic receptor stimulation was inhibiting renin release (Seymour,
Davis, Echtenkamp, Dietz and Freeman, 1981). Concentrations of iso-
prenaline and noradrenaline which had no effect on mean arterial pressure
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increased plasma renin activity and this effect was potentiated by prior
indomethacin administration. This potentiation of adrenergically
mediated renin responses by indomethacin does not necessarily imply
that prostaglandins were suppressing renin release but may result from
the removal of an inhibitory effect of prostaglandins on post junctional
adrenergic receptors (Frame, Hedquist and Astrom, 1974). It therefore
remains controversial as to whether prostaglandins are involved in the
renin response to sympathetic nerve stimulation. It seems likely that
g -adrenergic receptor stimulation can increase renin release by a mechan¬
ism independent of prostaglandin synthesis although an a-adrenergic
receptor mediated increase in renin release may require prostaglandin
synthesis. There may also be species variation, with adrenergically
mediated renin release being prostaglandin dependant in the rat but
prostaglandin independent in other species.
Despite the large body of evidence implicating a role for prosta¬
glandins in the control of renin release, their importance as regulators
of renin release under physiological conditions and the extent to which
they mediate the other intrinsic mechanisms of renin release remains
the subject of debate.
7. 5. 2 Stimulation of prostaglandin synthesis by angiotensin II
An increase in renin release in response to a variety of stimuli
results in an increase in angiotensin II formation which causes vaso¬
constriction and sodium retention both by a direct action and by stimula¬
tion of aldosterone secretion. Several lines of investigation have sug¬
gested that angiotensin II stimulates PGE2 and PGI2 synthesis which
may serve to modulate the action of angiotensin II by means of their
vasodilator and natriuretic actions.
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Infusion of angiotensin II into the renal artery of anaesthetised
dogs was demonstrated to result in the release of a PGE2-like substance
into the renal venous blood, as detected by a blood-bathed bioassay
technique (McGiff, Crowshaw, Terragno and Lonigro, 1970). The release
of this PGE2-like substance in response to angiotensin II was shown
to coincide with the recovery of renal blood flow (Aiken and Vane, 1973).
Intravenous infusion of angiotensin II into humans was found to increase
urinary PGE2 excretion (Frolich et al., 1975) and intrarenal infusion of
angiotensin II in anaesthetised dogs resulted in an increase in PGE2
excretion (Dunn, Liard and Dray, 1978). However, Blasingham and
Nasjletti, using a similar model failed to observe an increase in urinary
PGE2 excretion during intravenous angiotensin II infusion (Blasingham
and Nasjletti, 1980). An intravenous infusion of angiotesnin II into
anaesthetised cats was found to increase the amount of PGI2-like sub¬
stance in arterial blood (Swies, Radomski and Gryg lewski, 1979) and
an intrarenal infusion of angiotensin II increased the amount of PGI2-like
substance in the arterial blood of anaesthetised dogs and rats (Shebuski
and Aiken, 1980; Dusting and Mullins, 1980). That the increase in
PGI2 synthesis during angiotensin II infusion was not merely a result
of mechanical stimulation due to the vasoconstriction was demonstrated
by Mullane and Moncada who observed an increase in PGI,-like substance
in the venous blood of anaesthetised dogs when angiotensin II was infused
either intravenously or intrarenally. However, no increase in PGI2-
like substance was observed during infusions of concentrations of
adrenaline or 5-hydroxytryptamine which caused the same degree of
vasoconstriction (Mullane and Moncada, 1980). In a recent study,
however, no increase in immunoreactive 6-keto-PGFia was detected in
the plasma of conscious rabbits during intravenous infusion of angiotensin
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II although an increase in the plasma concentration of PGE2 was detected
(Nasjletti and Malik, 1982). This suggested that vascular PGI2 synthesis
was not stimulated by angiotensin II.
Isolated preparations have also been used to investigate the effects
of angiotensin II on prostaglandin synthesis. Needleman et al. demon¬
strated that angiotensin II released a PGE2-like substance when infused
into the isolated rabbit kidney (Needleman, Kauffman, Douglas, Johnson
and Marshall, 1973). The release of prostaglandin could be inhibited
by the angiotensin II antagonist [ 8-cys-teine ]-angiotensin II, suggesting
that the stimulation of prostaglandin synthesis by angiotensin II was a
specific receptor-mediated effect. Incubation of angiotensin II with
whole cell preparations of rat renal papillae increased the PGE2 content
in the tissue and in the incubating medium (Danon, Chang, Sweetman,
Nies and Oates, 1975). Angiotensin II also increased PGE2 release from
cultured rabbit reno-medullary interstitial cells, an effect which could
be inhibited by the anti- matertal drug, mepacrine (Zusman
and Reiser, 1977). This suggested that angiotensin II increased prosta¬
glandin synthesis by activation of phospholipase resulting in an increase
in arachidonic acid availability. Other investigators have failed to demon¬
strate any effect of angiotensin II on PGE2 synthesis by isolated rabbit
or rat renal medullary tissue (Sirois and Gagnon, 1974; Anees, Sweet,
Tan and Mulrow, 1979). Silberbauer et al. observed that angiotensin II
incubated with isolated sections of rat kidney resulted in an increase
in PGI2-like substance in the supernatant, as detected by its ability
to prevent ADP-induced platelet aggregation (Silberbauer, Sinzinger
and Winter, 1979). An increase in PGI2 release was also demonstrated
when angiotensin II was infused into the isolated rabbit kidney, although
the increase in PGI2 synthesis was much smaller than the increase in
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PGE2 synthesis (Needleman, Bronson, Wyche, Sivakoff and Nicolaou,
1978).
Angiotensin II has also been shown to increase prostaglandin
synthesis in other tissues besides the kidney. PGE2 and PGI2 release
from the isolated rabbit heart was increased during infusion of angio¬
tensin II and contrary to the kidney, PGI2 synthesis was stimulated
to a greater extent that) PGE2 synthesis (Needleman, Marshall and Sobel,
1975; Needleman ef at. , 1978). Cultured human vascular endothelial
cells have been shown to release PGE2 into the culture medium and
incubation with angiotensin II increased the PGE2 release (Gimbrone
and Alexander, 1975). Isolated perfused rabbit mesenteric blood vessels
released a PGE2-like substance in response to angiotensin II (Blumberg,
Denny, Marshall and Needleman, 1977) and isolated rat mesenteric
vasculature has been shown to release PGE2 and PGI2 when perfused
with angiotensin II (Nolan, Dusting and Martin, 1981; Dusting, Mullins
and Nolan, 1981). Perfusion of mesenteric vasculature with angiotensin
I also resulted in an increase in prostaglandin release although this
release could be inhibited by an angiotensin I converting enzyme inhibitor.
This suggests that angiotensin I requires to be converted to angiotensin
II in order to stimulate prostaglandin synthesis (Blumberg et at. , 1977;
Nolan et al., 1981). Angiotensin II can also induce release of a PGI2-
like substance from perfused guinea-pig and rat lungs (Grodzinska
and Gryglewski, 1980; Dusting et at., 1981). In a recent study, angio¬
tensin II had no effect on PGI2 production by cultured porcine aortic
endothelial cells (Whorton, Young, Data, Barchowsky and Kent, 1982).
It is apparent that although there is much in the literature to suggest
that angiotensin II stimulates prostaglandin synthesis in a number of
different tissues including the kidney, not all the experimental evidence
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supports such an action of angiotensin II. It should be noted that in
the majority of studies demonstrating an effect of angiotensin II on prosta¬
glandin synthesis, pharmacological doses of angiotensin II were used.
Such large concentrations may not represent the actions of angiotensin
II under physiological conditions.
Inhibition of prostaglandin synthesis by indomethacin augments
the renal vasoconstrictor action of angiotensin II in anaesthetised dogs
and sheep (Aiken and Vane, 1973; Beilby et at., 1981) and potentiates
the pressor response to angiotensin II in sodium replete and sodium
deplete humans (Negus, Tannen and Dunn, 1976; Speckart, Zia, Zisper
andHorton, 1977). In the sodium replete anaesthetised dog, inhibition
of prostaglandin synthesis with meclofenamate had no effect on systemic
blood pressure or renal blood flow. If, however, angiotensin II was
infused, meclofenamate administration resulted in an increase in systemic
blood pressure and a decrease in renal blood flow (Blasingham and
Nasjletti, 1980). In the sodium deplete anaesthetised dog, meclofenamate
administration increased systemic blood pressure and decreased renal
blood flow. This effect could be inhibited by prior administration of
the angiotensin II antagonist, saralasin. Similarly, in conscious dogs,
inhibition of prostaglandin synthesis with meclofenamate had no effect
on renal blood flow unless the renin-angiotensin system was stimulated
by sodium depletion whereupon meclofenamate administration resulted
in a decrease in renal blood flow (Blasingham et at., 1980). These
results suggested that increased levels of angiotensin II, whether by
exogenous infusion or due to sodium deprivation, resulted in increased
synthesis of prostaglandins which acted to modify the effects of angio¬
tensin II by causing a vasodilatation. However, Zimmerman failed to
observe any effect of meclofenamate on renal blood flow in Goldblatt
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hypertensive conscious dogs even though plasma renin activity was
elevated (Zimmerman, 1978), suggesting that although angiotensin II
formation was increased, prostaglandin synthesis had not been stimulated.
Several studies have attempted to demonstrate an increase in PGE2
synthesis during stimulation of the renin-angiotensin system by sodium
deprivation. Some investigators have observed an increase in renal
venous and urinary PGE2 levels during sodium deprivation (Oliver,
Pinto, Sciacca and Cannon, 1980; Rathaus, Podjarny, Weiss, Ravid,
Bauminger and Berrheim, 1980), whilst others have failed to observe any
change in urinary PGE2 levels during sodium depletion (Lifschitz,
Patak, Raclem and Stein, 1978; Blasingham et al., 1980). It therefore
remains controversial as to whether increased formation of angiotensin II,
following physiological stimulation of renin release, results in an increase
in prostaglandin synthesis.
Studies demonstrating an effect of prostaglandins to stimulate renin
release and studies demonstrating an effect of angiotensin II to stimulate
prostaglandin synthesis afford two pieces of evidence which are difficult
to reconcile within the same physiolsgical mechanism. Angiotensin II
has a direct negative feedback effect on the juxtaglomerular cells to
inhibit renin release (Vander and Geelhoed, 1965; Bunag, Page and
McCubbin, 1967). However, angiotensin II may also stimulate prosta¬
glandin synthesis within the kidney which in turn could result in an
increase in renin release constituting a positive feedback mechanism
(Stahl.Ahmad, Attallah(Bloch and Lee 1979), It has been suggested (Attallahet.al.
1982) that prostaglandins, by stimulation of renin release, have a pro-
hypertensive action and, by causing vasodilation secondary to stimula¬
tion of synthesis by angiotensin II, an anti-hypertensive action. It
seems likely that the degree of contribution of prostaglandins to these
37.
mutually antagonistic mechanisms varies with experimental circumstances
and therefore it is perhaps not surprising that agreement is lacking
regarding the overall nature and extent of prostaglandin involvement
in control of renal blood flow and systemic blood pressure. It is possible
that under both experimental and physiological conditions, stimuli result¬
ing in an increase in the prohypertensive prostaglandin-renin-angiotensin
system are associated with an offsetting secondary increase in the anti¬
hypertensive prostaglandins. Conversely, a primary increase in anti¬
hypertensive prostaglandins may be countered by a secondary increase
in the renin-angiotensin system. A delicate balance may therefore exist
between these two important opposing renal humoral systems in which
the final mechanisms regulating their positive feedback actions remain
obscure.
Alternatively, the synthesis and actions of prostaglandins in the
kidney may be compartmentalised such that a stimulus for renin release
may be mediated by prostaglandins synthesised in or near the juxta¬
glomerular cells. Modulation of the actions of the consequently formed
angiotensin II may occur by stimulation of prostaglandin synthesis in
the renal vasculature which may not necessarily result in a further in¬
crease in renin release.
It is apparent that there is a complex interaction between prosta¬
glandins and the renin-angiotensin system and that further investigation
is required to elucidate the precise nature of this interaction. Most
work in this field has focussed attention on PGE2. However, more recent
studies have suggested that PGI2 may be more integral in the relation¬
ship between prostaglandins and the renin-angiotensin system. It is
the aim of this thesis to attempt to further clarify the relationship between
PGI2 and the renin-angiotensin system.
38.
1.6 Choice of Animal Model
In choosing an animal model, it was important to ensure that the
renin-angiotensin system and the prostaglandin system were operating
under as physiological conditions as experimental design would allow.
It was also thought pertinent to choose an animal species in which the
responses to the renin-angiotensin system and renal prostaglandins
showed an analogy to the human situation.
Several studies have demonstrated that anaesthetic drugs, when
used in doses which produce a surgical plane of anaesthesia, stimulate
the release of renin in man and experimental animals (Kaldor, Gachalyi,
Kallau , Fekete and Foldrari, 1975; Johnson and Malvin, 1975; Yun,
Kelly, Bartter and Tate, 1978). The mechanisms by which anaesthetic
agents release renin appear to be as diverse as the pharmacological
properties of the anaesthetics themselves with each anaesthetic agent
apparently altering renin by a different mechanism (for review, see
Keeton and Campbell, 1980). It is therefore an obvious disadvantage
to investigate the effects of drugs on the renin-angiotensin system in
an animal which has been administered with an anaesthetic agent since
this will have resulted in prior stimulation of renin release.
Although anaesthesia itself has no effect on basal prostaglandin
levels, laparotomy performed under anaesthesia markedly elevates prosta¬
glandin levels (Terragno et al. , 1978). Under these conditions of acute
surgical stress renal venous PGE2 levels in the dog and urinary PGE2
and PGF2a levels in the rat are significantly higher than those found
in conscious animals (Terragno et al., 1978; Scherer, Schnermann,
Sofroniev and Weber, 1978).
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It was therefore apparent that an anaesthetised surgically stressed
animal did not represent a suitable model in which to investigate the
relationship between prostaglandins and the renin-angiotensin system
and all studies in this thesis were performed in conscious dogs.
The dog was favoured to other species for three main reasons.
Firstly, the larger anatomical size of the dog compared to rat or rabbit
was more practical for the insertion and maintenance of indwelling
catheters. Secondly, previous experience in this laboratory had demon¬
strated that the foxhound breed of dog had a docile temprement well
suited to chronic work and could be trained to sit in a quiet room for
several hours without becoming overstressed. Thirdly, as far as can
be ascertained from the literature, the dog provides a good analogy
with the human as far as the renin-angiotensin system and the renal
prostaglandin systems are concerned. The suitability of the rat as an
animal model for the study of renal prostaglandins has been questioned
since the renal vascular response to PGE2 in the rat differs from that
in other species. PGE2 results in renal vasodilation in the dog (Vander,
1968) and rabbit (Malik and McGiff , 1975), whilst in the rat, although
low doses of PGE2 result in renal vasodilatation (Ha3dor& Towers, 1982;
Jackson et,ali1982)larger doses of PGE2 may result in renal vasoconstriction
(Baer and Mc Giff, 1979). 1
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1.7 Manipulation of the Renin-Angiotensin System
1.7.1 Physiological stimulation of renin release
Brown et al. discovered that sodium depletion in humans elevated
plasma renin activity and that sodium loading suppressed plasma renin
activity (Brown, Davies, Lever and Robertson, 1963). This observa¬
tion has been corroborated by many investigators in both man and experi¬
mental animals (Romero, Staneloni, Dufan, Dohmen, Binia, Kliman and
Fasciolo, 1968; Brubacher and Vander, 1968; Keeton, Pettinger and
Campbell, 1976). During dietary sodium deprivation, total daily sodium
excretion falls to very low levels due to a decrease in the fractional
excretion of the filtered sodium load. Much of the increase in the
efficiency of sodium reabsorption occurs in the proximal tubule (Mohammed,
Diseala and Stein, 1974), therefore the tubular sodium concentration
and sodium load passing the macula densa segment of the distal tubule
will be decreased. This decrease in sodium transport to the macula
densa results in stimulation of renin release and the consequently formed
angiotensin II further conserves sodium both by a direct action and by
stimulation of aldosterone secretion.
Sodium depletion in experimental animals is achieved by initial
administration of frusemide followed by maintenance on a sodium free
diet. This procedure is routinely used in laboratories to physiologically
stimulate the renin-angiotensin system.
7. 7. 2 Pharmacologic interruption of the renin-angiotensin system
The renin-angiotensin system offers a number of sites which could
be selectively inhibited (Figure 1.4). Renin is released from the kidney
by such a variety of stimuli that it would be difficult to completely block
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Angiotensin II analogues, e.g. saralasin.
FIGURE 1.4: Pharmacologic interruption of the renin-angiotensin
system.
42.
can be at least partly inhibited by indomethacin (Frolich et al. , 1975)
and by 3-adrenergic receptor blocking drugs such as propranolol
(Michelakis and McAllister, 1972). Following release, renin cleaves
the leucyl-leucine bond that joins the amino-terminal deca peptide angio¬
tensin I to the remainder of the substrate, angiotensinogen which is
synthesised in the liver. The action of renin on angiotensinogen has
been antagonised by nonspecific proteases such as pepstatin (Gross,
Lazar and Orth, 1972) by antibody to renin (Romero, Hoobler, Kozak
and Warzynski, 1973) and more specifically by structural analogues
of the renin substate (Paulsen, Burton and Haber, 1973). The deca-
peptide angiotensin I is converted within the vascular bed of the lungs,
kidneys and other organs to the octapeptide angiotensin II by hydrolytic
removal of its C-terminal, his-leu dipeptide residue. This conversion
is catalysed by a membrane bound exopeptidase", a peptidyl carboxy-
hydrolase known as angiotensin I converting enzyme or kininase II,
the same enzyme being responsible for the hydrolytic removal of the
C-terminal dipeptide from bradykinin. The formation of angiotensin II
from angiotensin I provides two further sites where the renin-angiotensin
system could be inhibited, the inhibition of the converting enzyme and
antagonism of the vasoactive angiotensin II at the receptor.
The first group of compounds which offered any degree of specificity
and which were used extensively in research were angiotensin II analogues
found to have antagonist activity. Marshall et al. demonstrated that
4-Phe-8-Tyr-angiotensin II was a competitive receptor antagonist of
angiotensin II (Marshall, Vine and Needleman, 1970). Other analogues
of angiotensin II with aliphatic amino acids (alanine, isoleucine and
glycine) substituted for the phenylalanine residue in the 8-position
of angiotensin II were synthesised in other laboratories (Pals, Masucci,
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Sidpos and Denning, 1971; Turker, Hall, Yamamoto, Sweet and Bumpus,
1972). In addition, in most of these compounds the 1 position was
occupied by the non-mammalian amino-acid sarcosine since this substitu¬
tion was found to prolong the half-life of the peptides and thereby in¬
crease their potency. The most extensively characterised receptor
antagonist of angiotensin II is l-Sar-8-Ala-angiotensin II, also known
as saralasin. Saralasin has been used extensively to investigate the
physiological and pathophysiological role of angiotensin II (Agabiti-Rosei,
Brown, Brown, Fraser, Trust, Lever, Morton and Robertson, 1979;
Fagard, Amery, Lijnen and Reybrouck, 1977; North, Tan and Mulrow,
1977). However, saralasin and other angiotensin analogues are not
devoid of intrinsic agonist angiotensin-like activity, therefore caution
is required in the interpretation of the results (Anderson, Streeton and
Dalakos, 1977; Hollenberg, Williams, Burger, Ishikawa and Adams, 1976;
McGregor and Davies, 1976).
The first inhibitors of angiotensin I converting enzyme which were
potent and specific enough for extensive study were a series of peptides
found in the venom of the Brazilian viper, Bothrops jararaca. A crude
mixture of these peptides was first described by Ferreira as 'bradykinin-
potentiating factor' (Ferreira, 1965), but the peptides were also found
to be potent inhibitors of angiotensin I converting enzyme (Bakhle,
1968). Several peptides were isolated from the snake venom (Ferreira,
Bartlett and Greene, 1970; Ondetti, Williams, Sabo, Plusac,, Weaver
and Kocy, 1971), but the most thoroughly studied one was a nonapeptide
(Pry-Trip-Pro-Arg-Pro-Gln-Ile-Pro-Pro), the synthetic form of which
is designated SQ20881 or teprotide (Glu-Trip-Pro-Arg-Pro-Gln-Ile-
Pro-Pro). Teprotide and other similar peptides compete with angiotensin
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(N - [(25) - 3 - Mercapto - 2 - methyIpropionyl ] - I -
proline )
FIGURE 1.5: The binding of captopril to angiotensin I converting
enzyme.
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tensin I to angiotensin II. Although teprotide was effective in inhibiting
the effects of angiotensin I both on systemic blood pressure and renal
function (Kimbrough, Vaughan, Carey and Ayers, 1977; Niarchos,
Pickering, Case, Sullivan and Laragh, 1979), it did not have wide clinical
application since it was liable to enzymatic degradation and therefore
had to be administered intravenously. A programme of extensive structure-
activity studies was therefore initiated by Ondetti et al. to develop an
orally active inhibitor of angiotensin I converting enzyme. D-3-mercapto-
2-methylpropanoyl-l-proline, designated SQ14225 or captopril (Figure
1.5) was found to be the most potent orally active inhibitor of angiotensin
I converting enzyme (Cushman, Cheung, Sabo and Ondetti, 1977;
Ondetti, Rubin and Cushman, 1977). The salient features of captopril
with respect to binding to angiotensin converting enzyme are (a) binding
of the sulphydryl to zinc, (b) binding of the proline carboxylic acid to
a cationic site on the enzyme and (c) incorporation of the amino acid
proline, and a methyl side chain adjacent to proline, since the amino
acid increased affinity for the enzyme and the methyl group was thought
to increase activity by restricting the conformation of the molecule.
Captopril, like teprotide, is a competitive inhibitor of angiotensin I
converting enzyme and has a half-life of approximately three hours.
Captopril has been studied extensively and has been found to be an
effective anti-hypertensive agent in both clinical and laboratory situa¬
tions (Morton, Tree, Casals-Stenzel, 1982; Gavras, Brunner and Turin ,
1978). There has been controversy over the precise mechanism of the
anti-hypertensive action of captopril since elevated bradykinin levels
may be contributing to the hypotension in addition to inhibition of angio¬
tensin II formation. Some lines of investigation have also implicated
prostaglandins as a contributing factor towards the hypotension following
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captopril administration. The controversy surrounding the mechanism
of action of captopril will be discussed fully in Section IV.
1.8 Assessment of Renal Function
7. 8. 7 Renal blood flow
The major problem commonly encountered in conscious animal work
is that of recurrent infection, the most common cause of which is due
to indwelling catheters. For this reason it was thought preferable to
use as little chronic instrumentation in the dog models as possible.
Indwelling venous catheters were necessary for infusion of drugs and
fluids but a non-invasive method was used to measure renal blood flow.
Although non-invasive methods of measuring renal blood flow are less
accurate than the use of flow probes, the problems known to be en¬
countered during the use of indwelling flow probes in conscious animals
were such that they were not regarded to be a practical alternative to
a non-invasive method.
Non-invasive measurement of renal blood flow is based on the clear¬
ance of substances extracted almost completely by the kidney. A sub¬
stance can be envisaged whose uptake by the kidney from renal arterial
plasma by glomerular filtration and tubular secretion is complete such
that none appears in the venous plasma. This imaginary substance
would have an extraction efficiency E of 100%. The amount that appears
in the urine per minute (U x V) equals the amount in the renal arterial
plasma, U x V = C x P, where C is the clearance of the hypothetical
substance, and P is the plasma concentration of the substance in mg/100
ml. The first attempts to measure renal plasma flow used hippuran and
phenol red (Chassis, Ranges, Gold ring and Smith, 1938). The extraction
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efficiency of these compounds was between 80 and 95%. It was later
found that p-amino hippuric acid (PAH) was easier to measure than
hippuran (Smith, Finklestein, Aliminosa, Cranford and Graber, 1945)
and PAH which has been used to measure renal plasma flow for many
years is employed in the work, for this thesis.
In using PAH to measure renal plasma flow, it is assumed that plasma
perfuses tubules which are uniformly efficient in extracting PAH.
However, in various species the extraction efficiency of the juxtamedullary
nephrons is substantially lower than that of the cortical nephrons. It
should be noted that the extraction of PAH depends on a specific carrier
whose activity is theoretically saturable at high plasma concentrations
of PAH. However, clearance is not significantly depressed with the
technique usually employed.
In practice, PAH is given with a loading dose followed by a contin¬
uous intravenous infusion. A steady state is achieved 30 min - 2 hr
after the start of the infusion. To establish an appropriate plasma con¬
centration of PAH, an injection of 8 mg/kg should be given followed
by the establishment of a constant intravenous infusion of PAH at a rate
calculated to approximately equal or slightly exceed the estimated rate
of renal clearance. In all renal clearance studies, an important considera¬
tion is the accurate collection of timed urine collections which requires
that urine is collected via an indwelling catheter. Urine collection periods
should not be of less than .20 min duration, and plasma samples are taken
at the end of each urine collection.
To determine the average plasma concentration of a solute (P) over
a number of time intervals, a graphical interpolation can be performed.
Successive plasma concentrations (Px, P2, P3 etc) are plotted on semi-log
graph paper against elapsed time, taking zero time either as the time at
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which priming injection is administered or as the time at which the bladder
is emptied and the collection of urine is begun. The exact value of P
appropriate to each successive urine collection period is determined by
interpolating to the value at the mid-point of the urine collection period.
Perhaps the most apparent disadvantage of measuring renal plasma
flow by PAH clearance is that this method requires urine collections of
at least 20 min and the value for PAH represents a mean value for renal
plasma flow during that time. It may conceal fluctuations in the actual
plasma flow rate that might occur during that time and give a false
impression of the stability of renal plasma flow.
7. 8. 2 Glomerular filtration rate
A clearance study has also been employed for the measurement
of glomerular filtration rate. A substance used in the assessment of
glomerular filtration rate should be (a) metabolically inert and excreted
exclusively by glomerular filtration, i.e. neither reabsorbed nor
excreted by the tubules, (b) freely filterable through the glomerular
capillary membranes, i.e. neither protein bound nor large enough to
be held back in the process of ultrafiltration. The fructose polysaccharide
inulin fulfils these criteria and the renal plasma clearance of inulin is
generally accepted as the standard reference for glomerular filtration
rate in all vertebrates (Shannon and Smith, 1935). Several other sub¬
stances have been examined as substitutes for inulin including endogenous
creatinine which is continuously introduced at a constant rate into the
blood stream. Clearance of endogenous creatinine is the most extensively
used procedure for the assessment of glomerular filtration rate in clinical
work but it is generally accepted to be less accurate than inulin and
this thesis has employed inulin clearance as a measure of glomerular
filtration rate.
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As with PAH, inulin is given as a loading dose followed by a
continuous intravenous infusion, a steady state being achieved 30 min -
1 hr after the start of the infusion. An appropriate plasma concentration
of inulin is achieved by injection of 50-100 mg/kg followed by the
establishment of an intravenous infusion of inulin at a rate calculated
to slightly exceed the estimated rate of renal clearance. Accurate urine
collections should be of at least 30 min duration, plasma samples being
taken at the end of each collection period. The average plasma concentra¬
tion of inulin for each collection period is estimated as for PAH.
Similar to the measurement of renal plasma flow by PAH, the
obvious disadvantage in the measurement of glomerular filtration rate
by the clearance of inulin is that the value for inulin represents a mean
value for glomerular filtration rate during each 30 min collection period.
This may conceal any fluctuations in glomerular filtration rate which
occur during that time.
7.8.3 Renin release
The term 'renin release' indicates the movement of renin molecules
from the granular juxtaglomerular cells of the kidney into the blood
flowing through the afferent glomerular arteriole. By strictest definition,
'renin secretion' is the minute output of renin by the kidney into the
renal vein and is calculated by multiplying the renal plasma flow times
the renal vein plasma renin activity minus the aortic plasma renin activity.
However, it is not always possible, particularly in conscious animal
work, to obtain renal venous blood and arterial plasma renin activity
is taken to be indicative of renin secretion. Plasma renin activity is
a measure of the ability of plasma to generate angiotensin I in vitro
given the amount of renin and renin substrate present in the plasma
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sample. Plasma renin activity is usually expressed as ng angiotensin I
generated per ml of plasma per hr of incubation at 37°C (ng/ml/hr)
and is generally accepted as being a reflection of the level of activity
of the renin-angiotensin system in vivo.
1.9 Identification and Quantification of Prostaglandins
The extremely small amounts of prostaglandins normally present
in biological samples necessitates the use of highly sensitive and specific
methods for their analysis.
Biological assay methods have been used extensively for the detec¬
tion and estimation of prostaglandins and thromboxanes. The advantages
are good sensitivity together with specificity for biologically active com¬
pounds. Specificity can be enhanced by prior chromatographic procedures,
by the use of pharmacological antagonists to compounds other than prosta¬
glandins , and by assaying the sample on more than one type of tissue
preparation. Bioassay has proved to be invaluable in the detection of
new biologically active compounds and it was on such a system that Vane
et al. detected PGI2 (Moncada, Gryglewski, Bunting and Vane, 1976).
However, together with the obvious disadvantage that bioassay cannot
detect inactive metabolites, other analytical techniques have been demon¬
strated to have a higher sensitivity and specificity. The instability
of PGI2 makes it impossible to quantify except by bioassay, but other
techniques have been developed to quantify 6-keto-PGFia , the stable
hydrolysis product of PGI2, with the assumption that the concentration
of 6-keto-PGF].ct is directly related to the concentration of PGI2.
Radioimmunoassay (RIA) offers good specificity and is capable
of measuring prostaglandins and their metabolites in the nanogram and
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picogram range. This method can be applied to any prostaglandin
provided that approximately 10 mg of the pure compound is available
for the initial raising of the antibody. The unavailability of standards
is a limitation to the use of RIA for the analysis of certain metabolites.
Although RIA is time-consuming to set up, this disadvantage is com¬
pensated for by the speed of analysis allowed by the established
technique. Cross-reactivity may cause problems when analysing
structurally similar compounds, e.g.PGF2aand PGFxct. However, these
difficulties can be overcome by prior chromatographic separation of the
interfering compounds. The specificity of an RIA method must be
thoroughly confirmed by cross-reactivity, accuracy and precision tests
as the technique will not provide evidence of interference in any individual
sample. Ideally, the accuracy of RIA results should be confirmed by
another analytical method, e.g. gas chromatography-mass spectrometry.
The problem of interference in an individual sample is eliminated
when a prostaglandin is quantified by gas chromatography-mass spectro¬
metry (GC-MS) since the analyst can observe a characteristically shaped
ion current response and scrutinise each individual chromatogram for
interfering substances. The ability of GC-MS to produce a 'fingerprint'
of a molecule together with the obvious advantage of high precision
when used for quantification, has resulted in the technique being used
extensively for the identification, structural elucidation and quantifica¬
tion of prostaglandins and their metabolites.
The nature of the various polar functional groups in prostaglandins
and their metabolites necessitates sample derivitisation prior to gas
chromatography in order to achieve thermal stability, volatility and
hence good gas chromatographic properties. The carboxylic acid group
is rendered less polar by conversion to an ester, most commonly the
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methyl ester. A number of derivatives have been employed to protect
the hydroxyl groups, the most common of which is the trimethylsilyl
(TMS) ether (Luukainer, Vanden-Neuvel, Haahti and Horning, 1961).
A free ketone in the oj-side chain of a prostaglandin need not be
derivitised, however the 6-ketol moiety of 6-keto-PGFxa is particularly
labile and must be stabilised by conversion of the ketone to an oxime
(Green, 1969).
Following gas chromatography, the column eluant is introduced
into the mass spectrometer via a separator which removes most of the
carrier gas (Figure 1.6). In the ion source, ionisation of the sample
molecules occurs by bombardment with electrons of a certain energy,
generated from a rhenium filament and accelerated by a trap electrode.
This bombardment with electrons will ionise and fragment the sample
molecules. The per cent ionisation and extent of fragmentation depends,
in part, on the constitution of the molecule, on the electron energy,
and on the temperature of the ion source. The positively charged
molecular ions and fragment ions resulting from ionisation are accelerated
into the mass analyser. A portion of the ion beam (10%) is directed
toward an electrode, and its output signal results in a tracing referred
to as the total ion current. This indicates the optimum time to obtain
a complete mass spectrum. The analyser tube is curved and has a magnet
at its curvature. In order to obtain a complete mass spectrum, the
magnetic field is continually increased while a constant amount of sample
molecules are entering the ion source. This causes ions of increasing
mass to impinge on the electron multiplier which is positioned behind
an exit slit. The relationship between the mass of the ion (m), its charge
(e, usually 1), the magnetic field strength (H) and the accelerating





m+/e = R2 H2 / 2V
where R is the radius of the curvature of the analyser tube (a constant).
If V is held constant, then at a particular value of H, only one specific
ion of m/e will pass through the exit slit to reach the electron multiplier.
By continuously changing H, one ion after another is brought into focus
and its abundance is registered. The resulting mass spectrum provides
a 'fingerprint' for each compound and together with the chromatographic
retention time of the derivative provides a highly specific method of
identification.
In addition to the use of GC-MS to obtain a mass spectrum, it can
be used in the multiple ion detection (also called selected ion monitoring)
mode. The mass spectrometer is set to monitor only ion fragments of
interest. Usually these are of high relative abundance in the mass
spectrum (to confer sensitivity) and of high mass (to confer selectivity).
Throughout a GC run, the ions are focussed alternately on the detector
and their intensities are recorded separately as single ion chromatograms.
This method of detection offers much higher sensitivity than recording
the whole spectrum of ions and an additional advantage is that individual
components may be monitored over the complete time of elution of a GC
peak as distinct from a few milliseconds per ion when a mass spectrum
is recorded. In the multiple ion detection mode, the mass spectrometer
can be used quantitatively. This technique employs monitoring the
response of the sample relative to an internal reference standard and
comparing the response to a set of analytical calibration standards con¬
taining the same fixed amount of internal reference standard. The ref¬
erence internal standard chosen is usually an analogue of the compound
to be analysed and ideally is a stable isotope of the compound. These
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stable isotopes are normally formed by replacing selected hydrogen atoms
by deuterium in various positions of the molecule (for prostaglandins,
d^ compounds containing two deuteriums on C-3 and C-4 are normally
used). A fixed amount of internal reference standard is added to each
sample at the earliest possible stage in the analytical sequence, usually
before the first extraction step and can therefore compensate for varying
efficiencies during extraction, purification and derivatisation. A stable
isotope internal reference standard and unlabelled standard compound
will have virtually identical chromatographic characteristics and will
not be distinguished until final detection by the mass spectrometer.
At this stage, the instrument is set to record the selected ion chromato-
grams at the corresponding m+/e value of the labelled and unlabelled
compounds. The ions chosen are ones in which the deuterium atoms
in the internal standard are retained in the ion fragment. A calibration
curve may then be prepared by plotting the peak response ratio of the
standard/internal reference standard against the amount of standard
in the calibration standards and a comparison of the peak height ratio of
samples enables their quantification.
The sensitivity of the method (generally low nanograms) depends
on the cleanliness and the nature of the derivatised sample and normally
extensive chromatography is required prior to quantification by GC-MS.
GC-MS used in the multiple ion detection mode provides the most
specific assay method for the quantitative estimation of small amounts
of lipids present in complex biological mixtures and this technique has





2.1 Preparation of the Conscious Animal Model
In all studies detailed in this thesis, conscious foxhound dogs
were used. Eight male foxhounds weighing between 18 and 24 kg were
surgically prepared and the same eight animals used in all studies.
2. 7. 7 Pre-operative procedures
On the day of surgery, animals were premedicated with chlor-
promazine (Largactil, May & Baker, 20 mg i.v.) and anaesthesia was
induced with thiopentone (Pentothal, May & Baker UK, 0.5 mg/kg) .
The areas to be operated upon were clipped and loose hair was removed.
The animal was secured to the operating table and an endotracheal tube
was inserted. A suitable depth of anaesthesia was maintained by
administration of a mixture of oxygen : nitrous oxide : halothane
(Fluothane, May & Baker UK). The shaved skin was swabbed with
three antiseptic solutions:
1. Chloros (agricultural) diluted 1 : 10 with water.
2. Chlorhexidine (Hibitane, ICI, UK) diluted 1: 10
with ethanol.
3. Thiomersal solution: 0.1% w/v thiomersal in 50%
ethanol, 25% acetone and 25% water.
Thiomersal solution was also applied to the skin immediately prior to
making any incisions.
All surgical instruments were sterilised by autoclave, and those
persons partaking in the operative procedure scrubbed with Betadine
surgical solution and wore sterile gowns, masks, hats and gloves.
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2. 7. 2 Operative and post-operative procedures
(a) Formation of an isolated carotid artery loop
Mid and lateral incisions of 10-15 cm were made in the neck and
blunt dissection used to expose the common carotid artery. Small
vessels were ligated with either black silk (Surgisilk 4(1)) or thin
catgut (DW202 Chromic 3) ties to prevent bleeding. The superior
thyroid artery was ligated and the isolated carotid artery was cleared
of adventitia as far as the bifurcation of the carotid artery. The skin
between the two incisions was separated from the muscle layer, care
being taken to maintain an adequate blood supply. The skin was then
folded over the isolated section of the carotid artery and sutured with
polyamide (Blue polyamide 2) to form a loop. The incision on the neck
was sutured in a similar way and the wounds irrigated with thiomersal
solution. An elastic bandage was secured around the animal's neck and
pethidine (Roche UK, 25 mg i.m.) administered immediately following
surgery and again six hours later.
Animals were maintained on Septrin (Roche, UK) for five days
after the operation, to reduce the risk of post-operative infection.
The morning after the operation, the arterial loop was gently separated
from the neck wound and cleaned with a sterile swab. A plaster bandage
was then applied around the neck to prevent the animal from scratching
the wound. The plaster was changed every three days, when the wounds
were separated and swabbed with 1% cetrimide solution (Cetavlon, ICI,
UK). After ten days, the sutures were removed and the plaster
bandage replaced with a material collar until the wound was sufficiently
healed, whereupon no further protection was required. Each animal
was allowed one month to recover from the operation before any further
surgical procedures were undertaken.
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(b) Insertion of an indwelling venous catheter
A silastic catheter (Esco Ltd, UK, 1.0 mm i.d., 2.0 mm o.d.,
70 cm long) was introduced at the back of the neck and led subcutan-
eously down the back to the flank by a sterile metal rod. An incision
was made in the underside of a hind limb to expose the femoral vein,
and the catheter led to this site. A branch of the femoral vein was
cannulated and the catheter inserted and positioned in the inferior vena
cava via the femoral vein. The catheter was then secured and its
patency confirmed by flushing with sterile saline (sodium chloride
injection B.P. 0.9% w/v, Steriflex, Boots Co., UK; heparin sodium
1000 u/ml, Weddel Pharmaceuticals Ltd, UK). The incision in the hind
limb was then sutured with black silk. At the back of the neck, the
catheter terminated in a metal lever fitting, a one-way metal tap and a
metal obturator, and this was secured to a gauze collar. Pethidine
(25 mg i.m.) was administered on completion of surgery and again
six hours later.
Animals were maintained on penicillin (Crystamycin, Glaxo, UK,
0.5 mega unit/day) for five days to reduce the risk of post-operative
infection. A material collar secured around the neck prevented the
animal from interfering with the catheter. Every second day, after
removal of dead space, the catheter was flushed with sterile saline and
filled with heparinised saline (1000 u/ml). Animals were allowed seven
days to recover from this operative procedure before being incorporated
into an experimental regime.
59.
2.2 Treatment of Infection
Rectal temperature and body weight were recorded daily and a
chart kept. Pyrexia and loss of appetite were taken to indicate infection
and this was treated by administration of penicillin (0.5 mega unit/day
i.m.) for five days. Animals were removed from experimental studies
during this period. In the majority of cases, this antibiotic regime was
found to be successful. However, prolonged infection or interference
by the animal sometimes necessitated removal of the catheter. Catheter
patency was normally maintained for up to four weeks which meant that
each animal had at least two catheters inserted in order to complete the
series of studies.
2.3 Diet
All animals were fed a standard diet containing 50 mMoles sodium
and 40 mMoles potassium per day. The diet was supplemented with
ferrous sulphate (Laporte, UK, 200 mg/day).
Sodium depletion was induced by frusemide (Hoechst Ag., 200 mg
i.v.) and maintained by a diet containing less than 10 mMoles sodium/
day. Potassium chloride (slow K, Ciba UK) was given to maintain a
daily potassium intake of 40 mMoles. At the end of each sodium deplete
period, animals were housed in metabolic kennels and two 24-hour urine
collections taken to allow determination of sodium excretion. In all
cases, sodium excretion was found to be less than 8 mMoles/day indicat¬
ing that animals were maximally retaining sodium.
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2.4 Experimental Procedures
All studies were performed in a quiet room where animals had been
trained to sit or stand on a table, restrained by a collar and lead such
that they could turn through 90° but not 180°. The exact protocols for
the various studies are described in detail in the following sections,
however basic experimental procedures were common to all studies.
2. 4. 7 Administration of fluids and drugs
Intravenous infusions of fluids and drugs were made via the
indwelling venous catheter. All administrative tubing was sterile and
where possible, disposable sterile anaesthetic and y-junction extension
sets (Travenol Laboratories Ltd, UK) were used. Where disposable
tubing could not be used, sterility was achieved by storage in aqueous
hibitane. Tubing was connected from the pumps to the animal such that
three different solutions could be infused simultaneously (Figure 2.1).
Modest water diuresis was established by infusion of sterile dextrose
solution (Dextrose solution 5% w/v, Steriflex, Boots Co., UK), the
infusion rate being controlled by a Watson-Marlow roller pump. Infusion
of drug solutions was achieved by the use of a Harvard dual-syringe
infusion pump. Drug solutions were sterilised by passing them through
disposable sterile millipore filters (Millipore SA, France, 0.22 |iM pore
size).
2. 4. 2 Measurement of systemic blood pressure
To monitor systemic blood pressure, the isolated arterial loop was
shaved of hair and swabbed with alcoholic Hibitane. Local anaesthesia
was induced with 0.25 ml lignocaine injected subcutaneously at either
end of the loop. The carotid artery was then cannulated with a 19
gauge butterfly needle. The needle was carefully positioned in the
FIGURE2.1:Diagrammaticrepresentationofni linstrumentation.
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vessel and kept in position with elastoplast. The catheter was
connected to a portable pressure transducer (Statham P39) and the
arterial line flushed with sterile saline and filled with heparinised
saline (100 u/ml). The pressure transducer, which was secured to
the animal's collar, was connected to a Honeywell recorder and a
permanent record of systemic blood pressure kept on ultra-violet light
sensitive paper. During every 30 min. recording period, mean
arterial pressure was recorded for 25 min. and pulsatile pressure,
from which heart rate was derived, was recorded for 5 min. Prior to
the commencement of each study, the pressure recording system was
calibrated from 0 to 100 mm Hg using a mercury manometer.
2. 4. 3 Collection of blood and urine samples
After removal of the dead space, blood samples of up to 25 ml
were withdrawn from the arterial catheter. The blood was immediately
put into pre-cooled lithium-heparin tubes and kept on ice. The arterial
catheter was flushed with a small volume of sterile saline and filled
with sterile heparinised saline (100 u/ml). Blood samples were centri-
fuged within 20 min, at 4°C, 2000 g for 25 min. The plasma was then
aspirated and stored at -20°C until the time of assay.
Timed urine collections were made via a sterile catheter inserted
into the bladder. Urine was therefore collected continuously with
complete bladder emptying at the end of each collection period being
achieved by manual palpation. This allowed accurate urine flow rates
to be determined. Urine samples were stored at -20°C until the time
of assay.
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2.5 Estimations Performed on Plasma and Urine Samples
2. 5. 7 Estimation of renal plasma flow
After an initial loading dose of 8 mg/kg p-aminohippuric acid
(PAH) (20% aminohippurate sodium, Merck, Sharp and Dohme, USA)
diluted in sterile dextrose, was infused intravenously to maintain a
plasma concentration of approximately 3 mg/100 ml.
The concentration of PAH in the plasma and urine samples was
estimated by spectrophotometry using a continuous flow auto-analyser
system (Technicon Auto-Analyser System AAI) (Harvey and Brothers,
1962). In brief, the PAH in the plasma or urine was diazotised with
nitrite, and excess nitrite was destroyed with ammonium sulphate.
The diazotised PAH was coupled with N(l-napthyl)-ethylene diamine
dihydrochloride to produce the colour which was estimated in a col o ri-
meter at 550 nm and recorded on a chart recorder. The colour produced
in the plasma and urine samples was compared with that produced by
standard solutions.
Renal plasma flow, expressed as ml/min, was taken to be PAH
clearance (Cp^jj) and was calculated by:
UPAH
CpAH = 5^ x v
where Up^H = concentration of PAH in the urine (mg %)
PpAH = concentration of PAH in the plasma (mg %)
V = urine flow (ml/min)
2. 5. 2 Estimation of glomerular filtration rate
After an initial loading dose of 50-100 mg/kg, inulin (10% w/v,
T. Kerfoot & Co., UK) diluted with sterile dextrose, was infused
intravenously to maintain a plasma concentration of approximately 20 mg/
100 ml.
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The concentration of inulin in the plasma or urine samples was
estimated by spectrophotometry (Heyrousky, 1956) using a continuous
flow auto-analyser system (Dawborn, 1965). In brief, the plasma or
urine samples were diluted with 0.5N hydrochloric acid and the inulin
hydrolysed to fructose by heating at 60°C for 10 min. Protein in the
samples was removed by dialysis and colour developed by treating the
protein-free dialysate with concentrated hydrochloric acid and 3-
indoleacetic acid at 60°C for 8 min. The colour produced in the samples
was estimated in a colo r imeter at 520 ,nm, recorded on a chart recorder,
and compared with the colour produced by standard solutions.
Glomerular filtration rate, expressed as ml/min, was taken to be
inulin clearance (Cinulin) and was calculated by:
Uinulin
Cinulin = x V
Pinulin
where Uinulin = concentration of inulin in urine (mg %)
Pinulin = concentration of inulin in plasma (mg %)
V = urine flow (ml/min)





2. 5. 3 Estimation of urinary and plasma sodium and potassium
concen trat ion
Urinary and plasma sodium and potassium concentrations were
estimated by flame photometry (Corning 435 flame photometer). The
flame photometer was calibrated using Corning prepared standard
solutions of 200 mM/litre sodium and 100 mM/litre potassium using 3M
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lithium as internal standard. The sodium and potassium signals were
ratioed with the lithium reference signal to prevent changes in signal
level caused by fluctuations in the flame.
Sodium excretion (UNa+V) and potassium excretion (Uj^+V),
expressed as pM/min, were calculated by:
U.T +V = UXT + x VNa Na +




UK+V = UR+ x V
where 11^+ = concentration of potassium in the urine
(pM/ml)
V = urine flow (ml/min)
2. 5. 4 Estimation of urinary and plasma osmolality
Urinary and plasma osmolality was estimated by freezing point
determination on the principle that the colligative properties of a
solution change in proportion to the number of solute particles present.
The osmometer (Advanced Instruments, Digimatic Osmometer, 3D 11)
was calibrated using a series of prepared standards, and the osmolality
of the sample expressed as m osmoles/kg of water.
Solute excretion (Uqsm^K expressed as rp osm/min, was calculated
by:
U V = U x V
OSM OSM
where ^nmvi = concentration of osmoles in urine
(m osm/kg H20)
V = urine flow (ml/min)
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Osmolality clearance (COSM ), expressed as ml/min, was
calculated by:
x V
where UOSM = osraolality UI"ine (mosmol/kg H20)
Pqsm = osmolality of plasma (mosmol/kg H20)
V = urine flow (ml/min)






2. 5. 5 Estimation of plasma renin activity
Plasma renin activity was estimated using radioimmunoassay to
measure the quantity of angiotensin 1 generated by plasma samples
under standardised conditions. A commercially available radioimmuno¬
assay kit was used (CIS Cea Sorin angiotensin 1 radioimmunoassay kit,
USA).
In brief, an aliquot of a plasma sample was incubated at 37°C,
pH 5.5-6.0 for 1.5 h to maximise the action of renin. 2, 3-dimercapto-
propanol and 8-hydroxyquinoline were added to prevent degradation of
the angiotensin 1. Another aliquot of the plasma sample was incubated
at 2-4°C as a sample blank. After incubation, the reaction was stopped
by lowering the temperature to 2-4°C. Radioimmunoassay was then
performed upon the generated angiotensin 1, and the angiotensin 1
standards. Angiotensin 1 competed with the radioactive tracer for the
binding sites of the antibody and the immune complex formed was
separated from the free angiotensin 1 by adsorbing the latter on dextran-
coated charcoal. After centrifugation of the charcoal, the supernatant
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was decanted into scintillation vials and the bound radioactivity counted
in a g'-counter. Finally, a standard curve was plotted and the angio¬
tensin 1 concentration in the plasma sample determined.
The plasma renin activity (PRA), expressed as ng angiotensin 1/




where a = angiotensin 1 concentration in a sample aliquot
incubated at 37°C (ng/ml)
b = angiotensin 1 concentration in a sample aliquot
kept at low temperature (ng/ml)
t = time of incubation at 37°C (hr)
The intra-assay coefficient of variation was approximately 6% while the
inter-assay coefficient of variation was approximately 10%.
2.6 Estimation of Urinary 6-keto-PGFxa by Stable Isotope Dilution
and Combined Gas Chromatography-Mass Spectrometry
Before the quantification of urinary 6-keto-PGFia by GC-MS was
performed, the prostaglandin was extracted from the urine and the
extract purified in order to secure a high specificity of the assay and
optimise the signal : noise ratio.
2. 6. 7 Extraction and purification of 6-keto-PGFxa. from urine
(a) Amberlite XAD-2 extraction
6-keto-PGF^ was extracted from up to 50 ml volumes of urine.
To each urine sample, a constant amount of 3,3, 4,4-tetradeuterated
6-keto-PGF1a (100 ng in 20 jal MeOH) (cL, 6-keto-PGFx a, a gift from
the Upjohn Company, USA) and 5,8,9,11,12,14,15-tritiated 6-keto-PGFia
(0.025 iiCi in 50 pi MeOH) (3H-6-keto-PGF xa , Amersham Radiochemicals,
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UK) was added. A sufficient quantity of amberlite XAD-2 (BDH
Chemicals Ltd, UK) was washed thoroughly in methanol, acetone and
distilled water, fine particles and colloidal material being decanted.
After the washing procedure, the XAD-2 was suspended in distilled
water and the columns packed by sedimentation using 3 gm XAD-2/column,
held in place by a plug of glass wool. Urine samples were acidified to
pH 3.0-3.5 with IN hydrochloric acid and percolated through the
columns. The columns were washed with 2 x 10 ml distilled water before
the 6-keto-PGF].a was eluted with 2 x 10 ml methanol. The eluate was
taken to dryness on a rotary evaporater at 45°C.
(b) Silicic acid chromatography
In this chromatographic step, three solvent systems were used:
System I: toluene : ethyl acetate (60:40)
System II: toluene : ethyl acetate : methanol (60 : 40 : 0.5)
System III: toluene : ethyl acetate : methanol (60 : 40 : 20)
Columns were packed with an equilibrated slurry of activated silicic
acid (Unisil 100-200 mesh, Clarkson Chemical Co., USA) in solvent system
I, using 1.5 gm silicic acid/column held in place by a plug of glass wool.
The columns were washed with 6 ml solvent system III followed by 6 ml
solvent system I. The urinary extracts were then applied to the columns
dissolved in a mixture of 4 ml solvent system I and 1 ml solvent system III.
The columns were washed with 8 ml solvent system II before the 6-keto-
PGFiCt was eluted with 8 ml solvent system III. The eluate was evaporated
under air.
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(c) High pressure liquid chromatography
Straight phase high pressure liquid chromatography (HPLC)
was performed using a partsil PAC column of 10 cm length and 0.4 cm
internal diameter (Whatman Inc., USA). The column was fitted with
a 1 ml loop injector (Rheodyne, USA) and connected to a Perkin Elmer
Series 2 liquid chromatograph. A pre-column packed with Co : Pell
PAC (HPLC Technology Ltd, UK) was added to the system to remove
any particulate material from the sample and hence prolong the chromato¬
graphic efficiency of the main column. A solvent system of dichloro-
ethane : methanol : acetic acid (90 : 10 : 0.1) was used, and after
equilibration of the column, the flow rate was set at 1 ml/min. Samples
were injected dissolved in 300 ill of the solvent system and 1 ml fractions
of the column eluate were collected using an Ultorac fraction collector
.(LKB Ltd, Sweden).
As 6-keto-PGF|a contains no chromophore, it was not possible to
monitor its elution time by ultra-violet absorption. The tritiated 6-
keto-PGFja added to each urine sample before extraction was therefore
used as a marker. 100 |il aliquots of the 1 ml fractions of the column
eluate were added to 10 ml scintillation fluid (10 gm PPO and 0.5 gm
dimethyl POPOP dissolved in 2.5 1 toluene) and counted in a liquid
scintillation counter (Nuclear Chicago Ltd, UK). The relevant fractions
were combined and taken to dryness under air.
During the purification of a number of samples by HPLC, it was
necessary to ensure that the chromatographic properties of the column
remained stable. PGB2 has similar chromatographic properties to 6-keto-
PGF | a but is distinct from other prostaglandins in that it contains a
chromophore arid therefore absorbs ultra-violet light. The chromato¬
graphic properties of the column were checked by repeatedly noting the
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elution time of PGB2 by monitoring the ultraviolet absorption using a
Cecil CE212 variable wavelength spectrophotometer (Cecil Instruments,
UK). The absorption wavelength was set at 280 nm.
2. 6. 2 Recovery of 6-keto-PCFi a from extraction and purification
Procedures
Although the use of d4 6-keto-PGFj^a as internal standard
accounted for the loss of material during the extraction and purification
procedures, calculation of recoveries of 6-keto-PGFiCt proved useful
in indicating the overall variability of the method. Mean recoveries of
40% were found after the three successive chromatographic stages, the
bulk of the material being lost at the silicic acid stage.
2. 6. 3 Derivatisation of 6-keto-PCFxq
Prior to GC-MS, the 6-keto-PGFia had to be derivatised to a
molecule with the most suitable characteristics for mass spectrometry,
whilst at the same time possessing satisfactory gas chromatographic
properties. The methyl ester, methoxime, trimethyl silyl; methyl ester,
ethoxime, trimethyl silyl; andmethyl ester, butoxime, trimethyl silyl ether
derivatives of 6-keto-PGF1a were prepared and their mass spectra
compared. The methyl ester, methoxtaie, trimethyl silyl ether derivative
(6-keto-PGFj^a Me, MO, TMS) was found to be the most suitable since
it demonstrated ions in its mass spectrum of high relative abundance
and high mass, conferring sensitivity and specificity to the assay
(Figure 2.2).
The methyl ester was prepared by treatment of a methanolic
solution of the sample with an excess of an ethereal solution of diazo-
methane. The methanol in the sample has been found to be necessary




































FIGURE 2.2: The methyl ester, methoxime, trimethyl silyl derivative
of 6-keto-PGFia and its mass spectrum.
72.
was prepared by the reaction of ethereal N-methyl-N-nitroso-p-toluene-
suphonamide (Aldrich Chemicals Co., UK) with aqueous potassium
*
hydroxide and ethanol, and transferred into fresh diethyl ether with
the aid of a stream of nitrogen. This ethereal solution could be
satisfactorily stored at -20°C for short periods. The sample was
allowed to stand in the diazomethane for five minutes at room temperature
before being blown to dryness and vacuum dessicated.
The methyl oxime was prepared by treatment of the esterified
material with 100 ul of a 5 mg/ml solution of methoxyamine hydrochloride
(Supelco Inc., USA) in pyridine. The reaction was left to proceed
overnight at room temperature, then the samples were treated at 60°C
for 40 min before being blown to dryness and vacuum dessicated.
The methyl ester, methoxime derivative was then reacted to form
the trimethyl silyl ether by dissolving the esterified, oximated material
in 20 pi bis (trimethyl silyl) tri-fluoro-acetamide containing 1% trimethyl-
chlorosilane (Sigma Chemical Co., USA). The reaction was carried out
at 60°C for 20 min.
2. 6. 4 Quantification of 6-keto-PCF xq by gas chromatography-mass
spectrometry
The estimations of 6-keto-PGFia in the urinary extracts were
obtained using a VG-Micromass 70-70F mass spectrometer coupled to a
PYE 204 gas chromatograph by means of a single stage glass separator.
The gas chromatograph was equipped with a spiral glass column (1.25 m
x 4 mm i.d.) packed with 3% OV-1 on Supelcoport 100-200 mesh (Supelco
Inc., USA). The carrier gas in the gas chromatograph was helium and
the flow rate of the helium and the temperature of the column were
adjusted to obtain a suitable retention time for the 6-keto-PGFia Me,
MO, TMS. The retention time should be long enough to achieve good
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chromatographic separation but short enough to render the assay
practical. The column temperature and helium flow rate were set to
give the 6-keto-PGFj^ a Me, MO, TMS a retention time of approximately
7.5 min (approximately 250°C; 2.0 ml/min).
The chromatographic properties of the column tended to vary
from day to day even at a given temperature and helium flow rate.
This variability was dependent upon the extent to which the GC-MS
was being used, such that extensive use of the gas chromatograph
resulted in longer retention times. It was therefore desirable to obtain
an indication of the chromatographic efficiency of the column prior to
commencing an assay. This was achieved by plotting the retention
times of a mixture of fatty acid methyl esters on a logarithmic scale
against the number of carbon atoms in the esterified carboxylic acids
(Bergstrom, Ryhage, Samuelsson and Sjovall, 1963). This graph was
used to convert the observed retention time of the 6-keto-PGF!a Me,
MO, TMS into a carbon value. Having determined the carbon value,
the graph could then be used to indicate the expected retention time of
the 6-keto-PGFra Me, MO, TMS prior to each assay allowing any necessary
adjustments in the column temperature to be made. 6-keto-PGFiO, Me,
MO, TMS had a carbon value of 25.
Typical mass spectrometer operating conditions were:
Separator temperature: 250°C
Ion source temperature: 250°C
Electron energy: 22-70 eV (dependent on
instrument performance)
Accelerating voltage : 4 kV
For quantitative determinations, the mass spectrometer was used in the
multiple ion detection mode with fixed magnet current and voltage
scanning. The mass spectrometer was also operated at high resolution
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FIGURE 2.3: Representative ion chromatograms of Me, MO, TMS,
6-keto-PGFja.
A - ion chromatogram of 6-keto-PGFxa standard
(machine gain 5V).
B - ion chromatogram of 6-keto-PGFia from urine
sample (machine gain 50V).
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enabling separation of ions with very close masses. Although this
resulted in some loss in sensitivity, it ensured a high specificity of the
assay.
Heptacosafluorotributylamine (V.G. Micromass, UK) was bled slowly
into the mass spectrometer to produce a series of ion fragments of known
exact masses. The mass spectrometer was then tuned to the selected
6-keto-PGFMe, MO, TMS ion fragment by reference of its precise
mass to the precise mass of the nearest heptacosafluorotributylamine ion
fragment.
For the Me, MO, TMS derivative of 6-keto-PGFiCt, the mass spectro¬
meter was focussed to monitor the ion intensity at m/e 598 and the
corresponding deuterated ion, m/e 602, using a reference heptacosa¬
fluorotributylamine ion intensity of 501. Although the 598 ion of the
6-keto-PGFia Me, MO, TMS did not have such a large relative abundance
as the 418 or 508 ions (Figure 2.2), it was found necessary to use the
ion of higher mass in order to avoid interference from contaminants in
the sample.
Standards were composed of known quantities of derivatised
unlabelled and deuterated 6-keto-PGF^, the amount of deuterated material
being the same as that added to the urine samples prior to extraction.
Aliquots (5 |il) of the standards and urinary extracts were injected into
the GC-MS and the ion currents at the m/e 598 and 602 recorded
simultaneously as single ion chromatograms on a multi-pen recorder
(Rika denki Mitsui, Electronics Ltd, UK). Representative chromatograms
obtained from samples of dog urine are shown in Figure 2.3. Calibration
curves were constructed by plotting the quantity of unlabelled 6-keto-
PGFxa in each standard against the peak height ratio m/e 598/602 (Figure
2.4). The peak height ratios m/e 598/602 for the urinary extracts were
FIGURE2.4:Standardcurvefor6-keto-PGFiasperform dbyGC-MS
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calculated and the urinary 6-keto-PGFxct level estimated from the
standard curve.
A standard curve was constructed for each assay performed.
Any minor variation seen between standard curves was most likely due
to inaccuracy in standard preparation.
The y-intercept (0.05) of the standard curve was due, primarily,
to the inevitable presence of unlabelled molecules in the deuterated
6-keto-PGFxa and the value 0.05 sets the lower limit of sensitivity of
the method with a minimum measurable ratio set arbitrarily at 2 x 0.05.
Using 100 ng d^ 6-keto-PGFxa added to 50 ml dog urine, the normal
endogenous levels of 6-keto-PGFj^a (0.4 - 2.6 ng/ml) gave m/e 598/602
ratios in the range 0.3- 1.2. A 6-keto-PGFxa excretion rate of less than
35% of normal should therefore be measurable.
2. 6. 5 Parameters of the analytical method
(a) Precision
In order to determine how precisely the GC-MS technique could
quantify a known amount of 6-keto-PGFxa from a urine sample, and to
ensure that this precision was not affected by the initial volume of the
sample, the following test was performed.
In addition to the internal standard, 200 ng unlabelled 6-keto-
PGFxa was added to each of six aliquots of the same urine collection
(10 ml, 25 ml, 50 ml, 100 ml, 150 ml, 200 ml). A seventh aliquot of 50 ml
was extracted without prior 6-keto-PGFxa addition. Following purifica¬
tion and derivatisation, the 6-keto-PGFxa in the urine was quantified by
GC-MS. The results in Table 2.1 represent the estimated amounts of
6-keto-PGFxa in the various urinary aliquots following subtraction of
the endogenous level. The mean value for the 6-keto-PGFia quantified
from the urine samples represents 93% of the original material.
FIGURE2.5:Comparisonf6-keto-PGFjastandardcu vesusi gdardswhich havebeenextractedfromurinp iortderiva isationndsta dards whichhavebeenderivat sedonly. •representsunextractedstandar s; orepresentsxtractedstandard .
79.
TABLE 2.1:
Volume of urine Q 25 5Q og 5Q 20Q
sample (ml)
Quantity of g 80 ?5 gg m
6-keto-PGFi* (ng)
(b) Accuracy
In order to ensure that the accuracy of the method was not
affected by the prior chromatographic procedures, the following test
was performed.
Two standard curves were constructed, one set of standards
having been added to 50 ml aliquots of the same urine collection and
taken through the extraction procedure prior to derivatisation.
After accounting for the endogenous 6-keto-PGFiCt in the urine, there
was good agreement between the ratios obtained for the standards
taken through the extraction procedure and those derivatised without
prior extraction (Figure 2.5). Standards derivatised without prior
extraction were therefore routinely employed for the calibration curves.
(c) Sensitivity
The lower limit of measurement varied with two parameters.
Firstly, the signal/noise ratio of the particular urine extract and,
secondly, the sensitivity of the mass spectrometer. The sensitivity of
the mass spectrometer fluctuated markedly from day to day reflecting
variation in the condition of the ion source.
Generally, a 6-keto-PGF xct concentration of 0.2 ng/ml could be
measured from a urine sample.
SECTION III
Determination of the Physiological
Significance of Systemic PGI2 and
Its Relationship to Urinary 6-keto-PGFxa
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3.1 Introduction
PGI2 infused intravenously into man (Szczeklik, Szczeklik and
Nizankowski, 1980) or anaesthetised animals (Armstrong, Dusting,
Moncada and Vane, 1978) lowered systemic blood pressure by decreas¬
ing total peripheral vascular resistance. Infusion of large doses of
PGI2 (>30 ng/kg/min) into the renal artery of anaesthetised dogs
increased renal blood flow and also resulted in a decrease in systemic
blood pressure (Gerber et at., 1978b). This indicated that PGI2
in the renal venous blood was recirculated to cause a decrease in total
peripheral vascular resistance and raised the possibility that PGI2
may have a role as a circulating as well as a local hormone. The
demonstration that PGI2 was present in both arterial and venous blood
(Moncada, Korbut, Bunting and Vane, 1978) and was released from
the lung into the arterial circulation (Gryglewski, Korbut and
Ocetkiewicz, 1978) led to the hypothesis that PGI2 may act as a
circulating hormone in the control of systemic blood pressure.
If PGI2 were to be acting as a circulating hormone, it is possible
that systemic PGI2 may exert control on renal haemodynamics and
electrolyte excretion. It would therefore be important to investigate
the effects of intravenously infused PGI2 on these parameters.
Hill and Moncada (1979) infused PGI2 intravenously into
anaesthetised dogs at a rate of 300 ng/kg/min. Although there was
little change in renal blood flow, the significant fall in systemic blood
pressure caused by the high concentration of PGI2, resulted in
decreases in glomerular filtration rate, urine volume and electrolyte
excretion (Hill and Moncada, 1979). In this and other studies invest¬
igating the haemodynamic actions of PGI2, anaesthetised, surgically
traumatised animal preparations have been used. The use of conscious
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surgically untraumatised animals would be more valuable for the
evaluation of the physiological role of PGI2, particularly its role in
the control of renal haemodynamics and electrolyte excretion.
In the absence of specific antagonists or synthesis inhibitors,
useful information about the physiological actions of PGI2 can be
obtained from two means of investigation. First , by observing the
effects of infusion of low concentrations of PGI2 in unanaesthetised
animals and, secondly, by measuring its rate of production under
normal and stimulated conditions.
6-keto-PGFia can be detected in the urine but it is not possible
to determine whether this reflects circulating and/or renal production
of PGI2 since in addition to systemic vascular synthesis, many sites
within the kidney are capable of synthesising PGI2 (Grenier and
Smith, 1978; Terragno et at., 1978; Hassid et a!., 1979). Tracer
studies have demonstrated that, as well as being hydrolysed to 6-keto-
PGF-Lct, PGI2 is enzymatically metabolised by the blood vessels (Wong
et al., 1978), kidney (Wong et at., 1979) and liver (Wong et a!., 1980).
Like 6-keto-PGFia, these enzymatically produced metabolites are
excreted in the urine (Sun and Taylor, 1978). Assuming that endog¬
enous PGI2 is metabolised in the same way as exogenous PGI2 and that
the metabolites are excreted in a similar manner, it is possible that
endogenous PGI2 production may be more reliably reflected by measure¬
ment of one or more of its enzymatically produced metabolites rather
than by measurement of urinary 6-keto-PGFiCt. At the time of this
study, although the structures of the major urinary metabolites of
PGI2 had been elucidated, standards to allow their measurement were
not available. It was therefore pertinent to determine the precise
relationship between systemic PGI2 and urinary excretion of 6-keto-
PCFlCt.
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The aim of this section was to study the effects of intravenously
infused PGI2 on systemic and renal haemodynamics and electrolyte
excretion and to relate this to the urinary excretion of 6-keto-PGFia,
thereby allowing assessment of the physiological significance of PGI2.
3.2 Methods
Eight male conscious foxhounds were used, all animals being
surgically prepared as described in Section 2.1. On the day of each
study, sterile dextrose solution (5 gm/100 ml) was infused at 7 ml/min
for 30 min, then continued at 3 ml/min throughout the rest of the 4 hr
study period. This established a modest water diuresis. Loading doses
of PAH and inulin were administered, and the appropriate dilutions
intravenously infused at 0.5 ml/min. A one-hour equilibration period
was allowed. Vehicle buffer or PGI2, in concentrations of 7.5, 15 or 30
ng/kg/min, was infused intravenously at 0.5 ml/min for 4 hr. The
PGI2 was dissolved in 0.025M carbonate buffer at pH 9.8. In this
buffer, PGI2 has a half-life of 13 hr at room temperature (Cho and Allen,
1978). This was confirmed by detecting by spectrophotometry, the
appearance of 6-keto-PGFia in a solution of PGI2. In order to minimise
the quantity of hydrolysed PGI2 infused, the infusion solution was
replaced every 30 min by a fresh solution prepared from a PGI2 stock
kept on ice. During several studies, the activity of the PGI2 was
checked at intervals throughout the 4 hr period. This was achieved by
comparing the ability of the PGI2 in the infusion solution to prevent
ADP-induced platelet aggregation, with that of freshly prepared
standards. In all cases, the PGI2 in the infusion solution had the
predicted activity.
83.
Throughout the 4 hr infusion periods, systemic blood pressure
was monitored continuously, urine collections were made every 30 min
and arterial blood samples taken every 60 min (see Section 2.4.3).
Renal plasma flow, glomerular filtration rate, sodium, potassium and
osmolality excretion, plasma renin activity and urinary 6-keto-PGF xa
were estimated by techniques described fully in Section 2.5.
At least 48 hr were allowed between each study.
3.3 Statistical Comparisons
The object of the study was to compare the effect of buffer
infusion with infusion of different concentrations of PGI2, over time.
This protocol is typical of a repeat measurements study and necessitates
the use of the analysis of variance as a statistical method. The analysis
of variance assumes that the measurements were obtained under
independent conditions, that the data were normally distributed and
that each group had the same underlying standard deviation. In the
repeated measurements analysis of variance, the total variability is
partitioned into differences between experimental units, variation over
time, and residual variability. The analysis of variance therefore
comprises of three F-statistics performed using a critical F value accord¬
ing to Greenhouse and Geisser (F0.os = l(n-l)).
The first F-statistic (Fi) examines the variability between time
points between drugs. If this test is not significant then the trend
over time is similar for each treatment.
The second F-statistic (F2) looks at the trend over time. If this
test is not significant then there is no trend over time, that is, the
variable remains constant throughout the study.
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The third F-statistic (F3) examines the difference between
treatments with an underlying test for variability between animals.
This is performed by comparing means over total time and therefore
to be valid, it requires that the first F-test is not significant, i.e. all
treatments must show the same trend.
Significance for ail F-tests was taken at p <0.05.
The large daily fluctuations in plasma renin activity necessitated
a control blood sample for estimation of plasma renin activity to be
taken immediately prior to each study. The effect of PGI2 on plasma
renin activity was therefore statistically compared with the control value
using a student 2 tailed t-test. Significance was taken at p <0.05.
Although most statistical comparisons have been made using analysis
of variance, for convenience, the data in the tables and graphs in the
following sub-section are expressed as mean ± standard error.
3.4 Results
All data are summarised in Tables 3.1 - 3.3, and the values for
statistical analyses are summarised in Table 3.4.
3. 4. 7 Systemic blood pressure (Fig. 3. 1)
Statistical analysis demonstrated a similar, significant trend in
systemic blood pressure in all four infusions (Fi, p <0.1257; F2 ,
p <0.0001). This trend was for systemic blood pressure to increase
during each study, as observed by the small progressive increase during
the vehicle buffer and 7.5 ng/kg/min PGI2 infusion and the more
pronounced increases following the initial depression in systemic blood




























































































































































































































































Filtrationrac Buffer PGI27.5ng/kg/min PGI215ng/kg/min PGI230ng/kg/min






























































































































































































































































































































































































































































PlasmaReninActivity(ng/mlhr) Buffer1.7+0.5 PGI27.5ng/kg/min1.9+0.5 PGI215ng/kg/min.6+0.4 PGI230ng/kg/min1.4±0.4
1.7+0.6 2.0+0 6 1.7±0.3 2.1±0.5
1.7±0.5 1.9±0 4 1.5±0.3 1.4±0.3
1.6±0.7 1.9±0.3 1.4±0.4 1.5±0.3














































TABLE 3.4: Statistical analyses of results.
Parameter Fi f2 f3
Systemic blood pressure P <0.1237 P <0.0001 P <0.0026
Heart rate P <0.3974 P <0.2567 P <0.8515
Renal plasma flow P <0.5337 P <0.2916 P <0.2178
Glomerular filtration rate P <0.7750 P <0.1747 P <0.9235
Filtration fraction P <0.3019 P <0.1643 P <0.1427
Sodium excretion P <0.2193 P <0.0389 P <0.3820
potassium excretion P <0.7810 P <0.0111 P <0.3285
Urine flow P <0.7055 P <0.2714 P <0.1278
Osmolality excretion P <0.5923 P <0.2722 P <0.4252
Free water clearance P <0.5446 P <0.3167 P <0.1373
6-keto-PGFxa excretion P <0.1138 P <0.0095 P <0.0016
Statistical significance is taken at p <0. 05. Significance in F i
demonstrates that any trend in the parameter over time is dif¬
ferent between infusions. Significance in F2 demonstrates a
positive trend in the parameter over time for all infusions.
Significance in F3 demonstrates a difference in the response of
the parameter between infusions.
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Systemic blood pressure was not different during the low infusion
rate of PGI2 than during infusion of vehicle buffer. Mean systemic
blood pressures over the 4 hr periods were 99.6 + 0.8 mm Hg and
99.8 + 1.0 mm Hg for the vehicle buffer and 7.5 ng/kg/min PGI2 infusions
respectively.
The decrease in systemic blood pressure during the 15 and 30 ng/
kg/min PGI2 infusions was maximal 60 min after the start of the infusions.
At this point, when compared with the equivalent pressure during the
vehicle buffer infusion, systemic blood pressure was lowered by 9.3 + 1.6
and 10.3 + 2.1 mm Hg during the 15 and 30 ng/kg/min infusion rates
of PGI2 respectively. Statistical comparison demonstrated a significant
difference in the blood pressure response between treatments (F3,
p <0.0026). This reflects the much reduced systemic blood pressure
at the beginning of the 15 and 30 ng/kg/min PGI2 infusions compared
to the pressure during the vehicle buffer and 7.5 ng/kg/min PGI2 infu¬
sions. The 30 ng/kg/min PGI2 infusion did not decrease systemic blood
pressure to a greater extent than the 15 ng/kg/min PGI2 infusion which
may indicate a steep dose-response curve for PGI2 on systemic blood
pressure. After the first 60 min of the 15 and 30 ng/kg/min PGI2
infusions, systemic blood pressure showed a progressive increase,
approaching values observed during the vehicle buffer infusion. Since
the activity of the PGI2 had been tested, the increase in systemic blood
pressure despite continued PGI2 infusion, could not be attributed to
hydrolysis of the PGI2 infusion solution.
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FIGURE 3.1: The effect of intravenous PGI2 infusion on systemic
blood pressure and heart rate.
^ 0 vehicle buffer;
o o PGI2 7-5 ng/kg/min;
A A PGI2 15 ng/kg/min;
Q- • — • □ ?GI2 30 ng/kg/min.
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FIGURE 3.2: The effect of intravenous PGI2 infusion on renal plasma
flow, glomerular filtration rate and filtration fraction
^ ^ vehicle buffer;
O O PGI2 7-5 ng/kg/min;
A A PG12 15 ng/kg/min;
Q— • — • □ PGI2 30 ng/kg/min.
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3. 4. 2 Heart rate (Fig. 3. I)
No trend was demonstrated in heart rate during infusion of vehicle
buffer or during PGI2 infusion (Fi, p <0.3974; F2, p <0.2567). There
was no significant difference in heart rate between any of the treatments
(F3, p <0.8515). Mean heart rate was 81 +4, 86 + 3, 88 + 5 and 86 + 4
beats/min during the vehicle buffer and 7.5, 15 and 30 ng/kg/min PGI2
infusions respectively.
3. 4. 3 Renal plasma flow (Fig. 3.2)
Renal plasma flow did not demonstrate a trend during infusion
of vehicle buffer or during PGI2 infusion (Fi, p <0.5337; F2, p <0.2916).
Mean renal plasma flow rates over the 4 hr infusion periods were 298 ±28,
351 + 31, 316 + 29 and 351 + 33 ml/min during the vehicle buffer, and 7.5,
15 and 30 ng/kg/min PGI2 infusions respectively. Although renal plasma
flow was slightly higher during the 7.5 and 30 ng/kg/min PGI2 infusions
than during the vehicle buffer and 15 ng/kg/min PGI2 infusions, there
was no statistically significant difference in renal plasma flow between
treatments (F3, p <0.2178).
3. 4. 4 Glomerular filtration rate (Fig. 3.2)
Glomerular filtration rate did not demonstrate a trend during
infusion of vehicle buffer or during PGI2 infusion (Fi, p <0.7750;
F2, p <0.1747). There was a transient fall in glomerular filtration rate
60 min after the start of the 30 ng/kg/min PGI2 infusion which was
presumably consequent to the fall in systemic blood pressure. There
was no statistically significant difference in glomerular filtration rate
between treatments (F3, p <0.9235). Mean glomerular filtration rates





































FIGURE 3.3: The effect of intravenous PGI2 infusion on sodium
excretion and accumulated sodium loss.
vehicle buffer; o -
A A- PGI2 15 ng/kg/min; Q-
Q PGI2 7.5 ng/kg/min
— • Q] PGI2 30 ng/kg/min
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during the vehicle buffer, and 7.5, 15 and 30 ng/kg/min PGI2 infusion
rates, respectively.
3. 4. 5 Filtration fraction (Fig. 3.2)
Filtration fraction fluctuated markedly throughout the infusion
periods, particularly during PGI2 infusion. However, no general trend
was observed during any infusion (Fi, p <0.3019; F2, p <0.1643).
Mean values for filtration fraction over the 4 hr infusion periods were
0. 29 ± 0.02, 0. 26 ± 0.02, 0.28 ± 0.03 and 0.24 ± 0.02 for the vehicle buffer,
and 7.5, 15 and 30 ng/kg/min PGI2 infusion rates respectively. Filtra¬
tion fraction was lower during the 7.5 and 30 ng/kg/min PGI2 infusions
due to the small increase in renal plasma flow observed during these
infusions, without a similar increase in glomerular filtration rate. There
was, however, no statistical difference in filtration fraction between
treatments (F3, p <0.1427).
3. 4. 6 Urinary sodium excretion (Fig. 3.3)
Sodium excretion demonstrated a small progressive increase towards
the end of the vehicle buffer infusion which may be related to the
similar progressive increase observed in systemic blood pressure.
Sodium excretion also increased during all concentrations of PGI2 in¬
fusion (Fx, p<0.2193; F2, p <0.0389). Although the large standard
deviations prevented any statistically significant difference to be ob¬
served between treatments (F3, p <0.3820), the demonstrably larger
and earlier increase in sodium excretion during the 7.5 ng/kg/min PGI2
infusion was thought to be of consequence. Expressed as accumulated
sodium loss over the 4 hr period (Fig. 3.3), net sodium loss during























FIGURE 3.4: The effect of intravenous PGI2 infusion on potassium
excretion and accumulated potassium loss.
vehicle buffer; o--
A A PG12 15 ng/kg/min; Q_
_ _Q PGI2 7.5ng/kg/min
— PGI2 30 ng/kg/min
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13.2 + 4.8, 14.6±3.4 and 15.0 + 2.6 mM/4 hr during the vehicle buffer,
and 15 and 30 ng/kg/min PGI2 infusions respectively.
3. 4. 7 Urinary potassium excretion (Fig. 3.4)
Potassium excretion tended to fluctuate throughout the infusions.
However, statistical analysis demonstrated a similar significant trend
during all four infusions (Fi, p <0.7810; F2, p <0.0111). This trend
was a small maintained increase in potassium excretion observed 90 min
after the start of each infusion. Although potassium excretion was higher
during the 7.5 and 30 ng/kg/min PGI2 infusions, there was no statistically
significant difference in potassium excretion between treatments (F3,
p <0.3285). Expressed as accumulated potassium loss over the 4 hr
periods (Figure 3.4), net potassium loss was 12.2 + 2.6 and 11.6 + 2.4 mM/
4 hr for the 7.5 and 30 ng/kg/min PGI2 infusions compared with 9.6 + 2.1
and 9.7 + 2.3 mM/4 hr for the vehicle buffer and 15 ng/kg/min PGI2
infusions. The slightly higher potassium excretion during the 7.5 and
30 ng/kg/min PGI2 infusions may be related to the similarly elevated
renal plasma flow observed during these infusions.
3. 4. 8 Urine flow (Fig. 3.5)
Urine flow did not demonstrate any trend during infusion of
vehicle buffer or during PGI2 infusion (Fi, p<0.7055; F2, p <0.2714).
There was a transient fall in urine flow 60 min after the start of the
15 and 30 ng/kg/min PGI2 infusions. This was most likely a consequence
of the decreased systemic blood pressure. There was no statistically
significant difference in urine flow between treatments (F3, p <0.1278).
Mean urine flow rates over the 4 hr infusion periods were 3.6 ±0.3,
3.6 + 0.2, 3.2±0.3 and 3.6 + 0.4 ml/min during the vehicle buffer and
7.5, 15 and 30 ng/kg/min PGI2 infusions respectively.
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FIGURE 3.5: The effect of intravenous PGI2 infusion on urine flow,
osmolality excretion and free water clearance.
0 0 vehicle buffer;
Q_ o PGI2 7-5 ng/kg/min;
A A PG12 15 ng/kg/min;
□— - — .Q PGI2 30 ng/kg/min.
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3. 4. 9 Solute (osmolality) excretion (Fig 3,4)
There was no trend in solutft excretion during vehicle buffer
or PGI2 infusion (Fi, p <0.5923; F2, p <0.2722), nor was there any
difference in soldi® excretion between treatments (F3, p <0.4252).
Mean osmolality excretion rates over the 4 hr infusion periods were
548 + 40, 614 ± 43, 509 + 49 and 550 + 41 posm/min during the vehicle buffer
and 7.5, 15 and 30 ng/kg/min PGI2 infusions respectively.
3. 4. 10 Free water clearance (Fig. 3.5)
There was no trend in free water clearance during vehicle buffer
or PGI2 infusion (Fi, p <0.5445; F2, p <0.3167), nor was there any
difference in free water clearance between treatments (F3, p <0.1373).
Mean free water clearance rates over the 4 hr infusion periods were
1.9 ±0.2, 1.5 ±0.2, 1. 5"± 0.3 and 1.7 ±0.4 ml/min during the vehicle
buffer and 7.5, 15 and 30 ng/kg/min PGI2 infusions respectively.
3.4.11 Plasma renin activity (Fig. 3.6)
Plasma renin activity did not differ from the control value of
1.7 ±0.5 ng/ml/hr during the 4 hr infusion of vehicle buffer. PGI2
infusion had remarkably little effect on plasma renin activity. Neither
the 7.5 nor the 15 ng/kg/min PGI2 infusions altered plasma renin
activity from their control values of 1.9 ±0.5 and 1.6 ±0.4 ng/ml/hr
respectively. Plasma renin activity increased transiently from 1.4 ±0.4
to 2.1 ±0.5 ng/ml/hr 60 min after the start of the 30 ng/kg/min PGI2
infusion, but this increase was not statistically significant. Plasma
renin activity was returned to control levels by 120 min and remained






















FIGURE3.7:Urinary6-keto-PGFiaexcret ondu i gint avenousP I2i f si . £4vehiclebuffer;QPGI27.5ng/kg/min APGI215ng/kg/min;□_._30ng/kg/
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3. 4. 12 Urinary 6-keto-PCFia excretion (Fig. 3. 7)
6-keto-PGFia excretion increased during the first 90 rain of the
15 and 30 ng/kg/min PGI2 infusions before a steady state was achieved.
It was difficult to observe a similar trend during the vehicle buffer
or 7.5 ng/kg/min PGI2 infusion although statistical analysis of the
urinary 6-keto-PGFia excretion demonstrated a significant similar trend
during all infusions (Fi, p <0.1138; F2, p <0.0095). Urinary 6-keto-
PGFxct excretion increased corresponding to the increasing concentra¬
tions of PGI2 infused and there was a statistically significant difference
in the 6-keto-PGFia excretion between treatments (F3, p <0.0016).
Since 6-keto-PGFict excretion only reached a steady state 90-120
min after the start of the PGI2 infusion, when correlating 6-keto-PGFia
excretion rate with PGI2 infusion rate, only the last three values for
6-keto-PGF-Ld excretion during each infusion were incorporated in a
mean value. These mean urinary 6-keto-PGFia excretion rates were
2.1 ± 0.2, 6.1± 0.7, 9.7 + 0.9 and 14.9 + 1.5 ng/min during the vehicle
buffer, and 7.5, 15 and 30 ng/kg/min PGI2 infusions respectively. These
excretion rates represent 2-4% of the originally infused PGI2.
When the mean 6-keto-PGFia excretion rates were plotted against
the infusion rate of PGI2, a straight line, indicative of a linear relation¬
ship was observed (Figure 3.8). The line demonstrating this relation¬
ship had a correlation co-efficient of 0.9938 and was expressed by the
equation,
y = 0.42x + 2.70
In order to estimate an endogenous rate of entry of PGI2 into
the circulation, the mean basal rate of 6-keto-PGFia excretion was sub¬
tracted from each of the mean excretion rates during the PGI2 infusions.
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FIGURE3.8:LinearrelationshipbetweenPGI2infusir teandr nary excretionofPGFia.
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FIGURE3.9:Relationshipb tweenPGI2infusir tandr nary6-k to-PGFi excretionfollowi gsubt actifndog nous6-keto-PGFiaxcreti n andwiththelinconstrainedpassthr ugorigi .
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The increments in 6-keto-PGFxa excretion rates were then plotted
against PGI2 infusion rate and the line drawn constrained to pass through
the origin (Figure 3.9). In drawing such a graph, it was assumed that
the linear relationship between the rate of PGI2 infused and the quantity
of metabolite excreted, existed for PGI2 infusion below 7.5 ng/kg/min.
When constrained through the origin, the line had a correlation co¬
efficient of 0.9923 and was expressed by the equation,
y = 0.42x + 0.66
From this line, the endogenous 6-keto-PGFxa excretion rate could
be equated with a rate of entry of PGI2 into the circulation. This
estimation of the rate of entry into the circulation represents a maximum
value since contribution to the urine of 6-keto-PGFxa derived from PGI2
of renal origin cannot be excluded. On this basis, the calculated
endogenous rate of entry of PGI2 into the circulation of the conscious
dog had a maximal value of 4 ng/kg/min. Taking average body weight
as 20 kg, this represents a rate of entry of 80 ng/min.
3.5 Discussion
It has been suggested that PGI2 may contribute to the control
of systemic blood pressure, either as a circulating hormone, possibly
released from the lung (Gryglewski, et al. , 1978) , or as a local
hormone synthesised by the vascular endothelium (Armstrong et aL ,
1978). In the present study, intravenous infusion of PGI2 at 7.5 ng/kg/
min had no effect on systemic blood pressure and infusion of PGI2 at
15 or 30 ng/kg/min caused only transient decreases in systemic blood
pressure. When basal urinary 6-keto-PGFict excretion rate was equated
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with a rate of entry of PGI2 into the circulation, the estimated value
was 4 ng/kg/min. This rate of formation of PGI2 is well below the lowest
intravenous infusion rate of PGI2 which had no effect on systemic blood
pressure. It is therefore unlikely that endogenous PGI2 contributes
to the control of systemic blood pressure under normal conditions in
the conscious dog. The lack of sensitivity of the vasculature to
exogenous infusion of PGI2 suggests that even when PGI2 synthesis
is stimulated, it does not play a major role as a circulating hormone
in the control of systemic blood pressure. This conclusion is supported
by the demonstration that administration of PG12-specific antibodies
to normotensive or hypertensive rats fails to have any effect on systemic
blood pressure (Pace-Asciak, Carrara, Levine and Nicolaou, 1980).
The reversal of the hypotension observed during the early period
of the 15 and 30 ng/kg/min PGI2 infusions may have been due, at least
in part, to baroreceptor reflex since this compensatory mechanism is
responsive to decreases in mean systemic blood pressure (Ead, Green
and Neil, 1952). There may also have been a centrally mediated reflex
increase in sympathetic activity resulting in more noradrenaline being
released at the adrenergic terminals. Prolonged infusion of PGE2 into
the renal artery of conscious dogs results in an increase in systemic
blood pressure which can be positively correlated to an increase in plasma
renin activity (Hockel and Cowley, 1980). Since PGI2 is a more potent
renin secretagogue than PGE2 (Gerber et al. , 1979), it could be postul¬
ated that a similar mechanism was operating to prevent the prolonged
PGI2 infusion resulting in a sustained hypotension. However, it was
apparent from the results of the study that this was not the case. The
15 ng/kg/min PGI2 infusion had no effect on plasma renin activity and
the 30 ng/kg/min PGI2 infusion resulted in only a small increase in
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plasma renin activity, even though both these PGI2 infusions decreased
systemic blood pressure.
The lack of effect of intravenously infused PGI2 on renin release,
even in concentrations which lower systemic blood pressure, is surpris¬
ing in view of the amount of evidence supporting an important role for
PGI2 in the control of renin release. Most of the previous studies demon¬
strating the effect of PGI2 to increase renin release have been performed
on anaesthetised animal models or on isolated tissue preparations. It
is possible that under surgically traumatised conditions, the juxtaglomer¬
ular cells become more sensitive to the renin secretory activity of PGI2
and that in the conscious, untraumatised animal, PGI2 may not be so
potent in stimulating renin release.
There may also be a species difference in the effect of PGI2 to
stimulate renin release. A 4 hr intravenous infusion of 8 ng/kg/min
PGI2 into normal humans, which had no effect on mean arterial pressure,
resulted in an elevation in plasma renin activity which was sustained
for the duration of the infusion (Fitzgerald, Hossman, Hummerich and
Konrads, 1980). Intravenous infusion of 10 ng/kg/min PGI2 into
conscious rats had no effect on plasma renin activity but infusion of
100 ng/kg/min PGI2 resulted in a doubling of plasma renin activity (Weeks
and Compton, 1979). It would seem, therefore, that PGI2 is more potent
in stimulating renin release in normal humans than in conscious dogs
or rats.
Although the only detectable change in plasma renin activity in
the conscious dogs was a small increase 30 min after the start of the
30 ng/kg/min PGI, infusion, the blood samples for the plasma renin
activity determinations were taken from the carotid artery. It is pos¬
sible that a small increase in renin release may have occurred within the
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kidney during PGI2 infusion, without this increase being detected in
arterial blood.
PGI2 infusion had no dose-dependent action to increase renal plasma
flow. Small increases in renal plasma flow were observed during the
7.5 and 30 ng/kg/min PGI2 infusions but the 15 ng/kg/min PGI2
infusion had no effect on renal plasma flow. PGI2 infusion had no effect
on glomerular filtration rate even during the 7.5 and 30 ng/kg/min in¬
fusions when renal plasma flow was slightly elevated. This indicates
that the afferent and efferent arterioles had been dilated to the same
extent. The lack of a larger dose-dependent effect of intravenous PGI2
on the renal vasculature suggests that circulating PGI2 does not influence
renal haemodynamics. However, PGI2 is synthesised by the glomeruli
(Hassid et aI., 1979) and the arteries and arterioles in the cortex
(Terragno et at. , 1978) and may act as a local hormone in the control
of renal blood flow .
Studies using prostaglandin synthesis inhibitors to elucidate the
role of renal prostaglandins in the control of renal haemodynamics have
given conflicting results. In the anaesthetised dog, indomethacin
administration resulted in a decrease in renal blood flow and glomerular
filtration rate (Lonigro et al. , 1973; Feigen, Klainer, Chapwick and
Kadowitz, 1976). More recent studies in conscious dogs have demon¬
strated that administration of either indomethacin or meclofenamate has
no effect on renal blood flow or glomerular filtration rate unless the
renin-angiotensin system is stimulated by sodium depletion (Blasingham
et at., 1980; Deforrest et al., 1980). Under these conditions, admin¬
istration of indomethacin or meclofenamate decreases both renal plasma
flow and glomerular filtration rate. The lack of effect of indomethacin
on renal blood flow in the normal dog, and the demonstration that
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intravenously infused PGI2 has very little effect on renal plasma flow,
suggests that in the conscious animal when the extracellular fluid
volume is fully expanded and the activity of the renin-angiotensin system
is low, PGI2 does not play a significant role in the control of renal haemo-
dynamics.
The pattern of electrolyte excretion was altered by intravenous
PGI2 infusion. The greatest increase in sodium excretion was observed
during the 7.5 ng/kg/min PGI2 infusion, the 15 and 30 ng/kg/min PGI2
infusions demonstrating very little effect on sodium excretion until the
end of the infusions. The decrease in systemic blood pressure during
the first part of the 15 and 30 ng/kg/min PGI2 infusions may have been
preventing an early increase in sodium excretion. It would seem therefore
that low concentrations of PGI2 which do not affect systemic blood
pressure, can exert an influence on sodium excretion. Thus the en¬
dogenous rate of entry of PGI2 into the circulation (4 ng/kg/min), which
is too low to affect systemic blood pressure or renal plasma flow, may
be involved in the control of sodium excretion.
It is possible that the natriuretic action of the 7.5 ng/kg/min PGI2
infusion is a consequence of changes in renal blood flow not detected by
the present methodology. Renal vasodilatation in the kidney can cause
natriuresis independent of changes in glomerular filtration rate, either
as a result of decreases in peritubular capillary oncotic pressures or
increases in hydrostatic pressure (Earley and Friedler, 1965; Schrier
and De Wardener, 1971). PGI2 can also cause redistribution of renal
blood flow from the outer cortex to the juxtamedullary region (Gerber
et al., 1978a ■ Bolger et at., 1978). This may result in natriuresis either
by reducing the renal medullary osmotic gradient as a result of a washout
effect (Earley and Friedler, 1966) or by increasing preferentially
109.
perfusion of the inner cortical nephrons which may have a small intrinsic
capacity to reabsorb sodium (Stein, Osgood and Kunan, 1976). These
alterations in the Starling forces in the peritubular capillary circulation
caused by a redistribution of intrarenal blood flow, result in a decrease
in proximal tubular reabsorption of sodium (Lewy and Windhanger, 1968).
There was no change in free water clearance during the 7.5 ng/kg/
min PGI2 infusion suggesting that the effect of the PGI2 on sodium re-
absorption was primarily on the proximal tubule. If PGI2 were to have
decreased sodium reabsorption in the distal tubule, free water clearance
would have also decreased (Seldin, Eknoyan, Suki and Rector, 1966).
The close correlation between the increase in potassium excretion
and renal plasma flow in the 7.5 and 30 ng/kg/min PGI2 infusions also
suggests that the natriuresis observed during PGI2 infusion is a con¬
sequence of renal vasodilation and decreased proximal sodium reabsorption.
Potassium is completely reabsorbed by the proximal tubule and potassium
in the urine is derived from distal tubular secretion. Potassium competes
with hydrogen ions for an exchange mechanism with sodium in the distal
tubular lumen. A decrease in proximal tubule sodium reabsorption would
result in more sodium being available in the distal tubule to enter into
an exchange mechanism with potassium. Assuming there was no change
in ascending limb function, this could result in an increase in potassium
excretion.
PGI2 has been demonstrated to inhibit sodium transport in isolated
rabbit cortical collecting tubules (lino and Brenner, 1981). An increase
in solute delivery to the distal tubule and a decrease in distal tubule
sodium reabsorption has been demonstrated during PGI2 infusion in
anaesthetised dogs (Gullner et al. , 1980). However, in that study renal
blood flow was not measured and the observed effects on sodium
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reabsorption could have been consequent to changes in renal haemo-
dynamics.
It seems likely that the increase in sodium excretion observed
during the 7.5 ng/kg/min PGI2 infusion is due to decreased proximal
tubule reabsorption as a result of redistribution of intrarenal blood
flow although this could not be proved conclusively with the present
methodology.
Over the four-fold PGI2 infusion range, a linear relationship was
observed between the quantity of PGI2 intravenously infused and urinary
excretion rate of 6-keto-PGFxa . This demonstrates that although
6-keto-PGFxa is only one of several metabolites of PGI2 to be excreted
in the urine, its measurement does reliably reflect circulating PGI2
levels.
The mean basal 6-keto-PGFxa excretion rate of 2.1 ng/min has been
confirmed by a study in which the urinary 6-keto-PGFxa excretion rate
in anaesthetised dogs was approximately 2 ng/min, as measured by radio¬
immunoassay (Wilson, Loadholt, Privitera and Halushka, 1982). Basal
urinary 6-keto-PGFiCt excretion in humans is much lower than in dogs.
Measurement by radioimmunoassay of 6-keto-PGFiCt in the urine of a
group of female subjects gave a mean excretion rate of 0.62 ng/min
(Patrono, Ciabattoni, Cinotti, Pugliese, Maseri and Chierchia, 1979)
whilst in another group of subjects, measurement by gas chromatography-
mass spectrometry gave a mean urinary 6-keto-PGFxa excretion rate
of 0.2 ng/min (Fischer, Scherer and Weber, 1983).
Although there has been wide variation in the reported plasma
concentration of 6-keto-PGFja in humans, recent observations using
sensitive RIA and GC-MS have indicated that the plasma concentration
of 6-keto-PGFict is very low. Levels of approximately 5 pg/ml have
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been detected in human plasma by RIA (Siess and Dray, 1982) and levels
of less than 3 pg/ml were detected by GC-MS (Blair, Barrow, Waddell,
Lewis and Dollery, 1982). Measurement by GC-MS of 6-keto-PGFxa
in the plasma of conscious dogs demonstrated levels of 70-80 pg/ml
(Jackson, Gerkens, Brash and Branch, 1982). These levels were much
higher than those found in the plasma of humans.
It would seem therefore that there is a species difference between
humans and dogs in the amount of 6-keto-PGFxa present in the urine
and plasma. The urinary concentration of 6-keto-PGFxa in dogs is
approximately 10-fold higher than that in humans whilst the plasma con¬
centration of 6-keto-PGFxa in dogs is approximately 40-fold higher than
that in humans. This may represent a higher rate of synthesis of PGI2
in the dog and/or a difference in the metabolism of PGI2.
The estimated rate of entry of PGI2 into the circulation of the
conscious dog was 4 ng/kg/min. In man, measurement by GC-MS of
the urinary excretion rates of 2,3-dinor-6-keto-PGFia and 15-keto-
13,14-dihydro-2,3-dinor-6-keto-PGFxa during PGI2 infusion gave an
estimated rate of entry of PGI2 into the circulation of 0.08- 0.1 ng/kg/
min (FitzGerald, Brash, Falardeau and Oates, 1981). This represents
an approximately 40-fold difference between humans and dogs in the
rate of entry of PGI2 into the circulation and suggests that there is
a higher rate of synthesis of PGI2 in the dog.
After subtraction of the basal rate, the urinary excretion rates
of 6-keto-PGFi^ during PGI2 infusion represented 2-4% of the infused
PGI2. Infusion of large quantities of PGI2 with a small quantity of radio-
label over a short period of time into humans resulted in approximately
15% of the radioactivity being recovered as urinary 6-keto-PGFia
(Rosenkranz et a!., 1980). This suggests that less PGI2 is excreted
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as unchanged 6-keto-PGFia in dogs than in humans and indicates a
species difference in the metabolism of PGI2. 6-keto-PGFxa has been
identified as the major metabolite in human plasma during intravenous
PGI2 infusion (Rosenkranz, Fischer and Frolich, 1981), but a recent
study in dogs has demonstrated that following a bolus intravenous
injection, plasma 6-keto-PGFia declines rapidly and the major plasma
metabolite is 2,3-dinor, -13,14-dihydro-6,15-diketo-PGF;,a (Taylor,
Shebuski and Sun, 1983). Thus, whilst urinary 6-keto-PGFxa linearly
reflects circulating PGI2 levels, it would seem that, in the dog, 6-keto-
PGFxa is not the main urinary or plasma metabolite of PGI2. This may
be indicative of a greater capacity for 15-hydroxydehydrogenation and
8-oxidation of PGI2 in the dog than is apparent in man.
The estimation of the rate of entry of PGI2 into the circulation
represents a maximum value for two reasons. Firstly, the PGI2 may
be hydrolysed in the organ of production and may be entering the circula¬
tion as 6-keto-PGFxa . Secondly, basal urinary 6-keto-PGFia excretion
may represent not only 6-keto-PGFia from the systemic circulation but
also 6-keto-PGFia derived from PGI2 of renal origin. The demonstration
that 6-keto-PGFia, unlike PGE2 and PGF2a, does not enter the urine
by an organic acid pathway, but is freely filtered at the glomerulus
(Rosenkranz et al. , 1981a) suggested that the 6-keto-PGFia in the urine
was derived solely from the systemic circulation. However, there is
also evidence to suggest that PGI2 is synthesised by the epithelial and
mesangial cells of the glomerulus (Kreisberg , 1982; Scharschmidt
and Dunn, 1983). This PGI2 would probably enter the urine at the
glomerulus without being subjected to 15-hydroxydehydrogenation or
6-oxidation. It is also possible that 6-keto-PGFia could enter the
113.
tubular lumen at another site, distinct from the organic acid pathway.
Care must therefore be taken when interpreting urinary 6-keto-PGFia
data, particularly when relating it to changes in circulating PGI2 levels,
since it cannot always be assumed that the contribution of renal 6-keto-
PGFia to the urine remains constant. This may be particularly important
under conditions of stimulated renin release where urinary 6-keto-PGFxct
excretion may reflect predominantly renal PGI2 production.
A further consideration in the interpretation of urinary 6-keto-
PGFia data is that a change in urinary 6-keto-PGFia may not only reflect
a change in PGI2 synthesis, but may also represent a shift in the
metabolic pattern of PGI2. Thus an increase in 6-keto-PGFia excretion
may be due to an increase in PGI2 synthesis or may be the consequence
of reduced enzymatic metabolism of PGI2 resulting in an increased
excretion of unchanged 6-keto-PGFia. Were this to be the case, it
would obviously be advantageous to monitor more than one metabolite
of PGI2. However, over a physiological range of PGI2 production, it
seems unlikely that there would be large shifts in the metabolic pattern.
In conclusion, the present study has demonstrated that over the
4-fold PGI2 infusion range 7.5 - 30 ng/kg/min, urinary 6-keto-PGFia
linearly reflects the circulating PGI2 and therefore within this range,
its measurement provides a useful and reliable indication of the rate
of PGI2 synthesis. The estimated maximum endogenous rate of entry
of PGI2 into the circulation derived from the urinary 6-keto-PGFia
measurements was 4 ng/kg/min. This value was considerably lower
than the lowest intravenous PGI2 infusion rate of 7.5 ng/kg/min which
had no effect on systemic blood pressure. It therefore seems unlikely
that PGI2 is present in sufficient quantities in the systemic circulation
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to be acting as a circulating hormone in the control of systemic blood
pressure. It is also unlikely that the 4 ng/kg/min rate of entry of PGI2
into the circulation is sufficient to be exerting an influence on renal
haemodynamics since intravenous infusion of PGI2 up to 30 ng/kg/min
showed no significant effect on renal plasma flow. There remains, how¬
ever, the possibility that PGI2 synthesised within the kidney, acts as
a local hormone in the control of renal haemodynamics.
The increase in sodium excretion observed during the 7.5 ng/kg/
min PGI2 infusion suggests that low circulating levels of PGI2 are capable
of causing a natriuresis possibly as a result of changes in intra-renal
blood flow.
Intravenous PGI2 infusion had a negligible effect on renin release
and although it is still possible that local PGI2 synthesis plays a role
in the control of renin release, it would seem that in the dog, PGI2 is
not such an important renin secretagogue as was previously thought.
This study hasdemonstrated that the basal urinary excretion rate
of 6-keto-PGFiCt in the dog was higher than that in man although the
percentage of PGI2 excreted as 6-keto-PGFia was lower. The study
has also demonstrated a difference in the effect of PGI2 on renin release
between dog and man. This evidence suggests that there is species
difference in the rate of synthesis, pattern of metabolism and physiological
response to PGI2
SECTION IV
The Role of PGI? in the Control of Systemic Blood Pressure
and Renal Function During Inhibition of the
Renin-Angiotensin System with Captopril
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4.1 Introduction
Captopril is an important therapeutic agent and, as an inhibitor
of angiotensin I converting enzyme, has also proved to be a useful
pharmacological tool in delineating the function of the renin-angiotensin
system.
Under non-pathological circumstances and when a person or animal
has a normal salt intake, administration of a drug which blocks the renin-
angiotensin system has an almost imperceptible effect on systemic blood
pressure. Thus most previous studies with captopril have been restricted
to conditions of sodium depletion or renovascular hypertension when
angiotensin II becomes a prime factor in blood pressure control. Chronic
administration of captopril to salt depleted conscious dogs results in
a sustained reduction in systemic blood pressure, plasma aldosterone
concentration and glomerular filtration rate and an increase in renal
plasma flow, sodium excretion and plasma renin activity (McCaa, Hall
and McCaa, 1978; Hall, Guyton, Smith and Coleman, 1979). Captopril
also decreases systemic blood pressure and increases renal plasma flow
and plasma renin activity in Goldblatt hypertensive dogs and rats
(Zimmerman, Mommsen and Kraft, 1980; Vandongen, Tunney and
Martinez, 1981) and in patients with renovascular hypertension (Cody,
Tarazi, Bravo and Fo ad, 1978; Aitkinson, Brown, Fraser, Leckie,
Lever, Morton and Robertson, 1979). These studies have demonstrated
that under conditions where the renin^angiotensin system is stimulated,
angiotensin II plays an important role in the control of systemic and
renal haemodynamics and sodium excretion. It is possible that angio¬
tensin II exerts this control by a direct vasoconstrictor and anti-natri-
uretic action since infusion of aldosterone, whose increased release
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was previously thought to be responsible for mediating many of the
effects of angiotensin II, failed to reverse the effects of chronic
captopril administration on systemicblood pressure, renal plasma flow
or sodium excretion (Hall et a!., 1979).
Studies with the angiotensin II antagonist, saralasin (Hollenberg,
Williams, Taub, Ishikawa, Brown and Adams, 1977; Agabiti-Rosei et al.,
1979) and the earlier angiotensin I converting enzyme inhibitor teprotide
(Kimbrough et at. , 1977; Niarchos et al ., 1979), failed to produce
consistent evidence that angiotensin II was important in the control
of systemic and renal haemodynamics in normal, salt replete humans or
animals. In contrast to these results, however, captopril administration
has resulted in a decrease in systemic blood pressure and an increase
in renal plasma flow in sodium replete conscious rats (Johnston, Bernard,
Perrin, Arbeit, Liberthal and Levinsky, 1981) and dogs (Zimmerman
et aI., 1980a; Morton et al., 1982) and in normal humans (Hollenberg,
Meggs, Williams, Katz, Garnic and Harrington, 1981; MacGregor,
Markandu, Roulston and Jones, 1981). The two latter studies also
demonstrated an increase in sodium excretion associated with the captopril
administration. As might be expected, in all cases the drop in systemic
blood pressure following captopril administration in the salt replete state
was smaller than that caused by captopril during salt depletion or high
renin hypertension. The increase in renal plasma flow caused by
captopril in high and low renin states did not show such a marked dif¬
ference. The results of these studies demonstrating the effects of
captopril in the normotensive salt replete state have been taken to
indicate a tonic influence of the renin-angiotensin system on systemic
blood pressure, renal plasma flow and sodium excretion under normal
conditions.
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The ability of captopril to affect systemic and renal haemodynamics
during sodium repletion could, however, also indicate that captopril
may be mediating its effect through mechanisms independent of inhibi¬
tion of the renin-angiotensin system, and indeed much controversy exists
as to the specificity of action of captopril.
Some investigators have tried to restore blood pressure during
captopril administration by infusing angiotensin II. On an acute basis,
infusion of angiotensin II into captopril-treated salt replete and salt
deplete conscious dogs failed to restore systemic blood pressure to pre-
captopril levels (Tree and Morton, 1980). Captopril administration in
the salt deplete dogs also produced a shift to the right and a marked
downward shift in the angiotensin II/blood pressure dose-response curve.
This implied that diminution in the acute vasoconstrictor effect of angio¬
tensin II consequent to a reduction in its plasma concentration is not
the sole mechanism by which captopril lowered systemic blood pressure.
Chronic infusion of angiotensin II into captopril-treated salt-deplete
conscious dogs restored systemic blood pressure and renal plasma flow
to control levels (Hall et aI., 197 9b\ although high doses of angiotensin
II were used and lower dose chronic angiotensin II infusion failed to
return systemic blood pressure to control values. It would seem,
therefore, that a mechanism additional to inhibition of angiotensin II
formation may be mediating the hypotensive action of captopril. This
hypothesis was supported by investigations into the effects of captopril
in low-renin hypertensive states. Captopril was found to be effective
in lowering systemic blood pressure in patients with low-renin essential
hypertension (Gavras etal., 1978; Abe, Itoh, Imai, Satoh Haruyama,
Sakurai Goto, Otsuka and Yoshinaga, 1980) and in spontaneously hyper-
t
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tensive rats (Muirhead, Prewitt, Brooks and Brosius, 1978), angiotensin-
salt hypertensive rats (Muirhead, Brooks and Brosius, 1980), and DOCA/
salt hypertensive rats (Miyamori, Brown and Dollery, 1980) in all of
which plasma renin activity is known to be low.
By inhibiting angiotensin I converting enzyme, also known as
kininase II, captopril not only blocks the conversion of angiotensin I
to angiotensin II, but prevents the degradation of bradykinin (Erdos,
1977). Captopril may therefore cause increased circulating and renal
tissue concentrations of kinins. Bradykinin is a potent vasodilator and
infusion of bradykinin into the renal artery of dogs causes an increase
in renal blood flow, urine flow and sodium excretion (Barraclough and
Mills, 1965; Stein, Congbalay, Karsh, Osgood and Ferris, 1972;
Nasjletti, Colina-Churito and McGiff , 1975). Potentiation of these effects
due to inhibition of the degradation of bradykinin may contribute towards
the effects of captopril administration on renal haemodynamics. Direct
evidence for a contribution of increased bradykinin levels towards the
hypotensive or renal vasodilator effect of captopril, however, remains
conflicting.
Increased plasma kinin levels after captopril administration have
been reported in conscious rats (Matthews and Johnston, 1980) and
conscious salt-deplete dogs (McCaa et a/., 1978), whilst other investi¬
gators have failed to demonstrate any effect of captopril on plasma kinin
levels in hypertensive patients (Johnston, Millar, McGrath and Matthews,
1979; Crantz, Swartz, Hollenberg, Moore, Dluhy and Williams, 1981).
The renal kallikrein-kinin system is regarded as a local hormonal system
which by regulation of regional blood flow may be important in circulatory
homeostasis and blood pressure control (Levinsky, 1979; Carretero
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and ScLeli , 1980). Urinary kinins are thought to originate only from
renal tissue and may parallel intrarenal concentrations of these sub¬
stances (Yoshinaga, Abe, Miwa, Funiijama and Suzuki, 1964; Orstavik,
Nustad, Brandtzaeg and Pierce, 1976). Urinary kinin levels have been
found to increase after captopril administration in conscious salt-deplete
dogs (01sen&Arrigoni-Martelli 1979). In anaesthetised dogs,
captopril administration resulted in increased urinary kininr levels while
plasma levels did not change (Johnston, Clappison, Anderson and
Yasiyima, 1982). These results indicate that whilst an increase in renal
bradykinin may participate in the renal vasodilator action of captopril,
a contribution of circulating bradykinin to the hypotensive action of
captopril seems unlikely.
The vasodilator action of bradykinin is thought to be mediated
in part by a prostaglandin (McGiff et al. , 1973; Mullane and Moncada,
1980) and it has been demonstrated that bradykinin can stimulate PGE2
and PGI2 synthesis from a variety of vascular beds (Piper and Vane,
1969; Needleman et al., 1975; Blumberg et al., 1977; Hong, 1980).
Bradykinin has also been shown to stimulate PGE2 and PGI2 synthesis
in the kidney (McGiff et al. , 1973; Blasingham and Nasjletti, 1979;
Mullane and Moncada, 1980). Since bradykinin stimulates prostaglandin
synthesis, it has been proposed that captopril administration, by elevat¬
ing circulating or tissue kinins, may increase PGE2 and PGI2 levels.
These prostaglandins, by means of their vasodilator and natriuretic
properties, may consequently contribute to the actions of captopril.
Alternatively, since angiotensin II also promotes PGE2 and PGI2 synthesis
in a number of different tissues (McGiff et al. , 1970b; Shebuski arid
Aiken, 1980; Dusting and Mullins, 1980), captopril may reduce prosta¬
glandin synthesis by lowering angiotensin II levels.
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Several studies have investigated the contribution of prosta¬
glandins to the hypotensive and renal vasodilator actions of captopril
and the results have proved conflicting. Indomethacin has been shown
to inhibit an enhanced vasodepressor effect of bradykinin following captopril
administration in conscious rabbits, although this inhibition could not
be repeated in nephrectomised animals (Murthy, Waldron and Goldberg,
1978). An enhanced hypotensive and renal vasodilator response to brady¬
kinin following captopril administration in anaesthetised dogs was
associated with an increased release of PGI2-like material primarily from
the renal circulation and was inhibited by indomethacin (Mullane and
Moncada, 1980). In anaesthetised rats the vasodepressor response to
bradykinin was potentiated following captopril administration but indo¬
methacin was unable to inhibit this effect (Vandongen, Tunney, Barden
and Mahoney, 1982). This suggested that the potentiation of the vaso¬
dilator action of bradykinin was not mediated by a prostaglandin.
Similarly conflicting results have been obtained when the effect
of indomethacin on the hypotensive response to captopril has been
studied. Indomethacin pretreatment attenuated the hypotensive action
of captopril in DOCA/salt hypertensive rats but had no effect on the
captopril-induced increase in plasma renin activity (Miyamori et aI. ,
1980). Indomethacin also attenuated the fall in systemic blood pressure
after captopril administration in patients with reno-vascular hypertension
but again had no effect on the increase in plasma renin activity (Salvetti,
Arzilli, Pedrinelli and Beggi, 1980). However, other investigators have
demonstrated an attenuation by indomethacin of both the hypotension
and increased plasma renin activity due to captopril administration in
normotensive and hypertensive patients (Abe, Itoh, Satoh, Haruyama,
Imai, Goto, Satoh, Otsuka and Yoshinaga, 1979; Silberbauer, Stanek,
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and Temp] , 1982; Witzgall, Scherer and Weber, 1982). Conversely,
both indomethacin and aspirin treatment failed to modify the hypertensive
action of chronic captopril administration in spontaneously hypertensive
rats (Antonacio, Harris, Goldenberg, High and Rubin, 1979;
DiNicolantonio, Dusting, Hutchison and Mendelsohn, 1981) and no
attenuation by indomethacin of the hypotensive or renal vasodilator
action of captopril could be demonstrated in anaesthetised or conscious
dogs (Tobia and Giardino, 1981; Wong, Zimmerman, Kraft, Kounenis
and Friedman, 1981).
The depressor response to captopril has been positively correlated
to the change in 13,14-dihydro-15-keto-PGE2 in the plasma of sodium
replete and deplete humans (Swartz, Williams, Hollenberg, Levine, Dluhy
and Moore, 1980) and in patients with essential hypertension (Moore,
Crantz, Hollenberg, Kotesky, Leboff, Swartz, Levine, Podolsky, Dluhy
and Williams, 1981). No changes in plasma 6-keto-PGFiCt or TxB2 levels
were detected, although this may be due to the difficulty in measuring
the small quantities of these metabolites in the plasma. Other investi¬
gators have failed to demonstrate an effect of captopril on renal venous
PGE2 levels in haemorrhaged anaesthetised dogs (Wong and Zimmerman,
1980b)or on urinary PGE2 excretion in conscious dogs (Olsen and Arrigoni-
Martelli, 1979). No increase in urinary PGE2 excretion following captopril
administration could be demonstrated in normotensive or hypertensive
humans, despite an attenuation of the vasodepressor response by indo¬
methacin (Abe et al., 1979; Witzgall et a!., 1982). These 'in vivo'
studies looked at the effects of captopril on PGE2 synthesis only and it
is possible that PGI2, which is a more potent renin secretagogue (Jones
Wa+so*n&Ungar, 1981 ), may be a more important mediator of the effects of
captopril.
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Some evidence exists towards a direct action of captopril to increase
prostaglandin synthesis. Galler et al. demonstrated an increase in both
PGE2 and PGI2 synthesis by isolated rat glomeruli incubated with capto¬
pril but could not demonstrate a similar effect using aortic strips (Galler,
Backenroth, Folkert and Schlon d orff, 1982). In contrast to this, Vio
et al. observed an increase in PGI2 synthesis by rat aortic strips in¬
cubated with captopril but did not observe any increase in PGI2 synthesis
when renal medulla was incubated with captopril (Vio, Guivernau, Terragno
and Terragno, 1981).
In the first study in this section, captopril has been used as a
pharmacological tool to investigate the relative importance of the renin-
angiotensin system in the control of systemic and renal haemodynamics
if
and electrolyte excretion under conditions of differing sodium balance.
Studies were performed in conscious dogs in both sodium replete and
sodium deplete states. In addition, to determine whether PGI2 con¬
tributes in any way to the haemodynamic and/or renin secretory actions
of captopril, urinary 6-keto-PGFxa excretion has been measured before
and after captopril administration.
The second study in this section has further utilised captopril
to investigate the complex inter-relationships between the renin-angio¬
tensin system and PGI2. It is generally thought that the vasodilator
action of PGI2 plays an important role in modulating the vasoconstrictor
action of angiotensin II, particularly in the kidney. Indomethacin en¬
hances the renal vasoconstrictor and vasopressor action of exogenous
angiotensin II (Aiken and Vane, 1973; Negus et al. , 1976) and causes
an increase in renal vascular resistance which is much more pronounced
during sodium depletion (Blasingham and Nasjletti, 1980). It is possible
that angiotensin II stimulates PGI2 synthesis in the kidney which then
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serves to modulate its vasoconstrictor activity. It is also possible that
angiotensin II may be modulating the vasodilator action of PGI2 since
PGI2 is capable of stimulating renin release with a consequent increase
in angiotensin II formation.
In the second study, PGI2 was infused intravenously into
conscious dogs after angiotensin II formation was inhibited by
captopril. The vasodilator action of PGI2 after inhibition of angiotensin
II formation could then be compared to the expected action were angio¬
tensin II present. The PGI2 infusions were performed in conscious
sodium replete and deplete dogs. The effects of an alteration in the
control of systemic and renal haemodynamics by the renin-angiotensin
system on the vasodilator action of PGI2 could then be determined.
4.2 Study I Methods
Eight male conscious foxhounds were used, all dogs being surgically
prepared as described in section 2.L The animals were maintained on
diets containing either 50 mMoles sodium/day or less than 10 mMoles
sodium/day (detailed in section 2.3 ).
On the day of each study, dextrose solution (5 gm/100 ml) was
infused intravenously at 7 ml/min for 30 min, then continued at 3 ml/min
throughout the rest of the study. This established a modest water diuresis.
Loading concentrations of PAH and inulin were administered and the
appropriate dilutions infused intravenously at 0.5 ml/min. A 19 G butter¬
fly needle was inserted into the carotid artery and connected to a pres¬
sure transducer to allow continuous measurement of systemic blood
pressure. A one-hour equilibration period was allowed before the 4-
hour study commenced. After a 90 min control period, captopril (5 mg/
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kg) dissolved in a small quantity of saline was administered intravenously
as a bolus injection and its effects monitored for a further 150 min. *
Throughout the 4 hour study, urine collections were taken every
30 min via a catheter inserted into the bladder. Arterial blood samples
were taken during the control period and 30, 60 and 150 min after capto-
pril administration. Systemic blood pressure, renal plasma flow, glomer¬
ular filtration rate, sodium, potassium and osmolality excretion, plasma
renin activity and urinary 6-keto-PGF10( excretion were estimated by
techniques described fully in sections 2.5 - 2.6 . At least 48 hours
were allowed between each study.
4.3 Statistical Comparisons
All results are expressed as mean ± standard error. Statistical
comparisons for all parameters except 6-keto-PGFia excretion and plasma
renin activity were made using a student 2-tailed t-test between the
points after captopril administration and the control point immediately
preceding captopril administration. Although 6-keto-PGFia excretion
rates and plasma renin activity are graphically represented as mean
± standard error, they were not thought to be normally distributed.
Therefore statistical comparisons were made using the non-parametric
Wilcoxan's rank sum test for paired data. Again the points after captopril
administration were compared with the control point immediately preceding
captopril administration.




The effects of captopril administration on systemic blood pressure,
renal haemodynamics, electrolyte excretion, urinary 6-keto-PGF10c
excretion and plasma renin activity in sodium replete and sodium deplete
conscious dogs are summarised in Tables 4.1 - 4.3.
4. 4. 1 Systemic blood pressure (Fig. 4. 1)
Systemic blood pressure was slightly lower during sodium depletion
than when animals were maintained on a normal sodium intake. In the
sodium replete animals, captopril caused systemic blood pressure to
fall from 97 + 3 mmHg to 90 + 3 mmHg within 30 min of administration.
This decrease, though small, was statistically significant (p <0.01).
Systemic blood pressure showed a small upward trend towards the end
of the study. There was a greater fall in systemic blood pressure in
the sodium deplete animals where pressure decreased from 93 ± 2 mmHg
to 74 + 2 mmHg within 30 min of captopril administration. This decrease
was highly significant (p <0.001), however there was an upward trend
in the pressure towards the end of the 150 min period.
4. 4. 2 Heart rate (Fig. 4. 1)
Heart rate was not altered by sodium deprivation. Captopril
administration increased heart rate from 77 ± 7 beats/min to 100 + 7
beats/min (p <0.01) in the salt replete dogs and from 76 + 4 beats/min
to 106 + 9 beats/min (p <0.01) in the salt deplete. In both cases, the
maximum increase occurred within 30 min of captopril administration
after which heart rate started to decrease towards control values. Capto¬
















































































































































































































































































































































































































































































FIGURE 4.1: The effect of captopril administration on systemic blood
pressure and heart rate.
0 0 sodium replete dogs;
o -o sodium deplete dogs.
* p <0.05; ** p <0.01; *** p <0.001.
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4. 4. 3 Renal plasma flow (Fig. 4.2)
Sodium depletion had no effect on the control values for renal plasma
flow. In both sodium replete and deplete dogs, captopril caused an
increase in renal plasma flow which was maximal 90 min after administra¬
tion. In the salt replete dogs, renal plasma flow was increased by 68 ±
10 ml/min, from a control value of 310 ± 71 ml/min to 378 ± 60 ml/min
90 min after captopril administration (p <0.05). Captopril had a greater
effect on renal plasma flow in salt deplete dogs where an increase of
113 ± 16 ml/min was observed, from a control value of 350 ± 47 ml/min
to 463 ± 64 ml/min 90 min after captopril administration (p <0.05). In
both salt replete and salt deplete dogs, renal plasma flow started to
decrease towards control levels by 120 min after captopril administration.
4. 4. 4 Glomerular filtration rate (Fig. 4.2/
Glomerular filtration rate was not altered by sodium depletion.
Captopril administration had no effect on glomerular filtration rate in
the salt replete dogs. There was a transient decrease in glomerular
filtration rate in the salt deplete dogs 30 min after captopril administra¬
tion. This transient fall in glomerular filtration rate most likely reflects
the large fall in systemic blood pressure seen at this time.
4. 4. 5 Filtration fraction (Fig. 4.2)
Filtration fraction showed very little change after captopril ad¬
ministration in the salt replete dogs. There was a small decrease 60
min after captopril administration but this was not statistically significant.
Captopril caused a larger decrease in filtration fraction in the salt
deplete dogs, from 0.26 ± 0.02 to 0.19 ± 0.02 within 30 min of administra¬
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FIGURE 4.2: The effect of captopril administration on renal plasma
flow, glomerular filtration rate and filtration fraction.
0 0 sodium replete dogs;
__ _ .Q sodium deplete dogs.
*p <0.05; ** p <0.01; *** p <0.001.
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dogs is due initially to the reduced glomerular filtration rate 30 min
after eaptopril administration and then, although glomerular filtration
rate rises again, renal plasma flow also rises resulting in a maintained
reduction in filtration fraction. Filtration fraction in the salt deplete
dogs increases towards the end of the study when renal plasma flow
decreases.
4. 4. .6 Sodium excretion (Fig. 4.3)
Sodium excretion rates during the control periods were much
smaller during sodium deprivation than when animals were maintained
on a normal sodium intake. Captopril caused a large increase in sodium
excretion in the salt replete dogs within 30 min of administration and
sodium excretion continued to increase throughout the study. By 150
min after captopril administration, sodium excretion was increased from
a control value of 29 ± 10 jiM/min to 133 ±"22 (iM/min (p <0.01). Capto¬
pril also increased sodium excretion in the salt deplete dogs within 30
min of administration and although sodium excretion remained elevated,
it tended to fluctuate throughout the study. Sodium excretion was in¬
creased from a control value of 1.2 ± 0.6 iiM/min to 3.3 ± 1.3 uM/min
150 min after captopril administration in the salt deplete dogs (p <0.05).
4. 4. 7 Potassium excretion (Fig. 4.3)
Potassium excretion during the control periods was not altered
by sodium deprivation. Captopril caused an increase in potassium
excretion in both salt replete and salt deplete dogs, the maximum effect
being 90 min after administration. In the salt replete dogs, potassium
excretion increased from a control of 32 ± 6 uM/min to 57 ± 13 |iM/min
90 min after captopril administration (p <0.05). A similar increase was
133.
TIME (minsl
FIGURE 4.3: The effect of captopril administration on sodium and
potassium excretion.
^ ^ sodium replete dogs;
a ^ sodium deplete dogs.
* p <0.05; ** p <0.01; ***p <0.001.
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demonstrated in the salt deplete dogs where potassium excretion in¬
creased from a control value of 35 ± 5 pM/min to 59 ± 12 pM/min 90 min
after captopril administration (p <0.05). The increase in potassium
excretion following captopril administration follows a similar time course
to the changes in renal plasma flow, both parameters demonstrating
a maximum increase 90 min after captopril administration.
4.4.8 Urine flow (Fig. 4.4)
Urine flow showed a small increase after captopril administration
in the salt replete dogs but fell to control levels again by the end of
the study. There was a small decrease in urine flow after captopril
administration in the salt deplete dogs. This most likely reflects the
initial decrease in glomerular filtration rate observed after captopril
administration in the salt deplete dogs.
4. 4. 9 Solute, (bfijnolali'ty) e^cnetionfFig 4.4)
Solute excretion was not altered by sodium depletion. There
was an increase in solute excretion after captopril administration
in the salt replete dogs, probably as a consequence of the increase in
sodium excretion. There was no increase in osmolality excretion after
captopril administration in the salt deplete dogs.
4. 4. 10 Free water clearance (Fig. 4.4)
Free water clearance during the control periods was lower during
sodium deprivation than when animals were maintained on a normal sodium
intake. Free water clearance fluctuated throughout the studies and
there was no significant change after captopril administration in either
the salt replete or salt deplete dogs.
135.
FIGURE 4.4: The effect of captopril administration on urine flow,
osmolality excretion and free water clearance.
0 ft sodium replete dogs;
0 0 sodium deplete dogs.
* p <0.05; ** p <0.01; *** p <0.001.
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4.4. 7 7 6-keto-PGFxa excretion (Fig. 4.5)
Urinary 6-keto-PGFia excretion during the control periods was
not different during sodium deprivation than when animals were main¬
tained on a normal sodium intake. Captopril caused an increase in 6-
keto-PGFxct excretion which was maximal 90 min after administration
in both salt replete and salt deplete dogs. In the salt replete dogs6-keto-PGF^
excretion increased from a control value of 1.2 ± 0.2 ng/min to 2.1 ±
0.4 ng/min 90 min after captopril administration (p <0.02). A similar
increase in 6-keto-PGFia excretion was demonstrated in salt deplete
dogs where 6-keto-PGFia excretion increased from a control value of
1.3 ± 0.3 ng/min to 2.4 ± 0.9 ng/min 90 min after captopril administra¬
tion (p <0.05). The mean urinary 6-keto-PGFia excretion rates could
be equated with circulating PGI2 levels as defined by the relationship
between PGI2 infusion rate and urinary 6-keto-PGFia excretion demon¬
strated by Figure 3.9 in section 3.4.12. By this means, the calculated
rate of entry of PGI2 into the circulation 90 min after captopril administra¬
tion was 3.6 ng/kg/min in the salt replete dogs and 4.3 ng/kg/min in
the salt deplete dogs.
The time-course for the increase in 6-keto-PGFxa excretion
resembles that for the increase in renal plasma flow, both parameters
reaching a maximum 90 min after captopril administration.
4. 4. 72 Plasma renin activity (Fig, 4. 6)
Plasma renin activity was greatly increased by sodium deprivation
demonstrating the stimulation of the renin-angiotensin system. Plasma
renin activity showed a small progressive increase after captopril admin¬
istration in the salt replete dogs. However, this increase from a control
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*p<0.05.
FIGURE4.6:Theeffectofcaptopriladministrationplasmare inctivity. £sodiumrepletedogs;epletegs. **p<0.01.
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administration did not reach statistical significance. In the salt deplete
dogs, captopril administration resulted in an increase in plasma renin
activity from a control value of 8.8 ± 1.3 ng/ml/hr to 49.8 ± 19 ng/ml/hr
within 30 min of administration (p <0.01). Plasma renin activity then
fell to 26 + 8.1 ng/ml/hr by 150 min after captopril administration (p <0.01).
4.5 Study II Methods
Eight male conscious foxhounds were used, all animals being
surgically prepared as described in section 2.1. The dogs were main¬
tained on diets containing either 50 mM sodium/day or less than 10 mM
sodium/day as detailed in Section 2.3.
On the day of each study, dextrose solution (5 gm/100 ml) was
infused intravenously at 7 ml/min for 30 min, then continued at 3 ml/min
throughout the rest of the study. This established a modest water
diuresis. Loading concentrations of PAH and inulin were administered,
and the appropriate dilutions infused intravenously at 0.5 ml/min. A
19G butterfly needle inserted into the carotid artery and connected to
a pressure transducer allowed continuous measurement of systemic blood
pressure. A one hour equilibration period was allowed before the four
hour study was commenced. After a 90 min control period, captopril
(5 mg/kg) was administered intravenously as a bolus injection. 30 min
after the captopril administration, PGI2 in a concentration of 15 ng/kg/
min was infused intravenously at a rate of 0.5 ml/min. This infusion
was continued for 120 min. The PGI2 was dissolved in 0.025M sodium
carbonate buffer (pH 9.8) during the sodium replete study, and 0.025M
potassium carbonate buffer (pH 9.8) during the sodium deplete study.
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The infusion solution was replaced every 30 min by a fresh solution
made up from stock PGI2 kept on ice. The activity of the PGI2 in the
infusion solution was checked on several occasions by its ability to
prevent ADP-induced platelet aggregation. Throughout the 4 hour
study, urine collections were made every 30 min via a catheter inserted
into the bladder. Arterial blood samples were taken during the control
period, 30 min after captopril administration and 60 and 120 min after
the start of the PGI2 infusion.
Systemic blood pressure, renal plasma flow, glomerular filtration
rate, sodium, potassium and osmolality excretion and plasma renin activity
were estimated by techniques described fully in Section 2.5.
At least 48 hours were allowed between each study.
4.6 Statistical Comparisons
All results are expressed as mean ± standard error. Statistical
comparisons were not thought to be useful in this study since the results
involved the combined effects of two different drugs.
4.7 Results
The effects of captopril administration followed by infusion of PGI2
on systemic blood pressure, renal haemodynamics, electrolyte excretion
and plasma renin activity in salt replete and salt deplete dogs, are sum¬
marised in Tables 4.5 and 4.6.
4. 7. 7 Systemic blood pressure (Fig. 4. 7)
As demonstrated in section 4.4.1, systemic blood pressure during








































































































































































































































































































































































animals were maintained on a normal sodium intake. Captopril administra¬
tion caused an immediate fall in systemic blood pressure which was greater
in the salt deplete dogs. There was a further fall in systemic blood
pressure after the start of the PGI2 infusion in both salt replete and
salt deplete dogs. In the salt replete dogs, systemic blood pressure
fell from a value of 90.8 ± 3.9 mmHg after captopril administration to
83.7 ± 3.9 mmHg 60 min after the start of the PGI2 infusion, a decrease
of 7.1 ± 0.5 mmHg. In the salt deplete dogs, a smaller decrease in
systemic blood pressure was observed following PGI2 infusion, from
a value of 73.2 ±2 mmHg after captopril administration to 69.4 ± 2.8
mmHg 30 min after the start of the PGI2 infusion, a decrease of 3.8 ±
0.3 mmHg. These small decreases were transient, and by the end of
the study, systemic blood pressure had returned to the value reached
30 min after captopril administration, i.e. immediately prior to the start
of the PGI2 infusion.
4. 7. 2 Heart rate (Fig. 4. 7)
Heart rate was not altered by sodium depletion confirming the
results in section 4.4.2. Heart rate showed a small increase during
the control periods in both the salt replete and salt deplete dogs. There
was very little change in heart rate after captopril administration in
the salt replete dogs and although there was an initial increase in heart
rate during the PGI2 infusion, this increase was not maintained through¬
out the infusion period. In the salt deplete dogs, captopril caused an
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FIGURE 4.7: The effect of captopril administration and intravenous
PGI2 infusion on systemic blood pressure and heart rate.
^ 0 sodium replete dogs;
^ sodium deplete dogs.
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4. 7. 3 Renal plasma flow (Fig. 4.8)
Renal plasma flow during the control periods was not altered by
sodium depletion confirming the results in section 4.4.3. In the salt
replete dogs, renal plasma flow increased slightly from a control value
of 320 ± 40 ml/min to 363 ± 38 ml/min 30 min after captopril administra¬
tion, and then showed a further progressive increase during the PGI2
infusion, reaching a flow rate of 501 ± 57 ml/min by the end of the study.
Captopril administration caused a larger initial rise in renal plasma flow
in the salt deplete dogs, from a control value of 289 ± 34 ml/min to 395 ±
60 ml/min 30 min after captopril administration. This increase was main¬
tained for the duration of the study but there was no further increase
in renal plasma flow during the PGI2 infusion.
4. 7. 4 Glomerular filtration rate (Fig. 4.8)
Glomerular filtration rate during the control periods was not
altered by sodium deprivation, confirming the results in section 4.4.4.
Captopril administration had no effect on glomerular filtration rate in
either the salt replete or salt deplete dogs. There was a progressive
increase in glomerular filtration rate towards the end of the PGI2
infusion in the salt replete dogs, increasing from 83 + 6 ml/min immediately
prior to the start of the infusion, to 115 ± 12 ml/min by the end of the
study. Glomerular filtration rate fell during the first part of the PGI2
infusion in the salt deplete dogs, probably as a result of the large
decrease in systemic blood pressure seen at this time. Glomerular filtra¬
tion rate increased again towards the end of the PGI2 infusion, but












FIGURE 4.8: The effect of captopril administration and intravenous
PGI2 infusion on renal plasma flow, glomerular filtration





0 0 sodium replete dogs;
£ sodium deplete dogs.
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4. 7. 5 Filtration fraction (Fig. 4.8)
Filtration fraction fell after captopril administration in both salt
replete and salt deplete dogs due to the increase in renal plasma flow.
There was no further decrease in filtration fraction during the PGI2
infusion due to the increase in glomerular filtration rate during the
infusion period.
4. 7. 6 Sodium excretion (Fig. 4.9)
Sodium excretion was much reduced when the dogs were maintained
on the salt restricted diet. In the salt replete dogs sodium excretion
increased from a control value of 62 ± 32 nM/min to 89 ± 29 |iM/min 30
min after captopril administration. Sodium excretion showed a further
progressive increase during the PGI2 infusion, reaching a maximum
value of 196 ± 37 jiM/min by the end of the study. In the salt deplete
dogs, captopril administration caused sodium excretion to increase from
a control value of 2.0 ± 0.5 uM/min to 3.9 ± 0.4 nM/min after administra¬
tion. In contrast to the effects in the salt replete dogs, sodium excretion
showed a small progressive decrease during the PGI2 infusion, reaching
control values by the end of the infusion. This effect may be due to
the greatly reduced systemic blood pressure during the PGI2 infusion
in the salt deplete dogs.
4. 7. 7 Potassium excretion (Fig. 4.9)
Potassium excretion during the control period was not altered by
sodium depletion confirming the results in section 4.4.7. In the salt
replete dogs, potassium excretion increased from a control value of 37 +
4 iiM/min to 52 ± 8 |iM/min 30 min after captopril administration, but
showed no further increase during the PGI2 infusion. Potassium excretion
148.
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FIGURE 4.9: The effect of captopril administration and intravenous
PGI2 infusion on sodium and potassium excretion.
£ Q sodium replete dogs;
sodium deplete dogs.
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increased following captopril administration in the salt deplete dogs,
from a control value of 37 ± 4 uM/min to 53 ± 7 |iM/min 30 min after
administration but decreased again to 44 ± 5 uM/min within 30 min of
the start of the PGI2 infusion. This may be as a result of the reduced
systemic blood pressure during the PGI2 infusion in the salt deplete
dogs.
4. 7. 8 Urine flow (Fig. 4. 10)
There was a small decrease in urine flow rate after captopril
administration and during PGI2 infusion in the salt replete dogs. No
change in urine flow rate was observed in the salt deplete dogs through¬
out the study.
4.7.9 Sulute ^osmolality) excretion (Fig 4.1 ©)
Scluiie excretion during the control periods was slightly lowered
by sodium deprivation. Captopril administration had no effect on
Solute excretion irrespective of sodium status. Solute excretion
increased towards the end of the PGI2 infusion in the salt replete dogs
possibly as a result of the progressive increase in sodium excretion
throughout the infusion period. There was no change in osmolality ex¬
cretion during the PGI2 infusion in the salt deplete dogs.
4. 7. 10 Free water clearance (Fig. 4, 10)
Free water clearance during the control periods was slightly
lowered during sodium deprivation. There was a small decrease in free
water clearance after captopril administration and during the PGI, infusion
in the salt replete dogs but no change in free water clearance was observed
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FIGURE 4.10: The effect of captopril administration and intravenous
PGI2 infusion on urine flow, osmolality excretion and
free water clearance.
q £ sodium replete dogs;
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FIGURE 4.11: The effect of captopril administration and intravenous
PGI2 infusion on plasma renin activity.
0 0 sodium replete dogs;
sodium deplete dogs.
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4.7. 7 7 Plasma renin activity (Fig. 4. 7 7/
Control values for plasma renin activity were greatly increased
by sodium depletion demonstrating stimulation of the renin-angiotensin
system. In the salt replete dogs, plasma renin activity showed a
progressive increase after captopril and during PGI2 infusion, increas¬
ing from a control value of 1.9 ± 0.4 ng/ml/hr to 5.0 ± 1.0 ng/ml/hr
by the end of the study. In the salt deplete dogs, plasma renin activity
increased from a control value of 6.9 ± 0.7 ng/ml/hr to 54 ± 14 ng/ml/hr
within 30 min of captopril administration, after which, despite the PGI2
infusion, it decreased again to 24 ± 5 ng/ml/hr by the end of the study.
4.8 Discussion
Dietary sodium deprivation is used routinely as an effective physio¬
logical stimulus for renin release and under such conditions, the renin-
angiotensin system becomes important in the control of systemic blood
pressure. In the first study in this section, acute dietary sodium
restriction in conscious dogs resulted in elevated plasma renin activity
and greatly reduced urinary sodium excretion. Despite such stimulation
of the renin-angiotensin system, systemic blood pressure was also lowered
during sodium restriction. This decrease in blood pressure is most
likely due to a fall in extracellular fluid volume which would accompany
sodium depletion. The regime of sodium restriction had no effect on
heart rate or renal plasma flow.
Inhibition of angiotensin II formation by captopril in the salt deplete
dogs resulted in a large fall in systemic blood pressure within 30 min
of administration. This demonstrates the importance of angiotensin II
in the control of systemic blood pressure under these conditions. Although
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the attendant elevation of heart rate suggests that the baroreceptor
reflex is intact, blood pressure was not restored and there is evidence
to suggest that captopril prevents angiotensin II facilitated adrenergic
neurotransmission at the vascular neuroeffector junction thus impairing
sympathetic vascular control (Clough, Collis, Conway, Hatton and Veddie,
1982). Systemic blood pressure was also decreased after captopril
administration in the salt replete dogs. The fall in blood pressure was
maximal within 30 min of captopril administration as in the salt deplete
dogs but the decrease in pressure was quantitatively much smaller in
the salt replete than in the salt deplete dogs. These results confirm
those found in similar studies in dogs and man where captopril administra¬
tion in the salt replete state resulted in a qualitatively similar but
quantitatively smaller reduction in systemic blood pressure to that demon¬
strated in the salt deplete state (Zimmerman et al., 1980b; MacGregor
et al., 1981).
The effect of captopril to decrease systemic blood pressure in sodium
replete animals and man is a property not consistently shared with either
teprotide or saralasin. This has led to the proposal that stimulation
of the synthesis of the vasodilator PGI2 may be responsible for mediating
part of the hypotensive response to captopril.
In the present study, urinary 6-keto-PGFia has been measured
before and after captopril administration to reflect systemic PGI2 produc¬
tion. Urinary 6-keto-PGFia excretion increased after captopril administra¬
tion in both sodium replete and sodium deplete dogs. However, this
increase was not apparent until 90 min after captopril administration
and was not maintained throughout the study. The difference in time
courses between the fall in systemic blood pressure and the increase
in urinary 6-keto-PGFia excretion following captopril administration
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make it unlikely that PGI2 is contributing towards the hypotensive res¬
ponse. An estimation of the rate of PGI2 synthesis as reflected by the
urinary 6-keto-PGFxct excretion can be obtained from the standard
curve constructed in section 3.4.12. By this means, estimated rates
of PGI2 synthesis of 3.6 ng/kg/min and 4.3 ng/kg/min were obtained
for the sodium replete and sodium deplete dogs respectively, during
maximal stimulation by captopril. These levels of PGI2 in the systemic
circulation are well below those required to produce a hypotensive res¬
ponse since an intravenous infusion of PGI2 of 7.5 ng/kg/min in section
3.4.1 failed to lower systemic blood pressure. It therefore seems extreme¬
ly unlikely that the small increase in PGI2 synthesis observed after
captopril administration is contributing to the hypotensive action of
captopril either in the sodium replete or sodium deplete state. These
results, together with the lack of conclusive evidence towards a contribu¬
tion of other vasodilator mediators in the hypotensive action of captopril
suggest that the ability of captopril to lower systemic blood pressure
in the salt replete as well as the salt deplete state is directly related
to the inhibition of angiotensin II formation. Thus the renin-angiotensin
system may exert a tonic influence on the control of systemic blood pres¬
sure in the normal, sodium replete state. This is in contradiction with
the previously held view that angiotensin II is not a prime factor in
blood pressure control under normal circumstances.
Previous studies using saralasin to antagonise the action of angio¬
tensin II found that saralasin lowered systemic blood pressure under
conditions of sodium depletion but had a negligible effect on systemic
blood pressure under normal circumstances (Hollenberg et al. , 1977;
Agabiti-Rosei et at., 1979). However, results from such studies are
difficult to interpret owing to saralasin's residual agonist activity.
155.
Studies using teprotide have also failed to give consistent results as
to the effect of inhibition of angiotensin II formation on systemic blood
pressure in the salt replete state. Most investigators have been unable
to demonstrate a hypotensive action of teprotide during sodium replete
conditions (Kimbrough et al., 1977; Haber, 1976), whilst others have
demonstrated an effect similar to that found with captopril (Niarchos
et al. , 1979). The inconsistency of the results found with teprotide
may be partly due to the fact that this drug must be administered intra¬
venously and can therefore only inhibit the short-term effects of angio¬
tensin II. A gradual increase in the importance of the renin-angiotensin
system as sodium is lost is more likely than an all-or-none phenomenon
and captopril is the first drug to consistently reveal this effect. The
results of this study and of others showing a similar hypotensive res¬
ponse to both acute and chronic administration of captopril during sodium
repletion (Zimmerman et al., 1980b; Hollenberg et al. , 1981; MacGregor
et al. , 1981) support the view that the renin-angiotensin system exerts
a tonic influence on systemic blood pressure under normal conditions.
It has been postulated that angiotensin II produced intrarenally
may serve a local regulatory role in the control of renal haemodynamics
and sodium excretion (Schmidt, 1962; Thurau, 1963; Guyton, Langston
J
and Navar, 1964). Angiotensin I converting enzyme is present in the
kidney (Granger, Dolheim and Thurau, 1972; Caldwell, Seegal and
Hsu, 1976) and the presence of angiotensin II in the extravascular com¬
partment of the kidney has been demonstrated (Mendelsohn, 1979).
Experiments have shown that intrarenal infusions of subpressor doses
of angiotensin II which do not affect circulating angiotensin II levels
consistently result in decreased renal blood flow and glomerular filtration
rate (Barraclough, Jones and Marsden, 1967; Malvin and Vander, 1967;
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Navar and Langford, 1974). Intrarenal infusion of saralasin or tepro-
tide during conditions of sodium depletion lead to an increase in renal
blood flow, glomerular filtration rate, and sodium excretion (Trippodo,
Hall, Lohmeier and Guyton, 1977; Hall, Coleman, Guyton, Williamson-
Balfe and Salgado, 1979). However, a similar effect could not be demon¬
strated in animals on a normal sodium intake (Lohmeir, Cowley, Trippodo,
Hall and Guyton, 1979; Kimbrough et a!., 1977). It should be noted
that in the studies infusing saralasin or teprotide into sodium deplete
animals, the renal effects of these blockers were usually accompanied
by a decrease in systemic blood pressure. It is therefore possible that
inhibition of circulating as well as renal angiotensin II formation was
responsible for the observed effects on renal haemodynamics and sodium
excretion.
Although renal and/or circulating angiotensin II is important in
the control of renal haemodynamics and sodium excretion during sodium
depletion, controversy still exists as to the precise role of the renin-
angiotensin system in controlling renal function during conditions of
normal sodium intake. In the present study, captopril administration
results in an increase in renal plasma flow in the salt deplete and salt
replete states without causing any significant change in glomerular filtra¬
tion rate. In both the salt replete and deplete dogs, the response of
renal plasma flow to captopril was transient, reaching a maximum 90
min after drug administration. Captopril caused a somewhat larger in¬
crease in renal plasma flow in the salt deplete dogs than in the salt replete
dogs. This difference in vasodilator response was, however, of a much
lesser magnitude than the difference in hypotensive response to captopril
seen between the salt replete and salt deplete dogs. These results are
in agreement with those found by other investigators studying the effects
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of captopril in normotensive and hypertensive dogs (Zimmerman et al.,
1980a) and suggest that under normal conditions, the renin-angiotensin
system plays a role in the control of renal haemodynamics, the degree
of control increasing during sodium depletion.
Filtration fraction remained unchanged after captopril administra¬
tion in the sodium replete dogs but decreased in the sodium deplete
dogs due to the larger increase in renal plasma flow. This suggests
that, at least in the sodium deplete state, endogenous angiotensin II
controls renal haemodynamics by preferential constriction of the efferent
arterioles. In the present study, it is not possible to determine whether
the renal vasodilatation following captopril administration was due to
inhibition of intrarenal or circulating angiotensin II formation.
The renal vasodilatation following captopril administration can be
explained solely by the inhibition of a tonic influence of angiotensin II
on renal haemodynamics. However, there is a close correlation between
the increase in renal plasma flow and urinary 6-keto-PGFxa excretion in
both sodium replete and sodium deplete dogs. Urinary 6-keto-PGFia
excretion was increased to a slightly greater extent in the salt deplete
dogs following captopril administration than it was in the salt replete
dogs. This corresponds to the somewhat larger increase in renal plasma
flow and suggests that PGI2 may be mediating part of the renal vaso¬
dilator response to captopril. Since even the maximum urinary 6-keto-
PGFxct excretion rate reflects low levels of systemic PGI2 , it is unlikely
that the increase in PGI2 production is the sole mediator of the renal
vasodilator response to captopril. However, it is possible that PGI2
is contributing to the renal vasodilator action of captopril, particularly
if the urinary 6-keto-PGFia is reflecting predominantly increased renal
synthesis of PGI2. The demonstration that indomethacin caused a small
158.
but non-significant attenuation of the renal vasodilator response to
captopril (Wong et al., 1981) supports the proposal that PGI2 is playing
a minor role in the renal vasodilation. A recent study investigating
the contribution of PGE2 to the renal vasodilator response to captopril
in anaesthetised dogs demonstrated an increase in renal venous PGE2
concentration following captopril administration (Oliver, Sciacca and
Cannon, 1983). The same study failed to demonstrate any effect of
indomethacin on the renal vasodilator response to captopril and the
investigators concluded that although captopril resulted in an increase
in PGE2 synthesis, this prostaglandin was not contributing to the
observed renal vasodilatation. The results of the present study demon¬
strate that PGI2 synthesis is increased following captopril administration
and that this increase can be closely correlated with renal plasma flow.
Whilst this suggests a contribution of PGI2 to the renal vasodilator action
of captopril, such a conclusion cannot be made from the present results.
Captopril caused an increase in sodium excretion in both sodium
deplete and sodium replete dogs. The ability of captopril to cause an
increase in sodium excretion in the salt replete dogs confirms the finding
that chronic captopril administration increases sodium excretion in normal
man (MacGregor et al •, 1981). This is in disagreement with earlier
studies with saralasin and teprotide which failed to demonstrate an
effetet on sodium excretion in sodium replete conscious dogs (Hall,
Guyton, Trippodo, Lohmeier, McCaa and Cowley, 1977; Kimbrough
et al., 1977). Free water clearance fluctuated throughout the study
but there was no significant change after captopril administration which
would suggest that sodium peabsorption has been inhibited in the proximal
tubule. The decrease in free water clearance at the end of the study
in the salt replete dogs may reflect some inhibition of distal tubular
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sodium reabsorption. Potassium excretion also fluctuated after captopril
administration but tended to increase in both sodium replete and deplete
dogs. This increase in potassium excretion also suggests that sodium
reabsorption has been inhibited in the proximal tubule resulting in more
sodium being delivered to the distal tubule to enter into an exchange
mechanism with potassium. The increase in sodium excretion may be
due, at least in part, to the increase in renal plasma flow. An increase
in renal plasma flow without a concomitant increase in glomerular filtra¬
tion rate is capable of increasing sodium excretion, primarily by increas¬
ing peritubular capillary hydrostatic pressure. There may also have
been a redistribution of intrarenal blood flow which would affect sodium
reabsorption. It seems unlikely however that the increase in sodium
excretion is solely a consequence of the increase in renal blood flow,
particularly in the sodium replete dogs where the natriuresis following
captopril administration is large. PGI2 is capable of causing natriuresis
(Gerber et aI. , 1978a). However, an increase in sodium excretion was
observed within 30 min of captopril administration in both sodium replete
and deplete states while urinary 6-keto-PGFia was not increased until
90 min. It is also unlikely that the degree of stimulation of PGI2 synthesis
is large enough to exert such a significant effect on sodium excretion.
The renin-angiotensin system has a known ability to conserve sodium
by stimulating aldosterone release. Inhibition of angiotensin II formation
by captopril would result in lowered aldosterone levels which could result
in increased sodium excretion at least in the salt deplete animal. Infusion
of aldosterone during chronic captopril administration in conscious salt
deplete dogs, however, fails to prevent the increase in sodium excretion
(McCaa et al., 1978; Hall et al. , 1979b). It is unlikely that decreased
aldosterone release is responsible for the natriuresis observed after
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captopril administration in the salt replete dogs since under normal
conditions, plasma aldosterone levels are low and do not exert a large
influence on sodium reabsorption. Results from micropuncture studies
suggest that angiotensin II exerts a direct effect on the proximal tubule
to stimulate sodium reabsorption (Harris and Young, 1977) although
this effect could only be demonstrated with low doses of angiotensin II,
higher doses resulting in inhibition of sodium reabsorption. This dose-
dependant dual action of angiotensin II on sodium reabsorption has also
been demonstrated in isolated proximal tubules (Freedlender and Goodfriend,
1977) and high and low affinity binding sites for angiotensin II in the
proximal tubule have been identified (Freelander, Kirschmaum, Ris.Oken
and Candelora, 1980). Thus the large natriuresis observed after captopril
administration in the salt replete dogs may be partly due to the removal
of a direct effect of angiotensin II on the tubule to increase sodium re¬
absorption. Were angiotensin II to exhibit a bell-shaped dose-response
curve for sodium excretion then this may explain the less dramatic effect
of captopril on sodium excretion in the salt deplete dogs. During sodium
depletion, angiotensin II levels will be high and consequently may be
acting on the downward slope of the dose-response curve. In this situa¬
tion, inhibition of angiotensin II by captoprih would not be expected
to have such a large effect on sodium excretion as during sodium
repletion when low levels of angiotensin II were acting on the upward
slope of the dose response curve. This would imply that during sodium
depletion, other factors besides angiotensin II are responsible for con¬
servation of sodium.
The response of plasma renin activity to captopril administration
was much more pronounced in the salt deplete than in the salt replete
dogs. Plasma renin activity showed a small but progressive increase
161.
following captopril administration in the salt replete dogs but showed
a large increase, maximal within 30 min of drug administration in the
salt deplete dogs. This initial large increase in plasma renin activity
in the salt deplete dogs can be partly attributed to stimulation of the
renal baroreceptor mechanism due to the reduction in systemic blood
pressure following captopril administration. Angiotensin II inhibits
renin release by a short-loop negative feedback mechanism (Vander
and Geelhoed, 1965; Bunag et al., 1967) and therefore the rate of renin
secretion is the result of the strength of the stimulus causing release
and the degree of inhibition of release exerted by angiotensin II. Thus
with the removal of the negative feedback influence of angiotensin II
by captopril, renin release will increase due to the stimulus of sodium
depletion. In the sodium replete dogs, where there is no obvious stimulus
for renin release, removal of the negative feedback influence of angio¬
tensin II results only in a very modest increase in renin release. Although
PGI2 can increase renin release from the kidney (Whorton et at., 1981),
it seems unlikely that it is responsible for the increased plasma renin
activity observed following captopril administration. The increase in
plasma renin activity in the salt deplete dogs occurs well before the
observed increase in urinary 6-keto-PGFia. Although PGI2 may be con¬
tributing to the increased renin release in the salt replete dogs, it is
not the sole factor since plasma renin activity is still increased at the
end of the study when urinary 6-keto-PGFj.a excretion has returned
to control levels. In addition, the degree of stimulation of PGI2 synthesis
is unlikely to be sufficient to elicit a significant increase in plasma renin
activity since an intravenous infusion of a substantially higher concentra¬
tion of PGI2 in section 3 failed to have any effect on plasma renin activity.
Previous studies with indomethacin in normotensive and hypertensive
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animals and man have yielded conflicting results as to whether prosta¬
glandins are involved in the increased renin release evoked by captopril
(Miyamori etal., 1980; Salvetti et al., 1980; Abeetal., 1979;
Silberbauer et al., 1982). However, recent studies support the results
of the present investigation and suggest that, at least in the dog, PGI2
does not mediate the increase in plasma renin activity following captopril
administration either during sodium repletion or sodium depletion
(De Forrest, Waldron and Antonaccio 1982; Oliver et al., 1983).
It is not possible in this study to determine whether the increased
PGI2 synthesis, as reflected by the urinary 6-keto-PGFia excretion,
is due to a direct action of captopril or whether it is a consequence of
increased bradykinin levels. The fact that PGI2 synthesis was increased
in the sodium deplete as well as the sodium replete states suggests that
the higher angiotensin II levels during sodium depletion were not causing
stimulation of PGI2 synthesis since had this been the case, inhibition
of angiotensin II formation by captopril would have resulted in decreased
PGI2 synthesis. The evidence for stimulation of PGI2 synthesis by angio¬
tensin II is conflicting and the majority of studies have used in vitro
preparations and high concentrations of angiotensin II. Some studies
have demonstrated increased release of PGI2 from isolated lung
(Grodzinska and Gryglewski, 1980), mesentery (Dusting et al., 1981),
heart (Needleman et al., 1978), and kidney (Shebuski and Aiken, 1980).
Other studies have failed to demonstrate a stimulation of PGI2 synthesis
by angiotensin II in porcine aortic endothelial cells (Whorton, Young,
Data, Barchowsky and Kent, 1982) or rabbit kidney (Needleman, Bronson,
Wyche and Sivakoff, 1978).
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Studies investigating renal PGE2 synthesis during stimulation of renin
release and increased angiotensin II formation due to sodium depletion
have produced conflicting results. In the rat, an inverse relationship
was found between renal tissue PGE2 production and sodium intake
(Tobian and O'Donnel, 1976) and in the dog, renal venous PGE2 levels
increased following sodium restriction (Oliver et al. , 1980). An increase
in urinary PGE2 excretion has been demonstrated following sodium
restriction in the rabbit (Stahl, Ahmad, Attallah, Bloch and Lee, 1979)
and in man (Rathaus et a/., 1981) whilst other investigators have failed
to observe any change in urinary PGE2 excretion due to sodium depletion
in the rabbit (Lifschitz et al., 1978) or dog (Blasingham et al ., 1980)
or in plasma PGE2 levels in man (Zusman, Spector, Cadwell, Speroff,
Schneider and Mulrow, 1973). Studies with indomethacin or meclofenamate
have revealed that prostaglandin synthesis inhibition results in an
enhanced pressor and renal vasoconstrictor response to angiotensin II
(Negus et al., 1976; Aiken and Vane, 1973). It has also been demon¬
strated that prostaglandin synthesis inhibition results in a decrease
in renal blood flow in the sodium depleted conscious dog but has no effect
when animals are sodium replete (Zimmerman, Momsen and Kraft, 1980b;
De Forrest et al., 1980). This suggests that renal prostaglandins help
to maintain renal blood flow when angiotensin II levels are high. The
ability of indomethacin or meclofenamate to decrease renal blood flow
during sodium depletion in the absence of convincing evidence that PGE2
production is increased has led some investigators to postulate that
PGI2 is the important prostaglandin in maintaining renal blood flow during
stimulation of the renin-angiotensin system (Blasingham et a!., 1980).
The failure to observe an elevation of the urinary 6-keto-PGFia excretion
in the salt deplete state during the control periods in the present study
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suggests that this is not the case and it would seem that a reappraisal
of the role of prostaglandins in the control of renal haemodynamics
is necessary.
The results of this first study demonstrate that although PGI2
may contribute to the renal vasodilator response, the hypotensive, renal
vasodilator and natriuretic actions of captopril are due primarily to
inhibition of angiotensin II formation during both sodium deplete and
replete states. The ability of captopril to lower systemic blood pressure
and cause marked increases in renal blood flow and sodium excretion
in the salt replete dogs suggest that under normal conditions, the renin-
angiotensin system is an important factor in the control of blood pressure
and renal function.
The large vasodilator and natriuretic responses to captopril have
made it difficult to draw firm conclusions in the second study of this
section since many of the expected actions of PGI2 have been masked
by the consequent effects of inhibition of angiotensin II formation.
Captopril elicited a hypotensive response within 30 min in both salt
replete and salt deplete dogs. The responses were quantitatively similar
to those found in the previous study. PGI2 infusion resulted in a further
small decrease in systemic blood pressure in both the sodium replete
and deplete dogs. The PG12-induced hypotension following captopril
administration was not so pronounced as that produced by the same
concentration of PGI2 infused into dogs without prior treatment with
captopril (see section 3.4.1, Figure 3.1). The fall in systemic blood
pressure during PGI2 infusion was transient, a maximum hypotension
occurring 60-90 min after the start of the infusion, an effect also seen
in section 3.4.1. By the end of the study, despite continued PGI2
infusion, blood pressure had returned to the levels seen following capto¬
pril administration.
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Chronic infusion of PGE2 into the renal artery of dogs results in
a decrease in systemic blood pressure followed by a sustained hyper¬
tension (Hockel and Cowley, 1980). This was thought to be a result
of a stimulation of renin release with a consequent increase in angio¬
tensin II formation. It was thought that a similar mechanism may be
responsible for the failure of PGI2 infusion to cause a sustained fall
in systemic blood pressure. The lack of a significant increase in plasma
renin activity during PGI2 infusion together with an unsustained hypo¬
tension even when angiotensin II formation was inhibited by captopril
suggests that stimulation of the renin-angiotensin system was not res¬
ponsible for the transient effect of PGI2 on systemic blood pressure.
The infusion of PGI2 following captopril administration produced
a larger fall in systemic blood pressure in the sodium replete than in
the sodium deplete state. This may be due to the fact that in the sodium
deplete dogs, captopril caused greater vasodilatation of the vasculature.
PGI2 infusion also increased renal plasma flow to a greater extent in
sodium replete dogs than in sodium deplete dogs although prior captopril
administration had resulted in the same degree of renal vasodilatation in
both sodium replete and deplete states. In the sodium replete dogs
both renal plasma flow and glomerular filtration rate showed a progres¬
sive increase during the latter half of the PGI2 infusion. Since renal
plasma flow only showed a transient increase and glomerular filtration
rate did not change at all after captopril administration in the previous
study, the increases seen in the latter half of the present study can
be attributed to the effects of PGI2. The increase in renal plasma flow
and glomerular filtration rate during the PGI2 infusion are larger than
would be expected from the results in section 3.4.3, Figure 3.2, where
the same concentration of PGI2 elicited a smaller effect on renal plasma
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flow and no change in glomerular filtration rate. It is possible there¬
fore that inhibition of angiotensin II formation by captopril has allowed
PGI2 to have a greater vasodilator action on the renal vasculature.
Although filtration fraction decreased after captopril administration,
the increase in glomerular filtration rate prevented a further decrease
during the PGI2 infusion. This may indicate that the PGI2 is having
a preferential vasodilator action on the afferent arteriole. Alternatively,
inhibition of angiotensin II formation by captopril may have interfered
with autoregulatory feedback control of glomerular haemodynamics such
that any increase in renal plasma flow results in an increase in glomerular
filtration rate.
The inability of PGI2 to produce such changes in renal haemo¬
dynamics in the salt deplete dogs cannot be explained simply by the
effect of prior captopril administration since captopril caused the same
degree of renal vasodilatation in both sodium replete and deplete states.
The effect of exogenous PGI2 to cause vasodilatation may be related
to the number of free receptors. It has been demonstrated that the
vasoconstrictor response to exogenous angiotensin II is decreased during
sodium depletion due to increased prior receptor occupancy by the
elevated plasma angiotensin II levels (Brunner et at., 1962; Thurston
and Laragh, 1975). The urinary 6-keto-PGFia excretion data in the
previous study demonstrated that PGI2 production in the salt deplete
dogs was increased to a slightly higher level by captopril than it was
in the salt replete dogs. It is possible therefore, that increased prior
receptor occupancy is responsible for the lack of further renal vaso¬
dilatation during the PGI2 infusion in the sodium deplete dogs. However,
it is also possible that sodium depletion results in the vasculature being
less sensitive to the effects of PGI2 by some alternative mechanism.
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Sodium excretion showed a large increase during the PGI2 infusion
in the sodium replete dogs, although this effect could be due solely to
the effects of captopril administration since the previous study demon¬
strated that captopril administration alone results in a progressive in¬
crease in sodium excretion (Figure 4.3). The maximum increase in sodium
excretion is higher during the PGI2 infusion following captopril admin¬
istration than that observed following captopril administration alone.
This suggests that the PGI2 may be having an additive effect to increase
sodium excretion. Although the increase in sodium excretion could be
explained by the increased renal plasma flow resulting in decreased
proximal tubular reabsorption, the lack of increase in potassium excretion
and the decrease in free water clearance suggest that distal tubular
sodium reabsorption is also being inhibited. No such effect on distal
tubular sodium reabsorption was demonstrated either by captopril alone
(section 4.5.7) or by the infusion of the same concentration of PGI2
without prior captopril administration (section 3.5.7). Thus inhibition
of angiotensin II formation by captopril may have allowed the PGI2 to
exert an inhibitory effect on distal tubular sodium reabsorption. It is
unlikely, however, that this is a direct effect on the distal tubule since
no further increase in sodium excretion was demonstrated during PGI2
infusion in sodium deplete dogs when renal plasma flow also failed to
increase.
PGI2 infusion following captopril administration had no effect on
plasma renin activity in the salt replete dogs. This demonstrates that
the removal of the negative feedback influence of angiotensin II in no
way augments the effect of PGI2 on renin release. The increase in plasma
renin activity following captopril administration in the salt deplete dogs
was so large that any effect of PGI2 infusion would be completely masked.
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Both studies in this section have demonstrated that inhibition of
angiotensin II formation by captopril causes large changes in systemic
blood pressure, renal blood flow and sodium excretion in both salt replete
and salt deplete dogs indicating the importance of the renin-angiotensin
system in the control of these parameters. In the first study, the
estimated maximum rates of synthesis of PGI2 following captopril admin¬
istration were 3.6 ng/kg/min and 4.3 ng/kg/min for the salt replete
and salt deplete dogs respectively. By comparison to the effects of
intravenous infusion of PGI2 in Section III these levels were not thought
to be high enough to exert an effect on systemic haemodynamics. How¬
ever, had captopril administration resulted in a large increase in vascular
sensitivity to PGI2, these levels may have been sufficient to result in
vasodilatation. Inhibition of angiotensin II formation by captopril had
no effect on the hypotensive response to PGI2 although it did result
in a slightly greater renal vasodilator response to PGI2 in the sodium
replete dogs. Thus whilst the low levels of PGI2 demonstrated in the
first study were unlikely to have an effect on systemic blood pressure
even after inhibition of angiotensin II formation by captopril, it is possible
that they were sufficient to participate in the renal vasodilatation. It
should be noted, however, that the large effects of prior captopril admin¬
istration make it difficult to draw any firm conclusions.
The lack of effect of PGI2 on renal plasma flow following captopril
administration in the salt deplete dogs, in addition to the finding that
urinary 6-keto-PGFia was not elevated during the control period of
sodium deprivation, suggests that PGI2 is not important in maintaining
renal blood flow when the renin-angiotensin system is stimulated by
sodium depletion. The failure of PGI2 to increase renin release after
removal of the negative feedback influence of angiotensin II also questions
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the significance of PGI2 in the control of renin release. It would seem,
therefore, that in comparison to angiotensin II, PGI2 plays a very minor
role in the control of systemic blood pressure and renal function in either




The aim of this thesis was to investigate the complex interrelation¬
ship between PGI2 and the renin-angiotensin system. This was achieved
firstly by observing the actions of exogenous PGI2 on renal parameters
and secondly by interrupting the renin-angiotensin system and demon¬
strating whether or not this affected endogenous synthesis of PGI2 or
the expected actions of exogenous PGI2.
The use of conscious animals throughout this '.work proved to be
of great benefit. The disadvantages were that the surgical preparation
and training of each dog took 2 months and the maintenance of each
animal in a healthy state required constant attention. However, these
disadvantages were offset, firstly by the obvious advantage of being
able to study the prostaglandin and renin-angiotensin systems without
the use of anaesthesia. Secondly, once initiated into an experimental
regime, each dog could be used repeatedly for a number of different
studies, thereby acting as its own control. In this thesis, therefore,
the same animals were used in all studies and it was this advantage which
made it possible to make direct comparisons between the studies.
Endogenous PGI2 production was assessed by estimation of urinary
6-keto-PGFxa. The linear relationship observed between intravenous
PGI2 and urinary 6-keto-PGFxa demonstrated that measurement of urinary
6-keto-PGFia represented a useful and reliable indicator of PGI2 produc¬
tion. The GC-MS assay technique proved to be a reliable and highly
specific method and was therefore ideally suited for the precise analytical
work required in this thesis, particularly in the demonstration of the
relationship between PGI2 and its metabolite. However, GC-MS is not
as sensitive as some recently developed radioimmunoassays and the
chromatographic steps necessary to render the urine samples suitable
for analysis by GC-MS were found to be time-consuming and laborious.
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The author does therefore not consider GC-MS to be a practical
alternative to RIA for the estimation of prostaglandins when large sample
size is involved.
This thesis has confirmed that the renin-angiotensin system is
a very powerful humoral mechanism controlling systemic and renal haemo-
dynamics to varying degrees depending on the state of sodium balance.
Although it would be speculative to say that under physiological conditions,
PGI2 plays no role in the control of systemic or renal haemodynamics, it
is apparent that its contribution to the control of these parameters is
minor compared to that of the renin-angiotensin system. Likewise, it is
highly unlikely that PGI2 is an important modulator of the renin-angio¬
tensin system although it may act as a 'fine-control', preventing dramatic
fluctuations in renin release and affording some local protection of blood
flow within the kidney at times when angiotensin II formation is increased.
Since the discovery of prostaglandins by Von Euler in 1963, the
literature has witnessed a vast quantity of evidence implicating prosta¬
glandins in almost every physiological system in the body. Perhaps
the enthusiasm which the discovery of a new group of compounds inspired,
led to the role of prostaglandins as modulators of many body functions
being given an exaggerated importance. Although there can be no doubt
that prostaglandins are involved in many physiological processes, the
fact that millions of people ingest pharmacological doses of aspirin every
day with few apparent side-effects, suggests that the involvement of
prostaglandins in these processes is not essential.
This thesis has demonstrated that PGI2 plays a much less important
role in the control of renal function and the renin-angiotensin system
than the literature previously suggested. This is an observation which
could perhaps be applied to prostaglandin research in general and
172.
suggests that it is time to reassess the relevance of much of the work
in this field.
The development of angiotensin converting enzyme inhibitors such
as captopril has highlighted our incomplete knowledge of the complexities
of the renin-angiotensin system and further study of this important
humoral mechanism is essential.
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Footnote.
The action of the 5mg/kg dose of captopril to inhibit
Angiotensin 11 formation throughout the period of the study was
■H
reviously tested in an anaesthetised dog preparation. This was
achieved by demonstrating that the pressor response to
•Si
angiotensin 1 had been abolished.
